

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Circulation

136, e137-e161

DOI: 10.1161/cir.0000000000000509

Citation Report

#	ARTICLE	IF	CITATIONS
1	Complete and Removable Partial Prosthesis for a Child with Hypohidrotic Ectodermal Dysplasia. International Journal of Clinical Pediatric Dentistry, 2013, 6, 71-74.	0.8	6
2	Management of a growing Skeletal Class II Patient: A Case Report. International Journal of Clinical Pediatric Dentistry, 2013, 6, 48-54.	0.8	2
3	Iron Deficiency in Young Children: A Risk Marker for Early Childhood Caries. International Journal of Clinical Pediatric Dentistry, 2013, 6, 1-6.	0.8	15
4	Effect of Propolis on <i>Streptococcus mutans</i> Counts: An <i>in vivo</i> Study. International Journal of Clinical Pediatric Dentistry, 2013, 6, 22-25.	0.8	15
5	Evaluation of Dental Fear in Children during Dental Visit using Children's Fear Survey Schedule-Dental Subscale. International Journal of Clinical Pediatric Dentistry, 2013, 6, 12-15.	0.8	36
6	Oral Melanoacanthoma of a Rare Intraoral Site: Case Report and Review of Literature. International Journal of Clinical Pediatric Dentistry, 2013, 6, 40-43.	0.8	10
7	Evaluation of the Microleakage of Chlorhexidine-Modified Glass Ionomer Cement: An <i>in vivo</i> Study. International Journal of Clinical Pediatric Dentistry, 2013, 6, 7-11.	0.8	7
8	Agenesis of Multiple Primary Teeth and Its Rehabilitation: A Case Report. International Journal of Clinical Pediatric Dentistry, 2013, 6, 55-57.	0.8	8
9	Internal and External Root Resorption Management: A Report of Two Cases. International Journal of Clinical Pediatric Dentistry, 2013, 6, 44-47.	0.8	5
10	Classification of Interdental Space for Different Quadrants on the Basis of Standardization through Threshold Data and Its Comparison with BMI and Socioeconomic Status. International Journal of Clinical Pediatric Dentistry, 2013, 6, 16-21.	0.8	0
11	Management of Traumatic Injury to Maxillary Central Incisors associated with Inverted Mesiodens: A Case Report. International Journal of Clinical Pediatric Dentistry, 2013, 6, 30-32.	0.8	4
12	Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction. Advances in Experimental Medicine and Biology, 2017, 1067, 31-45.	1.6	10
13	Increased serum lysyl oxidase-like 2 levels correlate with the degree of left atrial fibrosis in patients with atrial fibrillation. Bioscience Reports, 2017, 37, .	2.4	11
14	“Pumping Iron” to Improve Exercise Performance in Heart Failure. Circulation, 2017, 136, 1384-1386.	1.6	3
15	Therapeutic Targets for the Multi-system Pathophysiology of Heart Failure: Exercise Training. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 87.	0.9	7
16	Pharmacologic Therapy for Heart Failure With Reduced Ejection Fraction: Closing the Gap Between Clinical Guidelines and Practice. Progress in Cardiovascular Diseases, 2017, 60, 187-197.	3.1	14
17	How Many Heart Failure Patients Might We SHIFT to a Lower Heart Rate?. Circulation: Heart Failure, 2017, 10, .	3.9	0
18	Mind the Gap: Current Challenges and Future State of Heart Failure Care. Canadian Journal of Cardiology, 2017, 33, 1434-1449.	1.7	19

#	ARTICLE	IF	CITATIONS
20	Prognostic Significance of Low Systolic Blood Pressure at Discharge in Patients with Heart Failure and Preserved Ejection Fraction. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 405-412.	2.2	0
21	Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 2017, 14, 434-443.	3.3	15
22	Targeting Cardiovascular Implant Infection. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	22
23	The Role of Cardiologists in the Management of Patients with Heart Failure. Advances in Experimental Medicine and Biology, 2017, 1067, 133-144.	1.6	1
25	Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease. Journal of the American Heart Association, 2017, 6, .	3.7	6
26	Certification Review for the Ortho PA. JBJS Journal of Orthopaedics for Physician Assistants, 2017, 5, e22.	0.0	0
27	Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives. Vascular Health and Risk Management, 2017, Volume 13, 369-382.	2.3	18
28	A Historical Perspective on Presentations of Hypertensive Acute Heart Failure. Journal of Cardiovascular Diseases & Diagnosis, 2017, 05, .	0.0	2
29	Target goal blood pressure in hypertension management. Journal of the Korean Medical Association, 2017, 60, 819.	0.3	1
30	Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic. American Journal of Cardiovascular Drugs, 2018, 18, 143-151.	2.2	13
31	Rethinking Chronic Obstructive Pulmonary Disease. Chronic Pulmonary Insufficiency and Combined Cardiopulmonary Insufficiency. Annals of the American Thoracic Society, 2018, 15, S30-S34.	3.2	9
32	Evolution of bendopnea during admission in patients with decompensated heart failure. European Journal of Internal Medicine, 2018, 51, e23-e24.	2.2	6
33	Stability of dobutamine in continuous ambulatory delivery devices. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 530-535.	1.5	3
34	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patientsâ€”who is doing what to whom and how?. European Journal of Heart Failure, 2018, 20, 1039-1051.	7.1	107
35	Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1 Association, 2018, 7, .	3.7	25
36	Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial. Contemporary Clinical Trials, 2018, 66, 45-50.	1.8	7
37	Autonomic Nervous System in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 925-927.	1.6	7
38	Cardiovascular magnetic resonance imaging in heart failure. Expert Review of Cardiovascular Therapy, 2018, 16, 237-248.	1.5	6

#	ARTICLE	IF	CITATIONS
39	Sex differences in heart failure. <i>Clinical Cardiology</i> , 2018, 41, 211-216.	1.8	98
40	A Review of the Role of the Pharmacist in Heart Failure Transition of Care. <i>Advances in Therapy</i> , 2018, 35, 311-323.	2.9	41
41	Treatment of Heart Failure with Preserved Ejection Fraction. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1067, 67-87.	1.6	39
42	Cardiopulmonary Exercise Testing in Patients Following Massive and Submassive Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	48
43	Palliative Care in Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 43.	0.9	8
44	Iron deficiency in chronic and acute heart failure: A contemporary review on intertwined conditions. <i>European Journal of Internal Medicine</i> , 2018, 52, 1-7.	2.2	25
45	Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1326-1334.	7.1	156
46	Biomarkers for heart failure: small molecules with high clinical relevance. <i>Journal of Internal Medicine</i> , 2018, 283, 530-543.	6.0	87
47	What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. <i>Current Cardiology Reports</i> , 2018, 20, 39.	2.9	27
48	Real-world management of heart failure in the Netherlands. <i>Netherlands Heart Journal</i> , 2018, 26, 240-241.	0.8	0
49	Usefulness of inferior vena cava ultrasonography in outpatients with chronic heart failure. <i>Clinical Cardiology</i> , 2018, 41, 510-517.	1.8	11
50	Nurses' decision making in heart failure management based on heart failure certification status. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2018, 47, 184-191.	1.6	4
51	Recurrent Acute Decompensated Heart Failure Admissions for Patients With Reduced Versus Preserved Ejection Fraction (from the Atherosclerosis Risk in Communities Study). <i>American Journal of Cardiology</i> , 2018, 122, 108-114.	1.6	15
52	The Importance of Heart Rate in Heart Failure and Reduced Ejection Fraction. <i>Journal of Cardiovascular Nursing</i> , 2018, 33, 453-459.	1.1	2
53	Exercise on transition uncoupling of ventilatory, gas exchange and cardiac hemodynamic kinetics accompany pulmonary oxygen stores depletion to impact exercise intolerance in human heart failure. <i>Acta Physiologica</i> , 2018, 223, e13063.	3.8	6
54	Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2018, 263, 80-87.	1.7	21
55	Digoxin use and lower risk of 30-day all-cause readmission in older patients with heart failure and reduced ejection fraction receiving β -blockers. <i>Clinical Cardiology</i> , 2018, 41, 406-412.	1.8	15
56	Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e004302.	3.9	68

#	ARTICLE	IF	CITATIONS
57	Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 749-756.	1.2	22
58	Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). <i>American Heart Journal</i> , 2018, 199, 130-136.	2.7	71
59	Selection of the Best of 2017 in Acute and Chronic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 298-299.	0.6	0
60	Remote Monitoring for Chronic Disease Management. <i>Cardiac Electrophysiology Clinics</i> , 2018, 10, 43-58.	1.7	6
61	Impact of the SPRINT Trial on Hypertension Management. <i>Annual Review of Medicine</i> , 2018, 69, 81-95.	12.2	6
62	Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 137, e30-e66.	1.6	500
63	Racial differences in dietary antioxidant intake and cardiac event-free survival in patients with heart failure. <i>European Journal of Cardiovascular Nursing</i> , 2018, 17, 305-313.	0.9	5
64	Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure. <i>ESC Heart Failure</i> , 2018, 5, 562-569.	3.1	23
65	Ventricular Arrhythmic Storm after Initiating Sacubitril/Valsartan. <i>Cardiology</i> , 2018, 139, 119-123.	1.4	14
66	Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection—Focus on Group II Pulmonary Hypertension. <i>Current Heart Failure Reports</i> , 2018, 15, 81-93.	3.3	5
67	Self-care in Heart Failure Hospital Discharge Instructions—Differences Between Nurse Practitioner and Physician Providers. <i>Journal for Nurse Practitioners</i> , 2018, 14, 18-25.	0.8	4
68	Heart Failure. Primary Care - Clinics in Office Practice, 2018, 45, 63-79.	1.6	1
69	Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 288.	6.1	93
70	Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction. <i>Clinical Medicine Insights: Cardiology</i> , 2018, 12, 117954681775160.	1.8	23
71	Feasibility of optimizing pharmacotherapy in heart failure patients admitted to an acute geriatric ward: role of the clinical pharmacist. <i>European Geriatric Medicine</i> , 2018, 9, 103-111.	2.8	9
72	Selección de lo mejor del año 2017 en insuficiencia cardiaca aguda y crónica. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 298-299.	1.2	2
73	Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study. <i>ESC Heart Failure</i> , 2018, 5, 95-100.	3.1	31
74	Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 392-400.	4.9	29

#	ARTICLE	IF	CITATIONS
75	Reversing the Cardiac Effects of Sedentary Aging in Middle Age—A Randomized Controlled Trial. <i>Circulation</i> , 2018, 137, 1549-1560.	1.6	135
76	Long-Term Prognostic Significance of Plasma B-Type Natriuretic Peptide Level in Patients With Acute Heart Failure With Reduced, Mid-Range, and Preserved Ejection Fractions. <i>American Journal of Cardiology</i> , 2018, 121, 731-738.	1.6	32
77	Heart failure with preserved ejection fraction: controversies, challenges and future directions. <i>Heart</i> , 2018, 104, 377-384.	2.9	76
78	Effects and Safety of Sodium Glucose Cotransporter 2 Inhibitors in Diabetes Patients With Drug-Refractory Advanced Heart Failure. <i>Circulation Journal</i> , 2018, 82, 1959-1962.	1.6	9
79	Essential Elements of Early Post Discharge Care of Patients with Heart Failure. <i>Current Heart Failure Reports</i> , 2018, 15, 181-190.	3.3	7
80	Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy. <i>Postgraduate Medicine</i> , 2018, 130, 299-307.	2.0	15
81	2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e000037.	2.2	72
82	Up-regulation of NOX1/NADPH oxidase following drug-induced myocardial injury promotes cardiac dysfunction and fibrosis. <i>Free Radical Biology and Medicine</i> , 2018, 120, 277-288.	2.9	28
83	Intraoperative Transesophageal Echocardiography and Right Ventricular Failure After Left Ventricular Assist Device Implantation. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 2096-2103.	1.3	27
84	New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides. <i>Journal of Medical Genetics</i> , 2018, 55, 287-296.	3.2	9
85	Combination Therapy of Renin Angiotensin System Inhibitors and β -Blockers in Patients with Heart Failure. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1067, 17-30.	1.6	7
86	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 86-92.	3.0	57
87	Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 28.	0.9	13
88	Standardization of BNP and NT-proBNP Immunoassays in Light of the Diverse and Complex Nature of Circulating BNP-Related Peptides. <i>Advances in Clinical Chemistry</i> , 2018, 85, 1-30.	3.7	25
89	Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators. <i>International Journal of Cardiology</i> , 2018, 261, 130-133.	1.7	6
90	Cardio-supportive devices (VRD & DCC device) and patches for advanced heart failure: A review, summary of state of the art and future directions. <i>Biomedicine and Pharmacotherapy</i> , 2018, 102, 41-54.	5.6	22
91	A Population-Based Study of Early Postoperative Outcomes in Patients with Heart Failure Undergoing Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 2281-2288.	2.1	8
92	In-Hospital Sepsis Mortality Rates Comparing Tertiary and Non-Tertiary Hospitals in Washington State. <i>Journal of Emergency Medicine</i> , 2018, 54, 785-792.	0.7	5

#	ARTICLE	IF	CITATIONS
93	YiQiFuMai injection for chronic heart failure. <i>Medicine (United States)</i> , 2018, 97, e9957.	1.0	2
94	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. <i>Circulation</i> , 2018, 138, e210-e271.	1.6	250
95	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Circulation</i> , 2018, 138, e272-e391.	1.6	468
96	NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure. <i>Circulation</i> , 2018, 137, 1671-1683.	1.6	122
97	The Patient with Advanced Chronic Heart Failure. , 2018, , 19-38.		0
98	Low- and High-renin Heart Failure Phenotypes with Clinical Implications. <i>Clinical Chemistry</i> , 2018, 64, 597-608.	3.2	52
99	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 483-490.	7.1	28
100	Developing and Sustaining a Career as a Transdisciplinary Nurse Scientist. <i>Journal of Nursing Scholarship</i> , 2018, 50, 20-27.	2.4	10
101	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> , 2018, 71, e13-e115.	2.7	3,332
102	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> , 2018, 71, 1269-1324.	2.7	2,414
103	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> , 2018, 71, e116-e135.	2.7	118
104	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , 2018, 104, 606-613.	2.9	16
105	Cell Spray Transplantation of Stem Cells for Ischemic Cardiomyopathyâ€”How Effective Are Dispersed Droplets?. <i>Transplantation</i> , 2018, 102, 1972-1973.	1.0	0
106	Guidelineâ€Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patientâ€Pooled Analysis From the KorHF and KorAHF Registries. <i>Journal of the American Heart Association</i> , 2018, 7, e009806.	3.7	25
107	Clinical efficacy and safety of nuanxin capsule for chronic heart failure. <i>Medicine (United States)</i> , 2018, 97, e11339.	1.0	4
108	Cardiovascular disease in survivors of childhood cancer. <i>Current Opinion in Pediatrics</i> , 2018, 30, 628-638.	2.0	43
109	PRO: Persistent Central Sleep Apnea/Hunter-Cheyne-Stokes Breathing, Despite Best Guideline-Based Therapy of Heart Failure With Reduced Ejection Fraction, Is a Compensatory Mechanism and Should Not Be Suppressed. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 909-914.	2.6	13
110	Effects of Ramadan fasting on the symptoms of chronic heart failure. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2018, 39, 395-400.	1.1	25

#	ARTICLE	IF	CITATIONS
111	Exercise-based cardiac rehabilitation for people with implantable ventricular assist devices. The Cochrane Library, 2018, 9, CD012222.	2.8	6
112	OBSOLETE: Biomarkers in Heart Failure, Use of. , 2018, , .		0
113	OBSOLETE: Neurohormonal Blockade. , 2018, , .		0
114	Add-on Immunoadsorption Shortly-after Optimal Medical Treatment Further Significantly and Persistently Improves Cardiac Function and Symptoms in Recent-Onset Heart Failureâ€”A Single Center Experience. Biomolecules, 2018, 8, 133.	4.0	4
115	Psychosocial and clinical outcomes of percutaneous versus surgical pulmonary valve implantation. Open Heart, 2018, 5, e000758.	2.3	4
116	Heart Failure. Annals of Internal Medicine, 2018, 169, 738.	3.9	2
117	Type-2 diabetes mellitus and cardiovascular disease. Future Cardiology, 2018, 14, 491-509.	1.2	197
118	Validity of Performance and Outcome Measures for Heart Failure. Circulation: Heart Failure, 2018, 11, e005035.	3.9	12
119	Association Between Inflammatory Markers and Myocardial Fibrosis. Hypertension, 2018, 72, 902-908.	2.7	29
120	Letter by Fung etÂal Regarding Article, â€œFrailty and Clinical Outcomes in Heart Failure: A Systematic Review and Meta-analysisâ€”, Journal of the American Medical Directors Association, 2018, 19, 1143-1146.	2.5	0
121	Relationship Between Noninvasive Assessment of Lung Fluid Volume and Invasively Measured Cardiac Hemodynamics. Journal of the American Heart Association, 2018, 7, e009175.	3.7	49
122	The Vulnerable Phase of Heart Failure. American Journal of Therapeutics, 2018, 25, e456-e464.	0.9	25
123	Moving From Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients With Multiple Comorbidities and Older Age. Clinical Medicine Insights: Cardiology, 2018, 12, 117954681880935.	1.8	33
124	Implementation of a Multidisciplinary Inpatient Cardiology Service to Improve Heart Failure Outcomes in Guyana. Journal of Cardiac Failure, 2018, 24, 835-841.	1.7	6
125	Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?. Circulation, 2018, 138, 2787-2797.	1.6	3
126	Letter by de las Nieves Lopez Regarding Article, â€œAnemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapiesâ€”, Circulation, 2018, 138, 2974-2975.	1.6	0
127	Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. Circulation: Heart Failure, 2018, 11, e005266.	3.9	143
128	Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2018, 320, 2231.	7.4	72

#	ARTICLE	IF	CITATIONS
129	Real-world presentation with heart failure in primary care: do patients selected to follow diagnostic and management guidelines have better outcomes?. Open Heart, 2018, 5, e000935.	2.3	6
130	Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2018, 14, 525-535.	2.1	9
131	Whole Cardiac Tissue Bioscaffolds. Advances in Experimental Medicine and Biology, 2018, 1098, 85-114.	1.6	17
132	Improving Provider Adherence to Guideline Recommendations in Heart Failure. Current Heart Failure Reports, 2018, 15, 350-356.	3.3	3
133	Sex Differences in the Management of Advanced Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 88.	0.9	14
134	Novel biomarkers in heart failure. What they add in daily clinical practice?. Hellenic Journal of Cardiology, 2018, 59, 193-195.	1.0	7
135	In-Hospital Initiation of Guideline-Directed Heart Failure Pharmacotherapy to Improve Long-Term Patient Adherence and Outcomes. Critical Care Nurse, 2018, 38, 16-24.	1.0	2
136	Absence of Myocardial Fibrosis Predicts Favorable Long-Term Survival in New-Onset Heart Failure. Circulation: Cardiovascular Imaging, 2018, 11, e007722.	2.6	42
137	Can Circulating B-Type Natriuretic Peptide Concentrations Guide Treatment of Obstructive Left Main Coronary Artery Disease?. Circulation, 2018, 138, 479-482.	1.6	1
138	Advanced Heart Failure Therapies and Cardiorenal Syndrome. Advances in Chronic Kidney Disease, 2018, 25, 443-453.	1.4	11
139	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2018, 138, e426-e483.	1.6	599
140	Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. Circulation: Heart Failure, 2018, 11, e005400.	3.9	36
141	Cardiac Resynchronization Therapy and Dynamic Changes in Right Ventricular Function. Circulation: Cardiovascular Imaging, 2018, 11, e008195.	2.6	1
142	A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload. Journal of Cardiac Failure, 2018, 24, 773-782.	1.7	18
143	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2018, 138, e484-e594.	1.6	330
144	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2018, 138, e595-e616.	1.6	76
146	Extraction of Ejection Fraction from Echocardiography Notes for Constructing a Cohort of Patients having Heart Failure with reduced Ejection Fraction (HFrEF). Journal of Medical Systems, 2018, 42, 209.	3.6	18
147	Correlation between B-Type Natriuretic Peptide and N-Terminal pro-B-Type Natriuretic Peptide in a Large Japanese Population at Risk of Stage A Heart Failure. Pulse, 2018, 6, 1-8.	1.9	4

#	ARTICLE	IF	CITATIONS
148	Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization. <i>JAMA Cardiology</i> , 2018, 3, 1206.	6.1	35
149	The non-neuronal cholinergic system in the heart: A comprehensive review. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 125, 129-139.	1.9	41
150	Revisiting the Diabetes-Heart Failure Connection. <i>Current Diabetes Reports</i> , 2018, 18, 134.	4.2	10
151	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 579.e1-579.e73.	2.3	126
152	Role of blood urea nitrogen in predicting the post-discharge prognosis in elderly patients with acute decompensated heart failure. <i>Scientific Reports</i> , 2018, 8, 13507.	3.3	20
153	Right heart dysfunction. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 613-623.	1.5	10
154	Acute Decompensated Heart Failure: A Pharmacotherapy Approach. <i>AACN Advanced Critical Care</i> , 2018, 29, 233-239.	1.1	0
155	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1601-1610.	7.1	27
156	How Heart Rate Should Be Controlled in Patients with Atherosclerosis and Heart Failure. <i>Current Atherosclerosis Reports</i> , 2018, 20, 54.	4.8	4
157	Effects of modest iron loading on iron indices in healthy individuals. <i>Journal of Applied Physiology</i> , 2018, 125, 1710-1719.	2.5	2
158	Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity. <i>American Journal of Cardiology</i> , 2018, 122, 1959-1964.	1.6	53
159	Effects of spironolactone in heart failure with preserved ejection fraction. <i>Medicine (United States)</i> , 2018, 97, e11942.	1.0	14
160	Ambulatory Intra Aortic Balloon Pump in Advanced Heart Failure. <i>Cardiac Failure Review</i> , 2018, 4, 1.	3.0	13
161	One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial. <i>JAMA Cardiology</i> , 2018, 3, 968.	6.1	121
162	Ischemic Cardiomyopathy: Contemporary Clinical Management. , 2018, , .		0
163	Effect of Î²-blocker Therapy on Hospital Readmission and Mortality in Heart Failure Patients With Concurrent Cocaine Use. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 518-523.	2.0	6
164	Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases. <i>American Heart Journal</i> , 2018, 202, 76-83.	2.7	7
165	Race and Beta-Blocker Survival Benefit in Patients With Heart Failure: An Investigation of Self-Reported Race and Proportion of African Genetic Ancestry. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	15

#	ARTICLE	IF	CITATIONS
166	Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes. Journal of the American Heart Association, 2018, 7, .	3.7	46
167	Left ventricular restoration devices post myocardial infarction. Heart Failure Reviews, 2018, 23, 871-883.	3.9	13
168	New heart failure reclassification: are we left with more questions than answers?. Postgraduate Medicine, 2018, 130, 449-451.	2.0	1
169	Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan. American Journal of Cardiovascular Drugs, 2018, 18, 473-482.	2.2	7
170	Natriuretic Peptideâ€“Guided Heart Failure Therapy After the GUIDE-IT Study. Circulation, 2018, 137, 2101-2103.	1.6	12
171	Biomarkers in Heart Failure, Use of. , 2018, , 293-302.		0
172	Preventable delays to intravenous furosemide administration in the emergency department prolong hospitalization for patients with acute heart failure. International Journal of Cardiology, 2018, 269, 207-212.	1.7	4
173	An Educational Intervention to Evaluate Nurses' Knowledge of Heart Failure. Journal of Continuing Education in Nursing, 2018, 49, 315-321.	0.6	11
174	Anemia and Iron Deficiency in Heart Failure. Circulation, 2018, 138, 80-98.	1.6	352
175	Impact of B-Type Natriuretic Peptide Level on Risk Stratification of Thromboembolism and Death in Patients With Nonvalvular Atrial Fibrillationâ€“The Hokuriku-Plus AF Registry â€“. Circulation Journal, 2018, 82, 1271-1278.	1.6	31
176	Treatment of Chagas Disease in the United States. Current Treatment Options in Infectious Diseases, 2018, 10, 373-388.	1.9	74
177	Acute rheumatic fever. Lancet, The, 2018, 392, 161-174.	13.7	139
178	Outcomes in Cardiogenic Shock Patients with Extracorporeal Membrane Oxygenation Use: A Matched Cohort Study in Hospitals across the United States. BioMed Research International, 2018, 2018, 1-8.	1.9	21
179	Biomarkers in Pulmonary Hypertension. Heart Failure Clinics, 2018, 14, 393-402.	2.1	20
181	Outcomes of â€œdiabetesâ€“friendlyâ€“vs â€œdiabetesâ€“unfriendlyâ€“beta-blockers in older nursing home residents with diabetes after acute myocardial infarction. Diabetes, Obesity and Metabolism, 2018, 20, 2724-2732.	4.4	13
182	Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure. The Cochrane Library, 0, , .	2.8	0
183	Heart Failure. Annals of Internal Medicine, 2018, 168, ITC81-ITC96.	3.9	11
184	Galectin-3 in the pathogenesis of heart failure: a causative mediator or simply a biomarker?. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H1256-H1258.	3.2	4

#	ARTICLE	IF	CITATIONS
185	Are serial measurements of plasma concentrations of natriuretic peptide useful in real-world practice in patients with heart failure?. International Journal of Cardiology, 2018, 269, 220-221.	1.7	1
186	Effect of sacubitril/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction. International Journal of Cardiology, 2018, 271, 169-173.	1.7	19
187	Is Excessive Polypharmacy a Transient or Persistent Phenomenon? A Nationwide Cohort Study in Taiwan. Frontiers in Pharmacology, 2018, 9, 120.	3.5	15
188	Heart Failure and Frailty in the Community-Living Elderly Population: What the UFO Study Will Tell Us. Frontiers in Physiology, 2018, 9, 347.	2.8	5
189	Circulating macrophage migration inhibitory factor (MIF) in patients with heart failure. Cytokine, 2018, 110, 104-109.	3.2	16
190	Medications that reduce emergency hospital admissions: an overview of systematic reviews and prioritisation of treatments. BMC Medicine, 2018, 16, 115.	5.5	19
191	Sex-Related Aspects of Biomarkers in Cardiac Disease. Advances in Experimental Medicine and Biology, 2018, 1065, 545-564.	1.6	17
192	Myocardial considerations in type 2 diabetes: 2018. Journal of Diabetes, 2018, 10, 784-788.	1.8	1
193	Ryanodine receptor dysfunction in human disorders. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 1687-1697.	4.1	101
194	Rationale for administering beta-blocker therapy to patients undergoing coronary artery bypass surgery: a systematic review. Expert Opinion on Drug Safety, 2018, 17, 805-813.	2.4	7
195	Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides?. Journal of Animal Science and Technology, 2018, 5, R65-R75.	2.5	21
196	Using Acellular Bioactive Extracellular Matrix Scaffolds to Enhance Endogenous Cardiac Repair. Frontiers in Cardiovascular Medicine, 2018, 5, 35.	2.4	22
197	Heart Failure with Hyperthyroidism Demonstrating Discrepancy between the Clinical Course and B-type Natriuretic Peptide Levels. Internal Medicine, 2018, 57, 1747-1749.	0.7	4
198	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. Circulation: Heart Failure, 2018, 11, e004926.	3.9	26
199	New, but still the same old story. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1528-1529.	0.8	0
200	Diagnostic concordance between NT-proBNP and BNP for suspected heart failure. Clinical Biochemistry, 2018, 59, 50-55.	1.9	37
201	Acquired Cardiac Disease in the Pediatric Intensive Care Unit. Pediatric Annals, 2018, 47, e280-e285.	0.8	2
202	Acute kidney injury in the UK: a replication cohort study of the variation across three regional populations. BMJ Open, 2018, 8, e019435.	1.9	25

#	ARTICLE	IF	CITATIONS
203	Impact of Clopidogrel on Mortality in Patients With Acute Heart Failure Stratified by Coronary Artery Disease: Findings From the Arabian Gulf Acute Heart Failure Registry (Gulf CARE). <i>Angiology</i> , 2018, 69, 884-891.	1.8	0
204	A peripheral blood transcriptome biomarker test to diagnose functional recovery potential in advanced heart failure. <i>Biomarkers in Medicine</i> , 2018, 12, 619-635.	1.4	10
205	Future Perspectives for Management of Stage A Heart Failure. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 557-565.	2.0	8
206	The therapeutic role of ivabradine in heart failure. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 199-207.	2.5	17
207	Non-response to Cardiac Resynchronization Therapy. <i>Current Heart Failure Reports</i> , 2018, 15, 315-321.	3.3	17
208	Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. <i>The Lancet Global Health</i> , 2018, 6, e1008-e1018.	6.3	113
209	Cutting Edge of Brain Natriuretic Peptide (BNP) Research—The Diversity of BNP Immunoreactivity and Its Clinical Relevance. <i>Circulation Journal</i> , 2018, 82, 2455-2461.	1.6	22
210	Validating Left Ventricular Filling Pressure Measurements in Patients with Congestive Heart Failure: CardioMEMS, Pulmonary Arterial Diastolic Pressure versus Left Atrial Pressure Measurement by Transthoracic Echocardiography. <i>Cardiology Research and Practice</i> , 2018, 2018, 1-6.	1.1	9
211	Cardiorenal Syndrome Revisited. <i>Circulation</i> , 2018, 138, 929-944.	1.6	207
212	Neurohormonal Blockade. , 2018, , 459-476.		0
213	Current challenges in managing comorbid heart failure and COPD. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 653-673.	1.5	30
214	Electrical manipulation of the failing heart. <i>Heart Failure Reviews</i> , 2018, 23, 885-896.	3.9	2
215	Myocardial tissue engineering strategies for heart repair: current state of the art. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 27, 916-920.	1.1	14
216	Management of Pulmonary Hypertension. <i>Heart Failure Clinics</i> , 2018, 14, 545-551.	2.1	4
217	NT-proBNP-guided and conventional therapies did not differ for readmission or mortality in acute decompensated HF. <i>Annals of Internal Medicine</i> , 2018, 169, JC21.	3.9	1
218	Left bundle branch block and the evolving role of QRS morphology in selection of patients for cardiac resynchronization. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 52, 353-374.	1.3	5
219	Non-natriuretic peptide biomarkers in heart failure with preserved and reduced ejection fraction. <i>Biomarkers in Medicine</i> , 2018, 12, 783-797.	1.4	10
220	Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	26

#	ARTICLE	IF	CITATIONS
221	Role of ivabradine and heart rate lowering in chronic heart failure: guideline update. Expert Review of Cardiovascular Therapy, 2018, 16, 515-526.	1.5	4
222	Prognostic Significance of Baseline Serum Sodium in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2018, 7, .	3.7	23
223	Role of Aldosterone Receptor Antagonists in Heart Failure With Preserved Ejection Fraction. Clinical Medicine Insights Therapeutics, 2018, 10, 1179559X1877135.	0.4	1
224	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). American Journal of Cardiology, 2018, 122, 821-827.	1.6	3
225	Clinical Trials and Applications of Galectin Antagonists. Trends in Glycoscience and Glycotechnology, 2018, 30, SE211-SE220.	0.1	35
226	Effects of a multidisciplinary disease management programme with or without exercise training for heart failure patients: Secondary analysis of a randomized controlled trial. International Journal of Nursing Studies, 2018, 87, 94-102.	5.6	11
227	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e698-e800.	1.6	536
228	Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure. Laboratory Investigation, 2019, 99, 371-386.	3.7	77
229	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary. Journal of the American College of Cardiology, 2019, 73, 1494-1563.	2.8	452
230	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. Journal of the American College of Cardiology, 2019, 73, e81-e192.	2.8	595
231	2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations. Clinical Hypertension, 2019, 25, 19.	2.0	31
232	Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study. BMC Cardiovascular Disorders, 2019, 19, 194.	1.7	6
233	Iron deficiency in heart failure, an underdiagnosed and undertreated condition during hospitalization. Annals of Hematology, 2019, 98, 2293-2297.	1.8	19
234	Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach. Drugs, 2019, 79, 1543-1556.	10.9	11
235	Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach. Journal of the American Heart Association, 2019, 8, e012514.	3.7	39
236	Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales. Frontiers in Cardiovascular Medicine, 2019, 6, 110.	2.4	23
237	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertension Research, 2019, 42, 1235-1481.	2.7	1,047
238	Challenges in routine clinical chemistry analysis. , 2019, , 141-163.		9

#	ARTICLE	IF	CITATIONS
239	Vagus nerve stimulation for the treatment of heart failure. <i>Bioelectronics in Medicine</i> , 2019, 2, 43-54.	2.0	6
240	Use of speckle tracking to assess heart failure with preserved ejection fraction. <i>Journal of Cardiology</i> , 2019, 74, 397-402.	1.9	21
241	Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. <i>Korean Circulation Journal</i> , 2019, 49, 469.	1.9	18
242	Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure. <i>Circulation Research</i> , 2019, 125, 265-281.	4.5	54
243	The Use of Palliative Care in Organ Transplant Patients and End-of-Life Issues. , 2019, , 1053-1066.		0
244	Inflammasome inhibition blocks cardiac glycoside cell toxicity. <i>Journal of Biological Chemistry</i> , 2019, 294, 12846-12854.	3.4	15
245	External Validation of the ELANâ€”HF Score, Predicting 6â€”Month Allâ€”Cause Mortality in Patients Hospitalized for Acute Decompensated Heart Failure. <i>Journal of the American Heart Association</i> , 2019, 8, e010309.	3.7	5
246	Efficacy and Safety of Cryoballoon Ablation in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractionâ€”A Multicenter Study â€”. <i>Circulation Journal</i> , 2019, 83, 1653-1659.	1.6	22
247	Factors associated with exercise capacity in patients with a systemic right ventricle. <i>International Journal of Cardiology</i> , 2019, 292, 230-235.	1.7	13
249	Background pharmacological therapy in the ANTHEMâ€”HF: comparison to contemporary trials of novel heart failure therapies. <i>ESC Heart Failure</i> , 2019, 6, 1052-1056.	3.1	6
250	Percutaneous Mitral Valve Interventions (Repair): Current Indications and Future Perspectives. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 88.	2.4	29
251	Alteration of medical therapy in patients with heart failure relative to change in symptom severity. <i>ESC Heart Failure</i> , 2019, 6, 1085-1087.	3.1	2
252	Clinical and Physiologic Implications of Negative Cardiopulmonary Interactions in Coexisting Chronic Obstructive Pulmonary Disease-Heart Failure. <i>Clinics in Chest Medicine</i> , 2019, 40, 421-438.	2.1	20
253	Evaluation of Cardiac Metabolism by Magnetic Resonance Spectroscopy in Heart Failure. <i>Heart Failure Clinics</i> , 2019, 15, 421-433.	2.1	4
254	Clinical and Socioeconomic Predictors of Heart Failure Readmissions: A Review of Contemporary Literature. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1304-1320.	3.0	32
255	Renin Activity in Heart Failure with Reduced Systolic Functionâ€”New Insights. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3182.	4.1	31
256	Prognostic Value of the Echocardiographic Probability of Pulmonary Hypertension in Patients with Acute Decompensated Heart Failure. <i>Journal of Clinical Medicine</i> , 2019, 8, 1684.	2.4	5
257	Heart Failureâ€”Related Fatigue. <i>Journal for Nurse Practitioners</i> , 2019, 15, e181-e184.	0.8	4

#	ARTICLE	IF	CITATIONS
258	A Contemporary Systematic Approach to Assessing the Patient with Heart Failure with Reduced Ejection Fraction: Multimodal Noninvasive and Invasive Evaluation. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-12.	1.1	1
259	Therapeutic targeting of mitochondrial ROS ameliorates murine model of volume overload cardiomyopathy. <i>Journal of Pharmacological Sciences</i> , 2019, 141, 56-63.	2.5	8
260	Coapting Cost and Clinical Outcomes in Transcatheter Intervention for Secondary Mitral Regurgitation. <i>Circulation</i> , 2019, 140, 1892-1894.	1.6	1
261	Hypertension Treatment in Diabetes. <i>Heart Failure Clinics</i> , 2019, 15, 551-563.	2.1	4
262	Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. <i>ESC Heart Failure</i> , 2019, 6, 1233-1242.	3.1	13
263	Hybrid comprehensive telerehabilitation in heart failure patients (TELEREH-HF): A randomized, multicenter, prospective, open-label, parallel group controlled trialâ€”Study design and description of the intervention. <i>American Heart Journal</i> , 2019, 217, 148-158.	2.7	38
264	The Impact of Transitions of Care Pharmacist Services and Identification of Risk Predictors in Heart Failure Readmission. <i>Journal of Pharmacy Practice</i> , 2021, 34, 567-572.	1.0	5
265	Sex differences in cardiometabolic disorders. <i>Nature Medicine</i> , 2019, 25, 1657-1666.	30.7	244
266	Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction. <i>Disease Markers</i> , 2019, 2019, 1-12.	1.3	9
267	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. <i>Heart Failure Clinics</i> , 2019, 15, 519-530.	2.1	2
268	Cardiac Laboratory Markers. <i>Physician Assistant Clinics</i> , 2019, 4, 519-526.	0.1	0
269	Activity Sensors to Evaluate the Effect of Sacubitril/Valsartan on Quality of Life in Heart Failure: rationale and design of the AWAKE-HF study. <i>ESC Heart Failure</i> , 2019, 6, 1313-1321.	3.1	4
270	Are degree of urbanisation and travel times to healthcare services associated with the processes of care and outcomes of heart failure? A retrospective cohort study based on administrative data. <i>PLoS ONE</i> , 2019, 14, e0223845.	2.5	3
271	Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 152-154.	1.6	18
272	Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer. <i>Radiation Oncology</i> , 2019, 14, 155.	2.7	6
273	Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors. <i>Cardiovascular Therapeutics</i> , 2019, 2019, 1-6.	2.5	5
274	Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1077.	7.4	220
275	Angiotensin Receptorâ€”Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1051.	7.4	8

#	ARTICLE	IF	CITATIONS
276	Number of Cardiologists per Cardiovascular Beds and In-Hospital Mortality for Acute Heart Failure: A Nationwide Study in Japan. <i>Journal of the American Heart Association</i> , 2019, 8, e012282.	3.7	13
277	Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation. <i>IJC Heart and Vasculature</i> , 2019, 25, 100418.	1.1	27
278	Treating Patients Following Hospitalisation for Acute Decompensated Heart Failure: An Insight into Reducing Early Rehospitalisations. <i>Cardiac Failure Review</i> , 2019, 5, 78-82.	3.0	3
279	The Impending Epidemic of Cardiovascular Diseases in Patients With Cancer in Japan. <i>Circulation Journal</i> , 2019, 83, 2191-2202.	1.6	10
280	Cardiotoxicity from immune checkpoint inhibitors. <i>IJC Heart and Vasculature</i> , 2019, 25, 100420.	1.1	79
281	Intra-aortic balloon pump in acute chest pain and cardiogenic shock – a long-term follow-up. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 337-341.	1.2	0
282	Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10-Year Assessment. <i>Journal of the American Heart Association</i> , 2019, 8, e012065.	3.7	8
283	The Integral Role of Nurse Practitioners in Community Paramedicine. <i>Journal for Nurse Practitioners</i> , 2019, 15, 725-731.	0.8	4
284	The PARAGON-Heart failure trial – another disappointment for heart failure patients with hypertension and preserved ejection fraction. <i>Blood Pressure</i> , 2019, 28, 276-278.	1.5	0
285	Pharmacogenetics in Cardiovascular Diseases. , 2019, , 133-179.		3
286	The use of ECMO in ICU. Recommendations of the Spanish Society of Critical Care Medicine and Coronary Units. <i>Medicina Intensiva (English Edition)</i> , 2019, 43, 108-120.	0.2	1
287	Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients. <i>ESC Heart Failure</i> , 2019, 6, 241-253.	3.1	27
288	Different prognostic associations of beta-blockers and diuretics in heart failure with preserved ejection fraction with versus without high blood pressure. <i>Journal of Hypertension</i> , 2019, 37, 643-649.	0.5	7
289	In Vivo and In Vitro Effects of Vasopressin V2 Receptor Antagonism on Myocardial Fibrosis in Rats. <i>American Journal of the Medical Sciences</i> , 2019, 357, 151-159.	1.1	0
290	Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction – A report from the JASPER registry. <i>Journal of Cardiology</i> , 2019, 73, 459-465.	1.9	19
291	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2. <i>American Journal of Medicine</i> , 2019, 132, e599-e609.	1.5	10
292	“Drugs Do Not Work on Patients Who Do Not Take Them”-Can We Do Better in Patient Adherence?. <i>Journal of Cardiac Failure</i> , 2019, 25, 352-354.	1.7	1
293	Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin-angiotensin system in chronic heart failure? The culmination of a 20-year journey. <i>European Heart Journal</i> , 2019, 40, 3353-3355.	2.2	1

#	ARTICLE	IF	CITATIONS
294	Nonischemic Causes of Cardiogenic Shock. Emergency Medicine Clinics of North America, 2019, 37, 493-509.	1.2	3
295	Economic evaluations of pharmacist-led medication review in outpatients with hypertension, type 2 diabetes mellitus, and dyslipidaemia: a systematic review. European Journal of Health Economics, 2019, 20, 1103-1116.	2.8	11
296	NT-proBNP and postoperative heart failure in surgery for aortic stenosis. Open Heart, 2019, 6, e001063.	2.3	10
297	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006125.	3.9	21
298	Current and Future Considerations in the Use of Mechanical Circulatory Support Devices: An Update, 2008â€“2018. Annual Review of Biomedical Engineering, 2019, 21, 33-60.	12.3	5
299	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation, 2019, 140, e294-e324.	1.6	342
300	Effect of Peritoneal Dialysis on Serum Fibrosis Biomarkers in Patients with Refractory Congestive Heart Failure. International Journal of Molecular Sciences, 2019, 20, 2610.	4.1	3
301	Plasma renin levels are associated with cardiac function in primary adrenal insufficiency. Endocrine, 2019, 65, 399-407.	2.3	7
302	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	3.9	63
303	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation, 2019, 140, 529-537.	1.6	81
304	Economic evaluation of cardiac magnetic resonance with fast-SENC in the diagnosis and management of early heart failure. Health Economics Review, 2019, 9, 13.	2.0	8
305	Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 321, 2101.	7.4	47
306	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. Journal of Cardiac Failure, 2019, 25, 584-619.	1.7	56
307	Neurocognitive Disorders in Heart Failure: Novel Pathophysiological Mechanisms Underpinning Memory Loss and Learning Impairment. Molecular Neurobiology, 2019, 56, 8035-8051.	4.0	30
309	Change in indication for cardiac resynchronization therapy?. European Journal of Cardio-thoracic Surgery, 2019, 55, i11-i16.	1.4	8
310	Firstâ€“inâ€“human experience with occlusion of the superior vena cava to reduce cardiac filling pressures in congestive heart failure. Catheterization and Cardiovascular Interventions, 2019, 93, 1205-1210.	1.7	16
311	Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. BMC Nephrology, 2019, 20, 171.	1.8	15
312	Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. Journal of Nephrology, 2019, 32, 499-516.	2.0	63

#	ARTICLE	IF	CITATIONS
313	Heart Failure With Preserved Ejection Fraction In Perspective. Circulation Research, 2019, 124, 1598-1617.	4.5	500
314	Predicting postpartum cardiac events in pregnant women with complete atrioventricular block. Journal of Cardiology, 2019, 74, 347-352.	1.9	10
315	First-dose idarubicin cardiomyopathy: a case of new heart failure after induction chemotherapy for acute myeloid leukaemia. BMJ Case Reports, 2019, 12, e228149.	0.5	3
316	A perâ€protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region. ESC Heart Failure, 2019, 6, 758-763.	3.1	10
317	ARNi: A Novel Approach to Counteract Cardiovascular Diseases. International Journal of Molecular Sciences, 2019, 20, 2092.	4.1	25
318	3D echocardiographic global longitudinal strain can identify patients with mildly-to-moderately reduced ejection fraction at higher cardiovascular risk. International Journal of Cardiovascular Imaging, 2019, 35, 1573-1579.	1.5	5
319	Should we keep levosimendan in our pharmacies? Yes, undoubtedly!.. Anaesthesia, Critical Care & Pain Medicine, 2019, 38, 211-212.	1.4	0
320	A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice. Journal of Biological Chemistry, 2019, 294, 9760-9770.	3.4	32
321	ProBNP That Is Not Glycosylated at Threonine 71 Is Decreased with Obesity in Patients with Heart Failure. Clinical Chemistry, 2019, 65, 1115-1124.	3.2	29
322	Dynamic iron status after acute heart failure. Archives of Cardiovascular Diseases, 2019, 112, 410-419.	1.6	5
323	Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction. European Heart Journal, 2019, 40, 3318-3332.	2.2	39
324	Psychometric evaluation of the Heart Failure Somatic Perception Scale in a European heart failure population. European Journal of Cardiovascular Nursing, 2019, 18, 484-491.	0.9	12
325	Echocardiography and cancer therapeutics-related cardiac dysfunction. Journal of Medical Ultrasonics (2001), 2019, 46, 309-316.	1.3	5
326	Understanding and Measuring Symptom Burden in Heart Failure: A Concept Analysis. Western Journal of Nursing Research, 2019, 41, 1423-1447.	1.4	5
327	Regulatory approval review of transcatheter mitral valve repair â€“ Difference in the indication between the USA and Japan. Journal of Cardiology, 2019, 74, 13-18.	1.9	3
328	Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES). BMC Cardiovascular Disorders, 2019, 19, 76.	1.7	28
329	Is rhythm control superior to rate control in patients with heart failure and preserved ejection fraction?. Journal of Cardiology, 2019, 74, 233-234.	1.9	0
331	Availability and delivery of cardiac rehabilitation in the Eastern Mediterranean Region: How does it compare globally?. International Journal of Cardiology, 2019, 285, 147-153.	1.7	11

#	ARTICLE	IF	CITATIONS
332	Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There is Meat on the Bone. <i>Journal of Clinical Medicine</i> , 2019, 8, 270.	2.4	44
333	RNA sequencing discloses the genome-wide profile of long noncoding RNAs in dilated cardiomyopathy. <i>Molecular Medicine Reports</i> , 2019, 19, 2569-2580.	2.4	8
334	Right Ventricular Size and Function in Chronic Heart Failure. <i>Heart Failure Clinics</i> , 2019, 15, 205-217.	2.1	8
335	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1264-1272.	2.8	139
336	Incident anaemia in older adults with heart failure: rate, aetiology, and association with outcomes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 361-369.	4.0	11
337	The relationship between coronary artery disease and cardiovascular events early after liver transplantation. <i>Liver International</i> , 2019, 39, 1363-1371.	3.9	30
338	Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e840-e878.	1.6	619
339	Increasing the Adoption and Diffusion of a Novel Pharmacological Therapy That Is Both Mortality Reducing and Cost-Effective. <i>Journal of the American Heart Association</i> , 2019, 8, e011783.	3.7	7
340	Heart failure readmissions: a losing battle or an opportunity for improvement?. <i>Postgraduate Medicine</i> , 2019, 131, 182-184.	2.0	3
341	Protecting the Evidence Base in a Predatory Environment. <i>Journal of Cardiovascular Nursing</i> , 2019, 34, 4-5.	1.1	0
342	Perindopril and a Galectin-3 Inhibitor Improve Ischemic Heart Failure in Rabbits by Reducing Gal-3 Expression and Myocardial Fibrosis. <i>Frontiers in Physiology</i> , 2019, 10, 267.	2.8	26
343	Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. <i>Circulation</i> , 2019, 139, 2285-2288.	1.6	129
344	Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction—The CIBIS-J Trial. <i>Circulation Journal</i> , 2019, 83, 1269-1277.	1.6	10
345	Cardiovascular profile and biophysical profile scores predict short-term prognosis in infants with congenital heart defect. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 1268-1276.	1.3	5
346	Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. <i>Cardio-Oncology</i> , 2019, 5, 1.	1.7	54
347	Mechanisms of cardiac collagen deposition in experimental models and human disease. <i>Translational Research</i> , 2019, 209, 138-155.	5.0	51
348	Epidemiological Aspects (Prevalence and Risk of Heart Failure Related to Blood Pressure). <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 3-11.	0.1	0
349	Biomarkers. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 199-213.	0.1	0

#	ARTICLE	IF	CITATIONS
350	Arterial Hypertension and Flash Pulmonary Edema. Updates in Hypertension and Cardiovascular Protection, 2019, , 231-244.	0.1	0
351	Inotropes and Vasoactive Agents: Differences Between Europe and the United States. Current Anesthesiology Reports, 2019, 9, 202-213.	2.0	1
352	Hyperkalemia Is Associated With Increased Mortality Among Unselected Cardiac Intensive Care Unit Patients. Journal of the American Heart Association, 2019, 8, e011814.	3.7	25
353	The Three Rs for Preventing Heart Failure Readmission: Review, Reassess, and Reeducate. Critical Care Nurse, 2019, 39, 85-93.	1.0	13
354	Prognostic significance of high-sensitivity cardiac troponin in patients with heart failure with preserved ejection fraction. Heart and Vessels, 2019, 34, 1650-1656.	1.2	18
355	Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II). Revista Espanola De Cardiologia (English Ed), 2019, 72, 1020-1030.	0.6	0
356	Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction. BMC Cardiovascular Disorders, 2019, 19, 83.	1.7	32
357	Cardiac troponins as biomarkers for cardiac disease. Biomarkers in Medicine, 2019, 13, 325-330.	1.4	28
358	Optimal blood pressure targets for patients with hypertension: a systematic review and meta-analysis. Hypertension Research, 2019, 42, 483-495.	2.7	31
359	Effects of blood pressure lowering in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. Hypertension Research, 2019, 42, 504-513.	2.7	15
360	Imaging Challenges in Tricuspid Regurgitation and Right Ventricular Failure. JACC: Cardiovascular Imaging, 2019, 12, 768-770.	5.3	2
361	Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction. Journal of Clinical Medicine, 2019, 8, 262.	2.4	43
362	Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities. Irish Journal of Medical Science, 2019, 188, 1169-1174.	1.5	2
363	Trending Towards Safer Breast Cancer Surgeries? Examining Acute Complication Rates from A 13-Year NSQIP Analysis. Cancers, 2019, 11, 253.	3.7	31
364	A mouse model of heart failure exhibiting pulmonary edema and pleural effusion: Useful for testing new drugs. Journal of Pharmacological and Toxicological Methods, 2019, 96, 78-86.	0.7	4
365	Empagliflozin Targeting the Real-World Heart Failure Population. Journal of Cardiac Failure, 2019, 25, 218-219.	1.7	1
366	Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors. Scandinavian Cardiovascular Journal, 2019, 53, 14-20.	1.2	5
367	Heart Failure Care Dyadic Typology. Journal of Cardiovascular Nursing, 2019, 34, 159-165.	1.1	34

#	ARTICLE	IF	CITATIONS
368	Impact of Hospice and Palliative Care Service Utilization on All-Cause 30-Day Readmission Rate for Older Adults Hospitalized with Heart Failure. American Journal of Hospice and Palliative Medicine, 2019, 36, 623-629.	1.4	3
369	Medication-Taking Behaviors and Perceptions Among Adults With Heart Failure (from the REasons for Tj ETQq1 1 0.784314 rgBT /Overl 1667-1674.	1.6	2
370	An update on the CardioMEMS pulmonary artery pressure sensor. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471982682.	2.1	22
371	Temporal Patterns of 14 Blood Biomarker candidates of Cardiac Remodeling in Relation to Prognosis of Patients With Chronic Heart Failureâ€”The Bioâ€”HiFT Study. Journal of the American Heart Association, 2019, 8, e009555.	3.7	27
372	Efficacy and safety of iron supplementation in patients with heart failure and iron deficiency: a meta-analysis. British Journal of Nutrition, 2019, 121, 841-848.	2.3	11
373	Mitophagy Is Essential for Maintaining Cardiac Function During High Fat Diet-Induced Diabetic Cardiomyopathy. Circulation Research, 2019, 124, 1360-1371.	4.5	306
374	A post-surgical adjunctive hypoxic therapy for myocardial infarction: Initiate endogenous cardiomyocyte proliferation in adults. Medical Hypotheses, 2019, 125, 16-20.	1.5	8
375	The Role of Troponin for Acute Heart Failure. Current Heart Failure Reports, 2019, 16, 21-31.	3.3	20
376	Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. Cardiovascular Research, 2019, 115, 922-934.	3.8	77
377	Cardiac and Neuromuscular Features of Patients With<i>LMNA</i>-Related Cardiomyopathy. Annals of Internal Medicine, 2019, 171, 458.	3.9	33
378	Optimisation of diagnosis and treatment of heart failure in a primary care setting. BMJ Open Quality, 2019, 8, e000660.	1.1	6
379	Efficacy and Safety of Fuzi Formulae on the Treatment of Heart Failure as Complementary Therapy: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-21.	1.2	8
380	Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoadsorption Treatment in Dilated Cardiomyopathy. Biomolecules, 2019, 9, 654.	4.0	6
381	Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure. The Cochrane Library, 2019, 10, CD013015.	2.8	7
382	<p>Analysis Of Re-Hospitalizations For Patients With Heart Failure Caused By Coronary Heart Disease: Data Of First Event And Recurrent Event</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1333-1341.	2.0	5
383	Cardiac Biomarkers Predict Long-term Survival After Cardiac Surgery. Annals of Thoracic Surgery, 2019, 108, 1776-1782.	1.3	9
384	Anthracycline Cardiotoxicity. Cardiology Clinics, 2019, 37, 355-363.	2.2	6
385	Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan. Circulation: Heart Failure, 2019, 12, e005691.	3.9	7

#	ARTICLE	IF	CITATIONS
386	Impact of Autonomic Regulation Therapy in Patients with Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005879.	3.9	50
387	Renin-angiotensin-aldosterone system and kidney interactions in heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2019, 20, 147032031988941.	1.7	6
388	Implantable device monitoring versus usual care for managing individuals with heart failure. <i>The Cochrane Library</i> , 2019, .	2.8	0
389	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , 2019, 42, 2298-2306.	8.6	157
390	Utility of Urine Biomarkers and Electrolytes for the Management of Heart Failure. <i>Current Heart Failure Reports</i> , 2019, 16, 240-249.	3.3	12
391	Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes. <i>Scientific Reports</i> , 2019, 9, 20168.	3.3	10
392	Heart failure with preserved ejection fraction: present status and future directions. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-9.	7.7	46
393	Managing hypertension in patients with heart failure. <i>Current Opinion in Cardiology</i> , 2019, 34, 359-366.	1.8	6
394	Towards Point-of-Care Heart Failure Diagnostic Platforms: BNP and NT-proBNP Biosensors. <i>Sensors</i> , 2019, 19, 5003.	3.8	38
395	Accuracy of left ventricular ejection fraction determined by automated analysis of handheld echocardiograms: A comparison of experienced and novice examiners. <i>Echocardiography</i> , 2019, 36, 2145-2151.	0.9	18
396	Role of Palliative Care in the Outpatient Management of the Chronic Heart Failure Patient. <i>Current Heart Failure Reports</i> , 2019, 16, 220-228.	3.3	12
397	Clinical Features of Patients With Acute Aortic Dissection After an Earthquake: Experience from the Kumamoto Earthquake 2016. <i>American Journal of Hypertension</i> , 2020, 33, 261-268.	2.0	6
398	Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making. <i>Current Heart Failure Reports</i> , 2019, 16, 274-284.	3.3	10
399	Monitoring for sleep-disordered breathing in heart failure. <i>European Heart Journal Supplements</i> , 2019, 21, M36-M39.	0.1	2
400	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failureâ€• Digest Version â€•. <i>Circulation Journal</i> , 2019, 83, 2084-2184.	1.6	446
401	Hypertension in Cancer Patients andÂSurvivors. <i>JACC: CardioOncology</i> , 2019, 1, 238-251.	4.0	68
402	Atrial Fibrillationâ€•Mediated Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007809.	4.8	26
403	Update in recent clinical trials in heart failure. <i>Current Opinion in Cardiology</i> , 2019, 34, 307-314.	1.8	2

#	ARTICLE	IF	CITATIONS
404	Evolving Use of Biomarkers in the Management of Heart Failure. <i>Cardiology in Review</i> , 2019, 27, 153-159.	1.4	16
405	How much drug-induced blood pressure reduction is effective and safe in heart failure?. <i>Journal of Hypertension</i> , 2019, 37, 1786-1787.	0.5	0
406	The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 447-451.	1.4	9
407	Cardiogenic pulmonary edema: mechanisms and treatment - an intensivist's view. <i>Current Opinion in Critical Care</i> , 2019, 25, 371-378.	3.2	18
408	Hemodynamic effects of inotropic drugs in heart failure. <i>Medicine (United States)</i> , 2019, 98, e18144.	1.0	1
409	Blended Collaborative Care to Treat Heart Failure and Comorbid Depression: Rationale and Study Design of the Hopeful Heart Trial. <i>Psychosomatic Medicine</i> , 2019, 81, 495-505.	2.0	17
410	Immune checkpoint inhibitor myocarditis. <i>Current Opinion in Cardiology</i> , 2019, 34, 303-306.	1.8	13
411	Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2019, 21, 68.	4.7	20
412	Improving the accuracy of heart failure diagnosis in low-resource settings through task sharing and decentralization. <i>Global Health Action</i> , 2019, 12, 1684070.	1.9	15
413	Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes. <i>FASEB Journal</i> , 2019, 33, 1209-1225.	0.5	28
414	Acute cardiac dyspnea in the emergency department: diagnostic value of N-terminal prohormone of brain natriuretic peptide and galectin-3. <i>Journal of International Medical Research</i> , 2019, 47, 159-172.	1.0	5
415	Is the ratio of pulmonary artery to aortic diameter akin to heart failure's hemoglobin A1c?. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 104-106.	0.6	0
416	Getting to the Heart of the Matter: A Regional Survey of Current Hospice Practices Caring for Patients With Heart Failure Receiving Advanced Therapies. <i>American Journal of Hospice and Palliative Medicine</i> , 2019, 36, 55-59.	1.4	7
417	Comparison between inferior vena cava ultrasound, lung ultrasound, bioelectric impedance analysis, and natriuretic peptides in chronic heart failure. <i>Current Medical Research and Opinion</i> , 2019, 35, 705-713.	1.9	25
418	Loop diuretics in chronic heart failure: how to manage congestion?. <i>Heart Failure Reviews</i> , 2019, 24, 17-30.	3.9	15
419	The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 20-36.	2.4	32
420	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e637-e697.	1.6	225
421	Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. <i>Clinical Cardiology</i> , 2019, 42, 277-284.	1.8	15

#	ARTICLE	IF	CITATIONS
422	Key Articles and Guidelines in the Management of Heart Failure: 2018 Update. Journal of Pharmacy Practice, 2019, 32, 77-92.	1.0	7
423	Corticotropin-Releasing Hormone Family and Their Receptors in the Cardiovascular System. Circulation Journal, 2019, 83, 261-266.	1.6	16
424	Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Failure Reviews, 2019, 24, 167-176.	3.9	57
425	Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis. International Journal of Cardiology, 2019, 280, 110-116.	1.7	33
426	Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. Advances in Therapy, 2019, 36, 298-317.	2.9	18
427	Left Ventricular End-Systolic Volume Can Predict 1-Year Hierarchical Clinical Composite End Point in Patients with Cardiac Resynchronization Therapy. Yonsei Medical Journal, 2019, 60, 48.	2.2	8
428	Contemporary Treatment of Heart Failure. Cardiac Electrophysiology Clinics, 2019, 11, 21-37.	1.7	3
429	No longer failing to treat heart failure. JAAPA: Official Journal of the American Academy of Physician Assistants, 2019, 32, 11-15.	0.3	1
430	Moving galectin-3 closer to the goal line. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H580-H582.	3.2	2
431	Inside OUES: fact or fiction?. European Journal of Preventive Cardiology, 2019, 26, 174-176.	1.8	4
432	Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction. IJC Heart and Vasculature, 2019, 22, 1-5.	1.1	19
433	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 347-357.	27.0	4,159
434	Angiotensinâ€“Neprilysin Inhibition in Acute Decompensated Heart Failure. New England Journal of Medicine, 2019, 380, 539-548.	27.0	848
435	Evaluation of analytical performances using standardized analytical protocols and comparison of clinical results of the new ADVIA BNP and NT-proBNP immunoassays for the Centaur XPT platform. Clinical Chemistry and Laboratory Medicine, 2019, 57, 911-917.	2.3	3
436	Relation between prognostic impact of hyperuricemia and sympathetic overactivation in patients with heart failure. Journal of Cardiology, 2019, 73, 233-239.	1.9	4
437	Utility of strain imaging in conjunction with heart failure stage classification for heart failure patient management. Journal of Echocardiography, 2019, 17, 17-24.	0.8	22
438	Breast Cancer and Heart Failure. Heart Failure Clinics, 2019, 15, 65-75.	2.1	10
439	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2018. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 2-11.	1.3	5

#	ARTICLE	IF	CITATIONS
440	Management in the Postanesthesia Care Unit of Complications in Cardiac Patients. , 2019, , 510-525.		0
441	Heart Failure with Preserved Ejection Fraction in Women. Heart Failure Clinics, 2019, 15, 9-18.	2.1	33
442	Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H289-H297.	3.2	15
443	Multistep virtual screening for rapid identification of G Protein-Coupled Receptors Kinase 2 inhibitors for heart failure treatment. Chemometrics and Intelligent Laboratory Systems, 2019, 185, 32-40.	3.5	9
444	Chronic Heart Failure: Impact of the Current Guidelines. Journal for Nurse Practitioners, 2019, 15, 125-131.e2.	0.8	0
445	Prediction of incident heart failure by serum amino-terminal pro-B-type natriuretic peptide level in a community-based cohort. European Journal of Heart Failure, 2019, 21, 449-459.	7.1	21
446	Empleo de ECMO en UCI. Recomendaciones de la Sociedad Española de Medicina Intensiva Crítica y Unidades Coronarias. Medicina Intensiva, 2019, 43, 108-120.	0.7	27
447	The 3A3B score: The simple risk score for heart failure with preserved ejection fraction - A report from the CHART-2 Study. International Journal of Cardiology, 2019, 284, 42-49.	1.7	19
448	Evidence of aldosterone synthesis in human myocardium in acute myocarditis. International Journal of Cardiology, 2019, 275, 114-119.	1.7	6
449	Rapid 5-lb weight gain is not associated with readmission in patients with heart failure. ESC Heart Failure, 2019, 6, 131-137.	3.1	6
450	Discrepant myocardial microvascular perfusion and mechanics after acute myocardial infarction: Characterization of the "Tako-tsubo effect" with real-time myocardial perfusion contrast echocardiograph. International Journal of Cardiology, 2019, 276, 1-7.	1.7	7
451	Medication dosing for heart failure with reduced ejection fraction " opportunities and challenges. European Journal of Heart Failure, 2019, 21, 286-296.	7.1	57
452	Contemporary Management of Heart Failure in the Elderly. Drugs and Aging, 2019, 36, 137-146.	2.7	8
453	Influenza Vaccine in Heart Failure. Circulation, 2019, 139, 575-586.	1.6	114
454	Arterial Hypertension. Contemporary Cardiology, 2019, , 21-38.	0.1	0
455	Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertension Research, 2019, 42, 293-300.	2.7	47
456	Adherence to guidelines in management of symptoms suggestive of heart failure in primary care. Heart, 2019, 105, 678-685.	2.9	34
457	Transfusion-associated circulatory overload" a systematic review of diagnostic biomarkers. Transfusion, 2019, 59, 795-805.	1.6	22

#	ARTICLE	IF	CITATIONS
458	Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. <i>Circulation</i> , 2019, 139, 1354-1365.	1.6	233
459	Updates in heart failure 30-day readmission prevention. <i>Heart Failure Reviews</i> , 2019, 24, 177-187.	3.9	37
460	Association Between Functional Impairment and Medication Burden in Adults with Heart Failure. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 284-291.	2.6	24
461	Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2019, 123, 187-195.	1.6	9
462	Evaluation of a Pharmacist-Driven Aldosterone Antagonist Stewardship Program in Patients With Heart Failure. <i>Journal of Pharmacy Practice</i> , 2019, 32, 158-162.	1.0	2
463	Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. <i>Acta Cardiologica</i> , 2019, 74, 100-107.	0.9	21
464	Impact of telemedicine on the clinical outcomes and healthcare costs of patients with chronic heart failure and mid-range or preserved ejection fraction managed in a multidisciplinary chronic heart failure programme: A sub-analysis of the iCOR randomized trial. <i>Journal of Telemedicine and Telecare</i> , 2020, 26, 64-72.	2.7	38
465	Sacubitril/Valsartan in Adult Congenital Heart Disease Patients With Chronic Heart Failure â A Single Centre Case Series and Call for an International Registry. <i>Heart Lung and Circulation</i> , 2020, 29, 137-141.	0.4	31
466	Stem cell therapy in heart failure: Where do we stand today?. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165489.	3.8	28
467	Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. <i>European Heart Journal</i> , 2020, 41, 1764-1774.	2.2	11
468	Impact of chronic kidney disease on in-hospital outcomes following left ventricular assist device placement: A national perspective. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 48-53.	1.6	5
469	Editorial commentary: Acute heart failure: A patient's curse or a provider's opportunity?. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 113-114.	4.9	0
470	Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report. <i>Journal of Pharmacy Practice</i> , 2020, 33, 553-557.	1.0	4
471	Antihypertensive treatment for hypertensive patients with heart failure using real-world Japanese data: subanalysis of the Retrospective study of antihypertensives for lowering blood pressure (REAL) study. <i>Clinical and Experimental Hypertension</i> , 2020, 42, 139-145.	1.3	2
473	Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 269-279.	2.1	9
474	Adherence to heart failure management medications following cardiac resynchronization therapy. <i>Current Medical Research and Opinion</i> , 2020, 36, 199-207.	1.9	3
475	Beta-blockers in heart failure patients with severe chronic kidney diseaseâtime for a randomized controlled trial?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 728-731.	0.7	1
476	Echocardiographic evaluation of the effects of sacubitrilâvalsartan on vascular properties in heart failure patients. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 271-278.	1.5	4

#	ARTICLE	IF	CITATIONS
477	A Compelling Case for Less Aggressive Arrhythmia Management in Patients With Chronic Heart Failure and Long-Standing Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2020, 26, 85-92.	1.7	3
478	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , 2020, 220, 41-50.	2.7	22
479	Potassium Binders for Hyperkalemia in Chronic Kidney Disease—Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis. <i>Mayo Clinic Proceedings</i> , 2020, 95, 339-354.	3.0	64
480	Cardiovascular Disease and Chronic Kidney Disease. , 2020, , 337-353.		0
481	A value proposition for natriuretic peptide measurement in the assessment of patients with suspected acute heart failure. <i>Clinica Chimica Acta</i> , 2020, 500, 98-103.	1.1	9
482	Emerging role of mitophagy in cardiovascular physiology and pathology. <i>Molecular Aspects of Medicine</i> , 2020, 71, 100822.	6.4	114
483	The selection of β -blocker after successful reperfusion in patients with ST-elevation myocardial infarction. <i>Perfusion (United Kingdom)</i> , 2020, 35, 338-347.	1.0	0
484	Angiotensin Receptor Blockers Effect on Serum Uric Acid—A Class Effect?. <i>Journal of Pharmacy Practice</i> , 2020, 33, 874-881.	1.0	8
485	Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. , 2020, , 520-548.		0
486	Heart Failure as a Consequence of Dilated Cardiomyopathy. , 2020, , 269-287.e2.		1
487	Cardiac Imaging in Heart Failure. , 2020, , 418-448.e5.		0
488	Neuromodulation in Heart Failure. , 2020, , 608-616.e2.		0
489	Decision Making and Palliative Care in Advanced Heart Failure. , 2020, , 705-718.e3.		0
490	Disease Prevention in Heart Failure. , 2020, , 487-500.e4.		0
491	Quality and Outcomes in Heart Failure. , 2020, , 697-704.e2.		0
492	Structural and myocardial dysfunction in heart failure beyond ejection fraction. <i>Heart Failure Reviews</i> , 2020, 25, 9-17.	3.9	32
493	Biomarkers in Heart Failure With Preserved Ejection Fraction: An Update on Progress and Future Challenges. <i>Heart Lung and Circulation</i> , 2020, 29, 62-68.	0.4	18
494	Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials. <i>Clinical Research in Cardiology</i> , 2020, 109, 194-204.	3.3	19

#	ARTICLE	IF	CITATIONS
495	The effectiveness of cardiac rehabilitation in non-ischemic dilated cardiomyopathy patients: A pilot study. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 627-634.	1.7	5
496	Hypertension and Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 99-106.	2.1	87
497	Sex Differences in Takotsubo Syndrome: A Narrative Review. <i>Journal of Women's Health</i> , 2020, 29, 1122-1130.	3.3	14
498	Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure. <i>International Journal of Cardiology</i> , 2020, 304, 116-121.	1.7	7
499	Risk factors associated with biochemically detected and hospitalised acute kidney injury in patients prescribed renin angiotensin system inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 121-131.	2.4	5
500	An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 131-132.	1.9	0
501	Predicting adults likely to develop heart failure using readily available clinical information. <i>Preventive Medicine</i> , 2020, 130, 105878.	3.4	7
502	Preventive Cardio-Oncology: The Time Has Come. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 187.	2.4	34
503	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 401.	6.1	51
504	A quality control system for ligand-binding assay of plasma renin activity: Proof-of-concept within a pharmacodynamic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 181, 113090.	2.8	2
505	ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. <i>Breast</i> , 2020, 49, 183-186.	2.2	9
506	Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 26-34.	4.5	40
507	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 338-351.	1.6	244
508	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020, 141, 352-361.	1.6	335
509	Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2020, 125, 643-650.	1.6	10
510	Iron deficiency in heart failure: getting to the guidelines. <i>Current Opinion in Cardiology</i> , 2020, 35, 133-137.	1.8	5
512	Clinical evaluation of capillary B-type natriuretic peptide testing. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 618-624.	2.3	0
513	Potassium binding for conservative and preservative management of chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 29-38.	2.0	5

#	ARTICLE	IF	CITATIONS
514	Effect of Heart Rate Reserve on Exercise Capacity in Patients Treated with a Continuous Left Ventricular Assist Device. <i>ASAIO Journal</i> , 2020, 66, 160-165.	1.6	11
515	Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 202.	6.1	57
516	Bioanalytical Assessment of Plasma Concentrations of Angiotensin-Converting Enzyme II Inhibitors and Angiotensin Receptor Blockers: A Pilot Study Among Patients Hospitalized With Acute Heart Failure. <i>American Journal of Therapeutics</i> , 2020, 27, e366-e370.	0.9	0
517	Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 258-263.	2.0	2
518	B-type natriuretic peptide and its role in altering Ca ²⁺ -regulatory proteins in heart failure—mechanistic insights. <i>Heart Failure Reviews</i> , 2020, 25, 861-871.	3.9	1
519	Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. <i>European Journal of Heart Failure</i> , 2020, 22, 303-312.	7.1	52
520	Iron and heart failure. <i>Revista Clínica Española</i> , 2020, 220, 43-48.	0.5	0
521	Comprehensive heart failure assessment: A challenge to modify the course of heart failure. <i>European Journal of Internal Medicine</i> , 2020, 71, 8-10.	2.2	2
522	Medical Therapies for Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2020, 75, 23-32.	2.7	61
523	Contemporary approach to treating heart failure. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 507-518.	4.9	9
524	Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 370-384.	1.9	16
525	Incidence, Predictors, and Impact on Survival of Long-term Cardiovascular Events After Liver Transplantation. <i>Transplantation</i> , 2020, 104, 317-325.	1.0	14
526	Differences in medical treatment and clinical characteristics between men and women with heart failure – a single-centre multivariable analysis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 539-546.	1.9	11
527	Feasibility, Effectiveness and Safety of Prehospital Intravenous Bolus Dose Nitroglycerin in Patients with Acute Pulmonary Edema. <i>Prehospital Emergency Care</i> , 2020, 24, 844-850.	1.8	5
528	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e007829.	3.9	18
529	Secondary Mitral Regurgitation. <i>New England Journal of Medicine</i> , 2020, 383, 1458-1467.	27.0	35
530	Endogenous CCN5 Participates in Angiotensin II/TGF- β 1 Networking of Cardiac Fibrosis in High Angiotensin II-Induced Hypertensive Heart Failure. <i>Frontiers in Pharmacology</i> , 2020, 11, 1235.	3.5	16
531	Circulating exosomal <sc>microRNAs</sc> as emerging non-invasive clinical biomarkers in heart failure: Mega bio-roles of a nano bio-particle. <i>IUBMB Life</i> , 2020, 72, 2546-2562.	3.4	26

#	ARTICLE	IF	CITATIONS
532	Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 445-451.	1.9	14
533	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1067-1076.	2.6	40
534	Use of potassium-binder patiomer for up-titration of renin-angiotensin-aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-4.	0.6	2
535	A novel risk score to predict cardiovascular complications in patients with coronavirus disease 2019 (COVID-19): A retrospective, multicenter, observational study. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 638-649.	2.7	7
536	Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. <i>Cell Metabolism</i> , 2020, 32, 537-547.e3.	16.2	116
537	Multidisciplinary Cardiac Rehabilitation and Long-Term Prognosis in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006798.	3.9	112
538	Beta Blockade in Patients After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020, 136, 170-171.	1.6	0
539	Implementation of a Disease Management Program in Adult Patients With Heart Failure. <i>Professional Case Management</i> , 2020, 25, 312-323.	0.4	8
540	A manifesto of collaborative longitudinal cardiovascular care in heart failure. <i>Heart Failure Reviews</i> , 2020, 25, 1089-1097.	3.9	2
541	Automated quantitative analysis of CZT SPECT stratifies cardiovascular risk in the obese population: Analysis of the REFINE SPECT registry. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 727-736.	2.1	11
542	Experimental model of congestive heart failure induced by transverse aortic constriction in BALB/c mice. <i>Journal of Pharmacological and Toxicological Methods</i> , 2020, 106, 106935.	0.7	6
543	Predictive Accuracy of Heart Failure-Specific Risk Equations in an Electronic Health Record-Based Cohort. <i>Circulation: Heart Failure</i> , 2020, 13, e007462.	3.9	17
544	Polygenic Score for β -Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e007012.	3.9	18
545	Clinical Implications of the Genetic Architecture of Dilated Cardiomyopathy. <i>Current Cardiology Reports</i> , 2020, 22, 170.	2.9	7
546	Exercise and Cognitive Training Intervention Improves Self-Care, Quality of Life and Functional Capacity in Persons With Heart Failure. <i>Journal of Applied Gerontology</i> , 2022, 41, 486-495.	2.0	6
547	Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study. <i>Cardiology and Therapy</i> , 2020, 9, 505-521.	2.6	2
548	Implications of obesity across the heart failure continuum. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 561-569.	3.1	43
549	Effect of patiomer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 656-661.	3.1	4

#	ARTICLE	IF	CITATIONS
550	Update of Pediatric Heart Failure. <i>Pediatric Clinics of North America</i> , 2020, 67, 889-901.	1.8	9
552	Interatrial shunt devices for the treatment of heart failure. <i>Trends in Cardiovascular Medicine</i> , 2020, 31, 427-432.	4.9	10
553	Evaluating the diagnostic and prognostic value of biomarkers for heart disease and major adverse cardiac events in patients with muscular dystrophy. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 564-573.	4.0	8
554	Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure. <i>Advances in Therapy</i> , 2020, 37, 3839-3849.	2.9	1
555	Spleen size improvement in advanced heart failure patients using a left ventricular assist device. <i>Artificial Organs</i> , 2020, 44, 700-708.	1.9	8
556	Heart failure-induced atrial remodelling promotes electrical and conduction alternans. <i>PLoS Computational Biology</i> , 2020, 16, e1008048.	3.2	5
557	Recurrent hospitalizations are associated with increased mortality across the ejection fraction range in heart failure. <i>ESC Heart Failure</i> , 2020, 7, 2406-2417.	3.1	24
558	Left Ventricular End-Systolic Volume Is a Reliable Predictor of New-Onset Heart Failure with Preserved Left Ventricular Ejection Fraction. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-7.	1.1	6
559	The Regulatory Role of T Cell Responses in Cardiac Remodeling Following Myocardial Infarction. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5013.	4.1	27
560	Vascular Endothelial Growth Factor (VEGF) Inhibitor Cardiotoxicity: What Should We Know?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.9	0
561	An Electronically delivered, Patient-activation tool for Intensification of medications for Chronic Heart Failure with reduced ejection fraction: Rationale and design of the EPIC-HF trial. <i>American Heart Journal</i> , 2020, 229, 144-155.	2.7	5
562	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2020, 142, e558-e631.	1.6	263
563	Guideline-directed medical therapy in heart failure patients: impact of focused care provided by a heart failure clinic in comparison to general cardiology out-patient department. <i>Egyptian Heart Journal</i> , 2020, 72, 53.	1.2	5
564	Recent Advances in β_2 -Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15218-15242.	6.4	8
565	Diagnosis and treatment of right ventricular dysfunction in congenital heart disease. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1625-1645.	1.7	11
566	The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives. <i>Journal of Human Hypertension</i> , 2020, 35, 1029-1037.	2.2	10
568	Intravenous iron in heart failure and chronic kidney disease. <i>Nefrologia</i> , 2021, 41, 403-411.	0.4	2
569	Early Mobilization in Older Adults with Acute Cardiovascular Disease. <i>Age and Ageing</i> , 2021, 50, 1166-1172.	1.6	5

#	ARTICLE	IF	CITATIONS
570	The efficacy of baroreflex activation therapy for heart failure. <i>Medicine (United States)</i> , 2020, 99, e22951.	1.0	4
571	Predictive Factors on the Incidence of Heart Failure in Patients with Ischemic Heart Disease: Using a 10-Year Population-Based Korea National Health Insurance Cohort Data. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8670.	2.6	0
572	Heart failure in the last year: progress and perspective. <i>ESC Heart Failure</i> , 2020, 7, 3505-3530.	3.1	52
573	Circulating Circular RNAs: Novel Biomarkers for Heart Failure. <i>Frontiers in Pharmacology</i> , 2020, 11, 560537.	3.5	13
574	Crossing the chasm: caution for use of angiotensin receptor-neprilysin inhibition in patients with cardiogenic shock—a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-4.	0.6	3
575	Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. <i>Circulation: Heart Failure</i> , 2020, 13, e006605.	3.9	55
576	Effect of an Early Palliative Care Telehealth Intervention vs Usual Care on Patients With Heart Failure. <i>JAMA Internal Medicine</i> , 2020, 180, 1203.	5.1	72
577	Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 682-687.	1.5	10
578	Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials. <i>Diabetes Therapy</i> , 2020, 11, 1925-1934.	2.5	15
579	Stakeholder Engagement for a Planned Automated Quality Measurement System. <i>SAGE Open</i> , 2020, 10, 215824402091945.	1.7	0
580	Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan. <i>ESC Heart Failure</i> , 2020, 7, 3003-3012.	3.1	11
581	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and Glomerular Filtration Rate in Patients With Acute Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 123.	2.4	6
582	Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 475-485.	1.5	4
583	Empowering People Living with Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 409-420.	2.1	4
584	Predictive Markers of Atrial Fibrillation in Patients with Transient Ischemic Attack. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104643.	1.6	3
585	Important Implications on the Use of Beta-Blockers for Nurse Practitioners and Clinicians. <i>Journal for Nurse Practitioners</i> , 2020, 16, 706-707.	0.8	0
586	Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 488.	7.4	391
587	Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2020, 9, e015738.	3.7	10

#	ARTICLE	IF	CITATIONS
588	Extracellular Superoxide Dismutase Is Associated With Left Ventricular Geometry and Heart Failure in Patients With Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e016862.	3.7	19
589	Clinical Implications of Hepatic Hemodynamic Evaluation by Abdominal Ultrasonographic Imaging in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e016689.	3.7	11
590	Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have no effect on the outcomes of endovascular revascularization in tibial arterial occlusive disease. <i>Vascular Pharmacology</i> , 2020, 131, 106764.	2.1	1
591	Association between compliance with quality indicators and hospitalisation expenses in patients with heart failure: a retrospective study using quantile regression model in China. <i>BMJ Open</i> , 2020, 10, e033926.	1.9	3
592	Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e015042.	3.7	37
593	Predictors of emergency medical services use by adults with heart failure; 2009–2017. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 475-480.	1.6	4
594	Systematizing Heart Failure Population Health. <i>Heart Failure Clinics</i> , 2020, 16, 457-466.	2.1	5
595	The role of diet and nutrition in heart failure: A state-of-the-art narrative review. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 538-551.	3.1	48
596	Lipid in the midst of metabolic remodeling – Therapeutic implications for the failing heart. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 120-132.	13.7	14
597	Heart, lungs, and muscle interplay in worsening activity-related breathlessness in advanced cardiopulmonary disease. <i>Current Opinion in Supportive and Palliative Care</i> , 2020, 14, 157-166.	1.3	5
598	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e000099.	2.2	45
599	Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure with volume overload: a prospective, randomized, controlled clinical trial. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 447.	1.7	16
600	Costs and healthcare utilisation of patients with heart failure in Spain. <i>BMC Health Services Research</i> , 2020, 20, 964.	2.2	42
601	Searching for Preclinical Models of Acute Decompensated Heart Failure: a Concise Narrative Overview and a Novel Swine Model. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 727-738.	2.6	2
603	Economic evaluation of a dedicated cardiac resynchronisation therapy preassessment clinic. <i>Open Heart</i> , 2020, 7, e001249.	2.3	6
604	Palliative Care in Dermatology: A Clinical Primer, Review of the Literature, and Needs Assessment. <i>Journal of the American Academy of Dermatology</i> , 2020, 85, 708-717.	1.2	3
605	The Role of Prognostic and Predictive Biomarkers for Assessing Cardiovascular Risk in Chronic Kidney Disease Patients. <i>BioMed Research International</i> , 2020, 2020, 1-13.	1.9	26
606	Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices. <i>American Journal of Cardiovascular Drugs</i> , 2020, 21, 383-393.	2.2	3

#	ARTICLE	IF	CITATIONS
607	Ultrasound imaging of congestion in heart failure: examinations beyond the heart. <i>European Journal of Heart Failure</i> , 2021, 23, 703-712.	7.1	87
608	Cardiopulmonary Rehabilitation in Pediatric Patients With Congenital and Acquired Heart Disease. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2020, 40, 370-377.	2.1	11
609	Sarcoid Heart Disease: an Update on Diagnosis and Management. <i>Current Cardiology Reports</i> , 2020, 22, 177.	2.9	8
610	Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 634-640.	1.5	1
611	Benefits of Tai Chi Exercise Among Adults With Chronic Heart Failure. <i>Journal of Cardiovascular Nursing</i> , 2020, 35, 423-434.	1.1	18
612	Iron deficiency and iron therapy in heart failure and chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 508-514.	2.0	7
613	Cost-Effectiveness of a Small Intrapericardial Centrifugal Left Ventricular Assist Device. <i>ASAIO Journal</i> , 2020, 66, 862-870.	1.6	15
614	Amelioration of ischemic cardiomyopathy in patients using physiological ischemic training. <i>Herz</i> , 2020, 46, 173-179.	1.1	0
615	Comparison of objective nutritional indexes for the prediction of in-hospital mortality among elderly patients with acute heart failure. <i>European Journal of Emergency Medicine</i> , 2020, 27, 362-367.	1.1	12
616	Trends in Left Ventricular Ejection Fraction for Patients With a New Diagnosis of Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006743.	3.9	4
617	The Upcoming Epidemic of Heart Failure in South Asia. <i>Circulation: Heart Failure</i> , 2020, 13, e007218.	3.9	37
618	Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 187-210.	3.0	10
619	Role of biomarkers of cardiac remodeling, myofibrosis, and inflammation in assessment of disease severity in euvolemic patients with chronic stable heart failure. <i>Journal of International Medical Research</i> , 2020, 48, 030006052094786.	1.0	4
620	Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2020, 5, 1430.	6.1	62
621	Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , 2020, 7, 3438-3451.	3.1	13
622	Outcomes of diuretics in rheumatic heart disease with compensated chronic heart failure: a retrospective study. <i>ESC Heart Failure</i> , 2020, 7, 3929-3941.	3.1	5
623	Systematic review of guidelines for the diagnosis and treatment of iron deficiency anemia using intravenous iron across multiple indications. <i>Current Medical Research and Opinion</i> , 2020, 36, 1769-1782.	1.9	11
624	Maximal Dynamic Inspiratory Pressure Evaluation in Heart Failure: A Comprehensive Reliability and Agreement Study. <i>Physical Therapy</i> , 2020, 100, 2246-2253.	2.4	5

#	ARTICLE	IF	CITATIONS
625	Interdisciplinary Model for Scheduling Post-discharge Cardiopulmonary Care of Patients Following Severe and Critical SARS-CoV-2 (Coronavirus) Infection. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 157.	2.4	0
626	Cardio-Oncology Preventive Care: Racial and Ethnic Disparities. <i>Current Cardiovascular Risk Reports</i> , 2020, 14, 1.	2.0	23
627	Neurohormonal Regulation of I_{Ks} in Heart Failure: Implications for Ventricular Arrhythmogenesis and Sudden Cardiac Death. <i>Journal of the American Heart Association</i> , 2020, 9, e016900.	3.7	10
628	Galectin-3: A Potential Prognostic and Diagnostic Marker for Heart Disease and Detection of Early Stage Pathology. <i>Biomolecules</i> , 2020, 10, 1277.	4.0	40
629	Management of Cardiac Toxicity Induced by Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2885.	2.4	24
630	Impact of Left Ventricular Function and Heart Failure Symptoms on Outcomes Post Ablation of Atrial Fibrillation in Heart Failure. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008461.	4.8	50
631	Impact of β -blocker therapy on right ventricular function in heart failure patients with reduced ejection fraction. A prospective evaluation. <i>Echocardiography</i> , 2020, 37, 1392-1398.	0.9	3
632	Comparison of effectiveness and survival after the MitraClip or Carillon procedure for severe functional mitral regurgitation: a single-center retrospective analysis. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2020, 5, 171-177.	1.0	1
633	Heterogeneous trends in burden of heart disease mortality by subtypes in the United States, 1999-2018: observational analysis of vital statistics. <i>BMJ, The</i> , 2020, 370, m2688.	6.0	59
634	Heart failure documentation in outpatients with diabetes and volume overload: an observational cohort study from the Diabetes Collaborative Registry. <i>Cardiovascular Diabetology</i> , 2020, 19, 212.	6.8	3
635	Biomarkers for Heart Failure Prognosis: Proteins, Genetic Scores and Non-coding RNAs. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 601364.	2.4	40
636	Sodium Intake and Heart Failure. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9474.	4.1	54
637	Chronic asymptomatic hyponatraemia following angiotensin receptor blocker-neprilysin inhibitor (ARNi) therapy: a case report. <i>Postgraduate Medical Journal</i> , 2022, 98, 165-165.	1.8	3
638	β -MAGGIC Risk Model Predicts Adverse Events and Left Ventricular Remodeling in Non-Ischemic Dilated Cardiomyopathy. <i>International Journal of General Medicine</i> , 2020, Volume 13, 1477-1486.	1.8	2
639	Relationship between Soluble (Pro)Renin Receptor and Renin Activity in Patients with Severe Heart Failure. <i>Journal of Clinical Medicine</i> , 2020, 9, 4110.	2.4	5
640	Impact of contrast-induced acute kidney injury on the association between renin-angiotensin system inhibitors and long-term mortality in heart failure patients. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2020, 21, 147032032097979.	1.7	1
641	Revisiting heart failure assessment based on objective measures in NYHA functional classes I and II. <i>Heart</i> , 2021, 107, 1487-1492.	2.9	8
642	Response to the Letter to the Editor "When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry". <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2020, 39, 179-180.	0.2	0

#	ARTICLE	IF	CITATIONS
643	Galectin-3 in Cardiovascular Diseases. International Journal of Molecular Sciences, 2020, 21, 9232.	4.1	82
644	Galectin-3 Plasma Levels Are Associated with Risk Profiles in Pulmonary Arterial Hypertension. Diagnostics, 2020, 10, 857.	2.6	4
645	Management and Treatment of Myocarditis in Athletes. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 65.	0.9	16
646	Nitrates in combination with hydralazine in cardiorenal syndrome: a randomized controlled proof-of-concept study. ESC Heart Failure, 2020, 7, 4267-4276.	3.1	3
647	Health Benefits of Tai Chi Exercise. Nursing Clinics of North America, 2020, 55, 581-600.	1.5	7
648	Natriuretic peptides for the detection of diastolic dysfunction and heart failure with preserved ejection fraction—a systematic review and meta-analysis. BMC Medicine, 2020, 18, 290.	5.5	23
649	Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions. BMC Cardiovascular Disorders, 2020, 20, 208.	1.7	18
650	Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database. Annals of Pharmacotherapy, 2020, 54, 958-966.	1.9	0
651	Early Detection of Heart Failure With Reduced Ejection Fraction Using Perioperative Data Among Noncardiac Surgical Patients: A Machine-Learning Approach. Anesthesia and Analgesia, 2020, 130, 1188-1200.	2.2	23
652	Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2020, 141, e841-e863.	1.6	143
653	Life-Course Reproductive History and Cardiovascular Risk Profile in Late Mid-Life: The CARDIA Study. Journal of the American Heart Association, 2020, 9, e014859.	3.7	8
654	ARNI in cardiovascular disease: current evidence and future perspectives. Future Cardiology, 2020, 16, 505-515.	1.2	18
655	Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors. Journal of Cardiovascular Translational Research, 2020, 13, 463-477.	2.4	12
656	Sex Differences Across the Lifespan: A Focus on Cardiometabolism. Journal of Women's Health, 2020, 29, 899-909.	3.3	2
657	An overview of heart failure in low- and middle-income countries. Cardiovascular Diagnosis and Therapy, 2020, 10, 244-251.	1.7	32
658	Soluble ST2 and Soluble Markers of Fibrosis: Emerging Roles for Prognosis and Guiding Therapy. Current Cardiology Reports, 2020, 22, 41.	2.9	15
659	Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1759-1767.	7.1	41
660	Noncardiac comorbidity clustering in heart failure: an overlooked aspect with potential therapeutic door. Heart Failure Reviews, 2022, 27, 767-778.	3.9	6

#	ARTICLE	IF	CITATIONS
661	Angiotensin Receptor–Neprilysin Inhibitors and the Natriuretic Peptide Axis. <i>Current Heart Failure Reports</i> , 2020, 17, 67-76.	3.3	12
662	Response to the Letter to the Editor “When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry”. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 179-180.	0.5	0
663	Reappraisal on pharmacological and mechanical treatments of heart failure. <i>Cardiovascular Diabetology</i> , 2020, 19, 55.	6.8	27
664	Contemporary use of devices in chronic heart failure in the Netherlands. <i>ESC Heart Failure</i> , 2020, 7, 1771-1780.	3.1	6
665	Clinical inertia in the treatment of heart failure: a major issue to tackle. <i>Heart Failure Reviews</i> , 2021, 26, 1359-1370.	3.9	41
666	Noninvasive Positive Pressure Ventilation for Acute Decompensated Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 271-282.	2.1	2
667	Prognostic significance of T1 mapping parameters in heart failure with preserved ejection fraction: a systematic review. <i>Heart Failure Reviews</i> , 2021, 26, 1325-1331.	3.9	12
668	Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. <i>Drug Metabolism and Disposition</i> , 2020, 48, 230-244.	3.3	62
669	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–The BRACE CORONA Trial. <i>American Heart Journal</i> , 2020, 226, 49-59.	2.7	118
670	Cardio-ankle vascular index predicts the 1-year prognosis of heart failure patients categorized in clinical scenario 1. <i>Heart and Vessels</i> , 2020, 35, 1537-1544.	1.2	8
671	Technology Applications of Capnography Waveform Analytics for Evaluation of Heart Failure Severity. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 1044-1054.	2.4	2
672	Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1407-1418.	3.5	37
673	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 723-735.	2.6	11
674	Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review. <i>Current Oncology Reports</i> , 2020, 22, 72.	4.0	5
675	Managing heart failure related peripheral oedema in primary care. <i>BMJ, The</i> , 2020, 369, m2099.	6.0	2
676	Palliative care in cardiology: knowing our patients’ values and responding to their needs. <i>Heart</i> , 2020, 106, 1693-1699.	2.9	3
677	Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers. <i>Disease Markers</i> , 2020, 2020, 1-21.	1.3	57
678	In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. <i>Cell Metabolism</i> , 2020, 32, 176-187.e4.	16.2	400

#	ARTICLE	IF	CITATIONS
679	Blockade of PAR α 1 Signaling Attenuates Cardiac Hypertrophy and Fibrosis in Renin α Overexpressing Hypertensive Mice. <i>Journal of the American Heart Association</i> , 2020, 9, e015616.	3.7	13
680	SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. <i>Heart Lung and Circulation</i> , 2020, 29, 973-987.	0.4	136
681	High fat diet altered cardiac metabolic gene profile in Psammomys obesus gerbils. <i>Lipids in Health and Disease</i> , 2020, 19, 123.	3.0	6
682	Right Heart Failure. <i>Cardiology Clinics</i> , 2020, 38, 175-183.	2.2	8
683	The Latest Clinical Understandings and Theory of the Cardiovascular Systems for Cardiovascular Emergencies and Their Management. <i>Heart Failure Clinics</i> , 2020, 16, ix-x.	2.1	0
684	Hypertension and heart failure: focus on high-risk populations. <i>Current Opinion in Cardiology</i> , 2020, 35, 381-388.	1.8	2
685	Association of Prior Left Ventricular Ejection Fraction With Clinical Outcomes in Patients With Heart Failure With Midrange Ejection Fraction. <i>JAMA Cardiology</i> , 2020, 5, 1027.	6.1	18
686	Elevated CA-125 as Humoral Biomarker of Congestive Heart Failure: Illustrative Cases and a Short Review of Literature. <i>Case Reports in Cardiology</i> , 2020, 2020, 1-5.	0.2	7
687	Prognostic Value of Serum N-Terminal Pro-Brain Natriuretic Peptide Level over Heart Failure for Stroke Events and Deaths in Patients with Atrial Fibrillation. <i>International Heart Journal</i> , 2020, 61, 492-502.	1.0	8
688	Changes in Care Delivery for Patients With Heart Failure During the COVID-19 Pandemic: Results of a Multicenter Survey. <i>Journal of Cardiac Failure</i> , 2020, 26, 635-636.	1.7	19
689	Renin-angiotensin system inhibition in COVID-19 patients. <i>Netherlands Heart Journal</i> , 2020, 28, 396-405.	0.8	15
690	Meta-Analysis Comparing Outcomes of Therapies for Patients With Central Sleep Apnea and Heart Failure With Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2020, 127, 73-83.	1.6	16
691	“Takotsubo effect” in patients with ST segment elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 711-720.	1.0	5
692	Artificial Intelligence in Cardiology: Present and Future. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1015-1039.	3.0	127
693	ProBNP processing is decreased by obesity in patients with heart failure. <i>Annals of Translational Medicine</i> , 2020, 8, 135-135.	1.7	4
694	Fragmented QRS is associated with intraventricular dyssynchrony and independently predicts nonresponse to cardiac resynchronization therapy” Systematic review and meta-analysis. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12750.	1.1	5
695	Real-world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 1039-1048.	3.1	14
696	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1644-1656.	2.8	46

#	ARTICLE	IF	CITATIONS
697	Gene therapy targeting cardiac phosphoinositide 3-kinase (p110 α) attenuates cardiac remodeling in type 2 diabetes. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H840-H852.	3.2	32
698	<i>ALOX5</i> , <i>LPA</i> , <i>MMP9</i> and <i>TPO</i> gene polymorphisms increase atherothrombosis susceptibility in middle-aged Mexicans. Royal Society Open Science, 2020, 7, 190775.	2.4	2
699	Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules, 2020, 10, 389.	4.0	99
700	Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature. ESC Heart Failure, 2020, 7, 1319-1330.	3.1	12
701	Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure. Circulation: Heart Failure, 2020, 13, e006963.	3.9	13
702	Sex-related differences in contemporary biomarkers for heart failure: a review. European Journal of Heart Failure, 2020, 22, 775-788.	7.1	55
703	Sacubitril/Valsartan Therapy Ameliorates Ventricular Tachyarrhythmia Inducibility in a Rabbit Myocardial Infarction Model. Journal of Cardiac Failure, 2020, 26, 527-537.	1.7	27
704	A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs. Cardiovascular Drugs and Therapy, 2020, 34, 215-221.	2.6	6
705	Evaluation and management of heart failure with preserved ejection fraction. Nature Reviews Cardiology, 2020, 17, 559-573.	13.7	339
706	The Emulation and Adaptation of a Global Model of Clinical Practice Guidelines on Chronic Heart Failure in BRICS Countries: A Comparative Study. International Journal of Environmental Research and Public Health, 2020, 17, 1735.	2.6	3
707	Increased iron absorption in patients with chronic heart failure and iron deficiency. Journal of Cardiac Failure, 2020, 26, 440-443.	1.7	7
708	Causes of impaired biventricular pacing in cardiac resynchronization devices with left ventricular sensing. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 332-340.	1.2	2
709	Acute heart failure. Nature Reviews Disease Primers, 2020, 6, 16.	30.5	237
710	Acute Decompensated Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2020, 16, 201-209.	2.1	4
711	Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study. Biomarkers, 2020, 25, 248-259.	1.9	2
712	Population-Level Sex Differences and Predictors for Treatment With Catheter Ablation in Patients With Atrial Fibrillation and Heart Failure. CJC Open, 2020, 2, 85-93.	1.5	3
713	In-Hospital Management of Sleep Apnea During Heart Failure Hospitalization: A Randomized Controlled Trial. Journal of Cardiac Failure, 2020, 26, 705-712.	1.7	15
714	The Multifaced Perspectives of Genetic Testing in Pediatric Cardiomyopathies and Channelopathies. Journal of Clinical Medicine, 2020, 9, 2111.	2.4	2

#	ARTICLE	IF	CITATIONS
715	Higher visit-to-visit blood pressure variability and N-terminal pro-brain natriuretic peptide elevation: influence of left ventricular hypertrophy and left ventricular diastolic function. Blood Pressure Monitoring, 2020, 25, 126-130.	0.8	5
716	Cardiac resynchronization therapy for the failing systemic right ventricle: A systematic review. International Journal of Cardiology, 2020, 318, 74-81.	1.7	19
717	Overexpression of FNTB and the activation of Ras induce hypertrophy and promote apoptosis and autophagic cell death in cardiomyocytes. Journal of Cellular and Molecular Medicine, 2020, 24, 8998-9011.	3.6	7
718	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <scp>BIOSTAT-CHF</scp> and <scp>ASIAN-CHF</scp> registries. European Journal of Heart Failure, 2020, 22, 1472-1482.	7.1	24
719	Cardiac Imaging in Oncology Patients in Europe: a Model for Advancement of CV Safety and Development of Comprehensive CV Care. Journal of Cardiovascular Translational Research, 2020, 13, 490-494.	2.4	5
720	Elevated Angiotensin 1-7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure. Circulation: Heart Failure, 2020, 13, e006939.	3.9	28
721	DNA methylation patterns from peripheral blood separate coronary artery disease patients with and without heart failure. ESC Heart Failure, 2020, 7, 2468-2478.	3.1	21
722	Caring for Critically Ill Adults With Coronavirus Disease 2019 in a PICU: Recommendations by Dual Trained Intensivists*. Pediatric Critical Care Medicine, 2020, 21, 607-619.	0.5	42
723	The renin angiotensin aldosterone system and COVID-19. Saudi Pharmaceutical Journal, 2020, 28, 977-984.	2.7	5
724	Cardiovascular diseases in survivors of childhood cancer. Cancer and Metastasis Reviews, 2020, 39, 55-68.	5.9	29
725	Atrial fibrillation ablation in congestive heart failure with preserved ejection fraction: Tackling the vicious twins. Journal of Cardiovascular Electrophysiology, 2020, 31, 689-691.	1.7	2
726	Association Between Physicians' Appropriate Use of Echocardiography and Subsequent Healthcare Use and Outcomes in Patients With Heart Failure. Journal of the American Heart Association, 2020, 9, e013360.	3.7	5
727	Introduction and Vision. Cardiovascular Drugs and Therapy, 2020, 34, 1-2.	2.6	1
728	Heart failure caregivers' support services: Implications for palliative care. Progress in Palliative Care, 2020, 28, 318-325.	1.2	2
729	Study protocol for a randomized controlled trial: Qiliqiangxin in heart failure: assessment of reduction in mortality (QUEST). BMC Complementary Medicine and Therapies, 2020, 20, 38.	2.7	8
730	Clinical Care Recommendations for Cardiologists Treating Adults With Myotonic Dystrophy. Journal of the American Heart Association, 2020, 9, e014006.	3.7	33
731	Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users. BMC Nephrology, 2020, 21, 61.	1.8	5
732	Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005984.	2.2	18

#	ARTICLE	IF	CITATIONS
733	Reviewing the clinical utility of ventricular assist device log files. Indian Journal of Thoracic and Cardiovascular Surgery, 2020, 36, 247-255.	0.6	1
734	Venom natriuretic peptides guide the design of heart failure therapeutics. Pharmacological Research, 2020, 155, 104687.	7.1	12
735	Chinese herbal preparations for chronic heart failure. Medicine (United States), 2020, 99, e18966.	1.0	3
736	Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure. CardioRenal Medicine, 2020, 10, 69-84.	1.9	23
737	Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. Circulation: Heart Failure, 2020, 13, e006623.	3.9	24
738	Disproportionate Emphasis on Proportionate Mitral Regurgitation—Are There Better Measures of Regurgitant Severity?. JAMA Cardiology, 2020, 5, 377.	6.1	28
739	Heart failure self-care, factors influencing self-care and the relationship with health-related quality of life: A cross-sectional observational study. Heliyon, 2020, 6, e03412.	3.2	32
740	Association Between Palliative Care and Death at Home in Adults With Heart Failure. Journal of the American Heart Association, 2020, 9, e013844.	3.7	28
741	Implementation of Guideline-Recommended Therapies for Patients With Heart Failure and Reduced Ejection Fraction: A Regional Arab Middle East Experience. Angiology, 2020, 71, 431-437.	1.8	7
742	Therapeutic efficacy of shenmai injection as an adjuvant treatment in dilated cardiomyopathy. Medicine (United States), 2020, 99, e19158.	1.0	2
743	Spinal cord neural network interactions: implications for sympathetic control of the porcine heart. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H830-H839.	3.2	12
744	Recovered Left Ventricular Ejection Fraction and Its Prognostic Impacts in Hospitalized Heart Failure Patients with Reduced Ejection Fraction. International Heart Journal, 2020, 61, 281-288.	1.0	17
745	Clinical Outcomes With Beta-Blocker Use in Patients With Recent History of Myocardial Infarction. Canadian Journal of Cardiology, 2020, 36, 1633-1640.	1.7	8
746	Update on Apneas of Heart Failure With Reduced Ejection Fraction: Emphasis on the Physiology of Treatment. Chest, 2020, 157, 1637-1646.	0.8	27
747	A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). Journal of Cardiovascular Translational Research, 2020, 13, 540-548.	2.4	5
748	Evaluating risk prediction models for adults with heart failure: A systematic literature review. PLoS ONE, 2020, 15, e0224135.	2.5	54
749	Ceruloplasmin, NT-proBNP, and Clinical Data as Risk Factors of Death or Heart Transplantation in a 1-Year Follow-Up of Heart Failure Patients. Journal of Clinical Medicine, 2020, 9, 137.	2.4	1
750	Diagnosis of Acute Heart Failure Using Inferior Vena Cava Ultrasound. Journal of Ultrasound in Medicine, 2020, 39, 1367-1378.	1.7	8

#	ARTICLE	IF	CITATIONS
751	Prognostic role of bronchial asthma in patients with heart failure. Heart and Vessels, 2020, 35, 808-816.	1.2	6
752	Regulatory RNAs in Heart Failure. Circulation, 2020, 141, 313-328.	1.6	133
753	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. Journal of the American Heart Association, 2020, 9, e013757.	3.7	240
754	Hyperuricemia and mortality in heart failure: Is it time to change the route?. European Journal of Internal Medicine, 2020, 72, 40-41.	2.2	4
755	Hierro e insuficiencia cardiaca. Revista Clinica Espanola, 2020, 220, 43-48.	0.6	2
756	The Biomarkers for Acute Myocardial Infarction and Heart Failure. BioMed Research International, 2020, 2020, 1-14.	1.9	53
757	Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006638.	3.9	12
758	Diagnostic and predictive value of speckle tracking echocardiography in cardiac sarcoidosis. BMC Cardiovascular Disorders, 2020, 20, 21.	1.7	32
759	Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. European Journal of Heart Failure, 2020, 22, 604-617.	7.1	33
760	Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction. International Journal of Cardiology, 2020, 302, 15-20.	1.7	17
761	LCZ696 (sacubitril/valsartan) for patients with heart failure. The Cochrane Library, 0, , .	2.8	0
762	Treatment outcome and its predictors among patients of acute heart failure at a tertiary care hospital in Ethiopia: a prospective observational study. BMC Cardiovascular Disorders, 2020, 20, 16.	1.7	18
763	High-sensitivity cardiac troponin T 30 days all-cause mortality in patients with acute heart failure. A Propensity Score-Matching Analysis Based on the EAHFE Registry. TROPICA4 Study. European Journal of Clinical Investigation, 2020, 50, e13248.	3.4	5
764	Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction. Open Heart, 2020, 7, e001112.	2.3	16
765	Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology, 2020, 72, 389-398.	7.3	346
766	Intracranial hemorrhage type and same-admission mortality in patients with left ventricular assist devices. Clinical Neurology and Neurosurgery, 2020, 193, 105790.	1.4	3
767	Atrial fibrillation in patients with heart failure with preserved ejection fraction. Current Opinion in Cardiology, 2020, 35, 260-270.	1.8	1
768	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clinical Research in Cardiology, 2020, 109, 1079-1098.	3.3	74

#	ARTICLE	IF	CITATIONS
769	Duchenne Muscular Dystrophy: the Heart of the Matter. <i>Current Heart Failure Reports</i> , 2020, 17, 57-66.	3.3	14
770	Surgical ventricular restorationâ€”meta-analysis of observational studies. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 36, 347-355.	0.6	0
771	Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 700-705.	1.4	9
772	Efficacy of Rapid Decongestion Strategy in Patients Hospitalized for Acute Heart Failure. <i>Circulation Journal</i> , 2020, 84, 958-964.	1.6	4
773	Impact of the Geriatric Nutritional Risk Index on In-Hospital Mortality and Length of Hospitalization in Patients with Acute Decompensated Heart Failure with Preserved or Reduced Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2020, 9, 1169.	2.4	16
774	Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 579-584.	2.6	7
775	Enhancing Clinical Pharmacy Specialist Involvement in Transitions of Care Focusing on Ambulatory Care Sensitive Conditions within a Veterans Affairs Healthcare System. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 47.	1.6	3
776	Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. <i>Circulation</i> , 2020, 141, 1903-1914.	1.6	448
777	Specialty-Based Variability in Diagnosing and Managing Heart Failure With Preserved Ejection Fraction. <i>Mayo Clinic Proceedings</i> , 2020, 95, 669-675.	3.0	6
778	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006645.	3.9	18
779	Impact of a Palliative Care Education Module in Patients With Heart Failure. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 1016-1021.	1.4	3
780	Molecular Characterization of Tc964, A Novel Antigenic Protein from <i>Trypanosoma cruzi</i> . <i>International Journal of Molecular Sciences</i> , 2020, 21, 2432.	4.1	1
781	Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 460-495.	1.8	388
782	Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu. <i>Digestive Diseases and Sciences</i> , 2021, 66, 263-272.	2.3	11
783	Impact of renin-angiotensin system inhibitors on outcomes after surgical or transcatheter aortic valve replacement. A meta-analysis. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 421-426.	0.6	1
784	When should we measure biomarkers in patients with atrial fibrillation to predict recurrences?. <i>American Journal of Emergency Medicine</i> , 2021, 39, 248-249.	1.6	7
785	Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study. <i>Clinical Nutrition</i> , 2021, 40, 571-580.	5.0	57
786	Postoperative Management of Patients After Transcatheter Mitral Valve Procedures. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 1477-1484.	1.3	1

#	ARTICLE	IF	CITATIONS
787	Sex Disparities in the Choice of Cardiac Resynchronization Therapy Device: An Analysis of Trends, Predictors, and Outcomes. Canadian Journal of Cardiology, 2021, 37, 86-93.	1.7	8
788	Anemia and iron deficiency in heart failure: extending evidences from chronic to acute setting. Internal and Emergency Medicine, 2021, 16, 167-170.	2.0	7
789	Inpatient Cardiac Rehabilitation of LVAD Patientsâ€™Updated Recommendations from the Working Group of the German Society for Prevention and Rehabilitation of Cardiovascular Diseases. Thoracic and Cardiovascular Surgeon, 2021, 69, 070-082.	1.0	14
790	Correction of iron deficiency in hospitalized heart failure patients does not improve patient outcomes. Annals of Hematology, 2021, 100, 661-666.	1.8	3
791	Association of Sacubitril/Valsartan with Metabolic Parameters in Patients with Reduced Ejection Fraction Heart Failure at a Multidisciplinary Clinic. Metabolic Syndrome and Related Disorders, 2021, 19, 115-118.	1.3	3
792	Intensity of Guideline-Directed Medical Therapy for Coronary Heart Disease and Ischemic Heart Failure Outcomes. American Journal of Medicine, 2021, 134, 672-681.e4.	1.5	3
793	Machine learning versus conventional clinical methods in guiding management of heart failure patientsâ€™a systematic review. Heart Failure Reviews, 2021, 26, 23-34.	3.9	57
794	Associations between hemodynamic parameters at rest and exercise capacity in patients with implantable left ventricular assist devices. International Journal of Artificial Organs, 2021, 44, 174-180.	1.4	7
795	Inpatient Initiation of Sacubitril/Valsartan. Annals of Pharmacotherapy, 2021, 55, 480-495.	1.9	2
796	Iron and cardiovascular diseases. Journal of Cardiology, 2021, 77, 160-165.	1.9	22
797	Use of sacubitril/valsartan as â€˜bridge to transplantâ€™in patients with end-stage hypertrophic cardiomyopathy. Future Cardiology, 2021, 17, 89-94.	1.2	1
798	A Systematic Review on the Use of Sacubitril/Valsartan Initiated Prior to Discharge in Hospitalized Patients With Heart Failure. Annals of Pharmacotherapy, 2021, 55, 378-389.	1.9	0
799	The emerging role of iron in heart failure and vascular calcification in CKD. CKJ: Clinical Kidney Journal, 2021, 14, 739-745.	2.9	9
800	Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers. Clinical Pharmacokinetics, 2021, 60, 337-351.	3.5	20
801	Systolic Blood Pressure and Outcomes in Older Patients with HFrEF and Hypertension. American Journal of Medicine, 2021, 134, e252-e263.	1.5	14
802	Is Digitalis Therapy Still Viable? Foxglove Therapy Makes a Comeback. American Journal of Medicine, 2021, 134, 1-2.	1.5	5
803	Effectiveness of point-of-care oral ivabradine for cardiac computed tomography. Journal of Cardiovascular Computed Tomography, 2021, 15, 226-231.	1.3	2
804	Biventricular pacemaker and defibrillator implantation in patients with chronic heart failure in China. ESC Heart Failure, 2021, 8, 546-554.	3.1	7

#	ARTICLE	IF	CITATIONS
805	Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life. <i>Journal of Cardiac Failure</i> , 2021, 27, 435-444.	1.7	6
806	Meta-analysis of the Usefulness of Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 142, 66-73.	1.6	27
807	Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H296-H304.	3.2	123
808	Directly Measured Adherence to Treatment in Chronic Heart Failure: LEVEL-CHF Registry. <i>American Journal of the Medical Sciences</i> , 2021, 361, 491-498.	1.1	4
809	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. <i>International Journal of Cardiology</i> , 2021, 327, 138-145.	1.7	19
810	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. <i>Postgraduate Medicine</i> , 2021, 133, 125-139.	2.0	8
811	Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department. <i>JAMA Cardiology</i> , 2021, 6, 200.	6.1	18
812	Myocardial Tissue Reverse Remodeling After Guideline-Directed Medical Therapy in Idiopathic Dilated Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2021, 14, e007944.	3.9	31
813	Prognostic relevance of Doppler echocardiographic re-assessment in HFrEF patients. <i>International Journal of Cardiology</i> , 2021, 327, 111-116.	1.7	5
814	Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction. <i>Journal of Applied Physiology</i> , 2021, 130, 256-268.	2.5	13
815	2021 ACC/AHA Key Data Elements and Definitions for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2053-2150.	2.8	29
816	An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 427-437.	1.6	88
817	Contemporary Strategies to Manage High Blood Pressure in Patients with Coexistent Resistant Hypertension and Heart Failure With Reduced Ejection Fraction. <i>Cardiology and Therapy</i> , 2021, 10, 9-25.	2.6	1
819	Heart failure with preserved ejection fraction: disease burden for patients, caregivers, and the health-care system. <i>Postgraduate Medicine</i> , 2021, 133, 140-145.	2.0	8
820	Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe. <i>Journal of Clinical Hypertension</i> , 2021, 23, 556-567.	2.0	16
821	2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2021, 143, e72-e227.	1.6	1,009
822	2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2021, 143, e35-e71.	1.6	644
823	Cardiac contractility modulation for the treatment of moderate to severe HF. <i>Expert Review of Medical Devices</i> , 2021, 18, 15-21.	2.8	19

#	ARTICLE	IF	CITATIONS
824	Clinical significance of left atrial geometry in dilated cardiomyopathy patients: A cardiovascular magnetic resonance study. <i>Clinical Cardiology</i> , 2021, 44, 222-229.	1.8	9
825	Heart failure after myocardial infarction: incidence and predictors. <i>ESC Heart Failure</i> , 2021, 8, 222-237.	3.1	243
826	High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide in acute heart failure: Data from the ACE 2 study. <i>Clinical Biochemistry</i> , 2021, 88, 30-36.	1.9	6
827	A bridge to transplantation: The life experiences of patients with a left ventricular assist device. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2021, 50, 106-112.	1.6	0
828	Early use of remote dielectric sensing after hospitalization to reduce heart failure readmissions. <i>ESC Heart Failure</i> , 2021, 8, 1047-1054.	3.1	28
829	The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. <i>Cell Metabolism</i> , 2021, 33, 629-648.e10.	16.2	137
830	Impact of hypertension on left ventricular function in patients after anthracycline chemotherapy for malignant lymphoma. <i>International Journal of Cardiology</i> , 2021, 323, 126-132.	1.7	5
831	Patient Characteristics Are Not Associated With Documentation of Weight and Heart Failure Related Sign and Symptom Assessment in Skilled Nursing Facilities. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1265-1270.e1.	2.5	1
832	Myocardial injury in severe and critical coronavirus disease 2019 patients. <i>Journal of Cardiac Surgery</i> , 2021, 36, 82-88.	0.7	10
833	Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 544-551.	2.4	16
834	A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 125-131.	1.9	6
835	Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure. <i>Clinical Diabetes</i> , 2021, 39, 105-116.	2.2	0
836	Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1011-1015.	0.9	6
837	Association between evidence-based medication at discharge and outcomes in patients with heart failure: a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2021, 26, 81-89.	3.9	6
838	Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 826-839.	0.7	22
839	Engineered cardiac tissue: Concepts and future. , 2021, , 133-151.		0
840	Cardiovascular Complications. , 2021, , 557-578.		0
841	Dietary and Nutritional Recommendations for the Prevention and Treatment of Heart Failure. <i>Contemporary Cardiology</i> , 2021, , 251-263.	0.1	0

#	ARTICLE	IF	CITATIONS
842	French annual national observational study of 2015 outpatient and inpatient healthcare utilization by approximately half a million patients with previous heart failure diagnosis. Archives of Cardiovascular Diseases, 2021, 114, 17-32.	1.6	5
843	Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty. Diagnostics, 2021, 11, 133.	2.6	8
844	Application value of myocardial work technology by non-invasive echocardiography in evaluating left ventricular function in patients with chronic heart failure. Quantitative Imaging in Medicine and Surgery, 2022, 12, 244-256.	2.0	6
845	Perioperative Management of the Cancer Patient. , 2021, , 113-126.		0
846	A Practical Risk Score for Prediction of Early Readmission after a First Episode of Acute Heart Failure with Preserved Ejection Fraction. Diagnostics, 2021, 11, 198.	2.6	13
847	Severe Acute Respiratory Infection Surveillance during the Initial Phase of the COVID-19 Outbreak in North India: A Comparison of COVID-19 to Other SARI Causes. Indian Journal of Critical Care Medicine, 2021, 25, 761-767.	0.9	11
848	Atherosclerosis Imaging. , 2021, , 81-110.		0
849	The association of deficiencies of water-soluble vitamin intake with health-related quality of life and prognosis in patients with heart failure. Quality of Life Research, 2021, 30, 1183-1190.	3.1	2
850	Assessment of chronic disease self-management in patients with chronic heart failure based on the MCID of patient-reported outcomes by the multilevel model. BMC Cardiovascular Disorders, 2021, 21, 58.	1.7	3
851	Serum iron: a new predictor of adverse outcomes independently from serum hemoglobin levels in patients with acute decompensated heart failure. Scientific Reports, 2021, 11, 2395.	3.3	5
852	Remote Monitoring in Chronic Heart Failure Patients: Is Non-Invasive Remote Monitoring the Way to Go?. Sensors, 2021, 21, 887.	3.8	19
853	Association between depressive symptoms and quality of life in outpatients and inpatients with heart failure. Revista Da Escola De Enfermagem Da U S P, 2021, 55, e03686.	0.9	3
854	Efficacy and safety of thyroxine therapy on patients with heart failure and subclinical hypothyroidism. Medicine (United States), 2021, 100, e23947.	1.0	1
855	Gender differences in the impact of frailty on 90-day hospital readmission in heart failure patients: a retrospective cohort study. European Journal of Cardiovascular Nursing, 2021, 20, 485-492.	0.9	11
856	Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management. Korean Circulation Journal, 2021, 51, 579.	1.9	3
857	Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease. European Journal of Clinical Pharmacology, 2021, 77, 955-960.	1.9	5
858	Health Promotion and Self-Management Among Patients with Chronic Heart Failure. , 2021, , 269-285.		1
859	Gender-Related Differences in Heart Failure Biomarkers. Frontiers in Cardiovascular Medicine, 2020, 7, 617705.	2.4	31

#	ARTICLE	IF	CITATIONS
860	Sex Differences in Right Ventricular Dysfunction: Insights From the Bench to Bedside. <i>Frontiers in Physiology</i> , 2020, 11, 623129.	2.8	15
861	Neurological complications of heart failure. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 177, 77-89.	1.8	1
862	Ivabradine in Cardiovascular Disease Management Revisited: a Review. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1045-1056.	2.6	16
863	Deletion of P21-activated kinase-1 induces age-dependent increased visceral adiposity and cardiac dysfunction in female mice. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1337-1349.	3.1	8
864	Overview of Ventricular Assist Devices and the Total Artificial Heart. <i>Dimensions of Critical Care Nursing</i> , 2021, 40, 3-13.	0.9	4
865	Subjects with coronary artery disease and reduced ejection fraction have longer (GT)n repeats in the heme-oxygenase 1 gene promoter. <i>Heart and Vessels</i> , 2021, 36, 615-620.	1.2	7
866	Clinical Implications of Uric Acid in Heart Failure: A Comprehensive Review. <i>Life</i> , 2021, 11, 53.	2.4	16
867	Myocarditis and Pericarditis. , 2021, , .		1
868	Crosstalk between Iron and Arteriosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 308-314.	2.0	7
869	Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 602363.	2.4	14
870	Independent predictors of a positive response to pacemaker implantation in patients with chronic heart failure. <i>Journal of V N Karazin Kharkiv National University: Series Medicine</i> , 2021, , .	0.0	0
871	Endothelial Klf2-Foxp1-TGF β 2 signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling. <i>Theranostics</i> , 2021, 11, 1609-1625.	10.0	17
872	Sobrevida de Pacientes com Insuficiência Cardíaca Aguda e Fração de Ejeção Intermediária em um País em Desenvolvimento – Estudo de Coorte no Sul do Brasil. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 14-23.	0.8	8
873	Complexity in genetic cardiomyopathies and new approaches for mechanism-based precision medicine. <i>Journal of General Physiology</i> , 2021, 153, .	1.9	25
875	Diabetes and Heart Failure. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2021, 3, 21.	0.1	0
876	Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance. <i>Libyan Journal of Medicine</i> , 2021, 16, 1973762.	1.6	1
877	Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure. <i>Scientific Reports</i> , 2021, 11, 2058.	3.3	11
878	Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Cureus</i> , 2021, 13, e13604.	0.5	0

#	ARTICLE	IF	CITATIONS
879	Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, 9, 538-545.	3.2	4
880	Safety and Effectiveness of an Accelerated Intravenous Iron Administration Protocol in Hospitalized Patients With Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 365-370.	2.0	5
881	Association of Subclinical Heart Maladaptation With the Pooled Cohort Equations to Prevent Heart Failure Risk Score for Incident Heart Failure. <i>JAMA Cardiology</i> , 2021, 6, 214.	6.1	2
882	Ventricular arrhythmias among patients with implantable cardioverter-defibrillator during the COVID-19 pandemic. <i>Journal of Arrhythmia</i> , 2021, 37, 407-413.	1.2	6
883	Efficacy of medical and ablation therapy for inappropriate sinus tachycardia: A single-center experience. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1053-1061.	1.7	4
884	Prognostic role of transferrin saturation in heart failure patients. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1639-1646.	1.8	23
885	Graft-derived Cell-free DNA - Twilight Years of the Endomyocardial Biopsy?. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	1.0	0
886	Chronic vagus nerve stimulation is associated with multi-year improvement in intrinsic heart rate recovery and left ventricular ejection fraction in ANTHEM-HF. <i>Clinical Autonomic Research</i> , 2021, 31, 453-462.	2.5	7
887	Risk-Based Approach for the Prediction and Prevention of Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007761.	3.9	19
888	Regional Disparities in Adherence to Guidelines for the Treatment of Chronic Heart Failure. <i>Internal Medicine</i> , 2021, 60, 525-532.	0.7	1
889	Sex differences in factors associated with heart failure and diastolic left ventricular dysfunction: a cross-sectional population-based study. <i>BMC Public Health</i> , 2021, 21, 415.	2.9	16
890	Determinants of Hospital Variation in Cardiac Rehabilitation Enrollment During Coronary Artery Disease Episodes of Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007144.	2.2	16
891	Clinical, Echocardiographic, and Therapeutic Characteristics of Heart Failure in Patients with Preserved, Mid-Range, and Reduced Ejection Fraction: Future Directions. <i>International Journal of General Medicine</i> , 2021, Volume 14, 459-467.	1.8	4
892	Potential of modern investigations for detecting and monitoring asymptomatic congestion in patients with heart failure. <i>Russian Journal of Cardiology</i> , 2021, 26, 4265.	1.4	1
893	Coenzyme Q10 for heart failure. <i>The Cochrane Library</i> , 2021, 2021, .	2.8	12
894	Early Mobilization in People With Acute Cardiovascular Disease. <i>Canadian Journal of Cardiology</i> , 2021, 37, 232-240.	1.7	12
895	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. <i>ESC Heart Failure</i> , 2021, 8, 861-871.	3.1	20
896	Epidemiological Impact of Myocarditis. <i>Journal of Clinical Medicine</i> , 2021, 10, 603.	2.4	53

#	ARTICLE	IF	CITATIONS
897	Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 626375.	3.5	11
898	Effect of Early Rehabilitation on Physical Function in Patients Undergoing Coronary Artery Bypass Grafting: A Nationwide Inpatient Database Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 618.	2.4	13
899	New Hemodynamic Insights in Pulmonary Vascular Disease and Heart Failure with Preserved Ejection Fraction. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.9	0
900	A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study. <i>ADCES in Practice</i> , 2021, 9, 16-23.	0.2	0
901	Heart Failure Guidelines: Preserved Ejection Fraction and Comorbidities. <i>Critical Care Nurse</i> , 2021, 41, 80-80.	1.0	0
902	Impact of New Grading System and New Hemodynamic Classification on Long-Term Outcome in Patients With Severe Tricuspid Regurgitation. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e011805.	2.6	8
903	A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 309-322.	2.6	12
904	Awareness and Knowledge Among Internal Medicine House-Staff for Dose Adjustment of Cardiovascular Drugs in Chronic Kidney Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 177-184.	2.2	2
905	Web Tabanlı EĞİTİMİN Kardiyovasküler Hastalıkların Yönetimine Etkisi. <i>Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi</i> , 0, , .	0.4	0
906	Impact of Sacubitril/Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 167-175.	2.2	8
907	Application of Animal Models in Diabetic Cardiomyopathy. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 129-145.	4.7	12
908	Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.C.A. Registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1691-1700.	1.8	26
909	Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e018689.	3.7	18
910	Sacubitril/valsartan: from the PARADIGM-HF trial results to heart failure patients in internal medicine. A narrative review. <i>Italian Journal of Medicine</i> , 2021, 15, .	0.3	0
911	Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?. <i>Circulation: Heart Failure</i> , 2021, 14, e008090.	3.9	5
912	Embracing Genetic Diversity to Improve Black Health. <i>New England Journal of Medicine</i> , 2021, 384, 1163-1167.	27.0	71
913	Unfractionated and Low-Molecular-Weight Heparin for Bridging Patients with Left Ventricular Assist Device: An Event-Based Analysis. <i>ASAIO Journal</i> , 2021, 67, 1277-1283.	1.6	1
914	Cardiac Contractility Modulation in Patients with Heart Failure with Reduced Left Ventricular Ejection Fraction. <i>Hearts</i> , 2021, 2, 156-169.	0.9	4

#	ARTICLE	IF	CITATIONS
915	Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 361-368.	2.0	3
916	Diretrizes Brasileiras de Hipertensão Arterial – 2020. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 516-658.	0.8	340
917	Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines – Heart Failure Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e018696.	3.7	23
918	Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps. <i>Journal of the American Heart Association</i> , 2021, 10, e017684.	3.7	10
919	Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis. <i>ESC Heart Failure</i> , 2021, 8, 1885-1891.	3.1	6
920	Updates in Cardiac Amyloidosis Diagnosis and Treatment. <i>Current Oncology Reports</i> , 2021, 23, 47.	4.0	17
921	Representation of Women Physicians in Heart Failure Clinical Practice. <i>Cardiac Failure Review</i> , 2021, 7, e05.	3.0	4
922	Racial and ethnic disparities in heart failure: current state and future directions. <i>Current Opinion in Cardiology</i> , 2021, 36, 320-328.	1.8	57
923	Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 343-348.	1.9	0
924	Effect of Î2-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam Study. <i>ERJ Open Research</i> , 2021, 7, 00624-2020.	2.6	2
925	Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction?. <i>Egyptian Heart Journal</i> , 2021, 73, 26.	1.2	3
926	Carvedilol versus metoprolol succinate in the treatment of patients with heart failure with reduced ejection fraction and patients with acute myocardial infarction. <i>Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini</i> , 2021, 2021, 36-39.	0.0	0
927	The Role of the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease: Pathogenetic Insights and Clinical Implications. , 0, , .		0
928	Automated cardiac volume assessment and cardiac long- and short-axis imaging plane prediction from electrocardiogram-gated computed tomography volumes enabled by deep learning. <i>European Heart Journal Digital Health</i> , 2021, 2, 311-322.	1.7	9
929	SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021, 8, 2210-2219.	3.1	26
930	Heart Failure Risk Distribution and Trends in the United States Population, NHANES 1999-2016. <i>American Journal of Medicine</i> , 2021, 134, e153-e164.	1.5	16
931	Effect of defibrillation on the performance of an implantable vagus nerve stimulation system. <i>Bioelectronic Medicine</i> , 2021, 7, 3.	2.3	3
932	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. <i>European Journal of Heart Failure</i> , 2021, 23, 352-380.	7.1	630

#	ARTICLE	IF	CITATIONS
933	Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione. American Journal of Cardiovascular Drugs, 2021, 21, 589-593.	2.2	1
934	Diabetes and Heart Failure. Journal of Korean Diabetes, 2021, 22, 12-20.	0.3	0
935	Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal?. Current Opinion in Cardiology, 2021, 36, 413-419.	1.8	12
936	Neprilysin inhibition does not alter dynamic of proenkephalinâ€A 119â€159 and proâ€substance P in heart failure. ESC Heart Failure, 2021, 8, 2016-2024.	3.1	3
937	Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart, 2021, 8, e001585.	2.3	30
938	Delayed diagnosis of dilated thyrotoxic cardiomyopathy with coexistent multifocal atrial tachycardia: a case report. BMC Cardiovascular Disorders, 2021, 21, 124.	1.7	7
939	Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2021, 10, e019636.	3.7	80
940	Frailty in Acute and Chronic Coronary Syndrome Patients Entering Cardiac Rehabilitation. Journal of Clinical Medicine, 2021, 10, 1696.	2.4	24
941	Evidence-Based Management of Acute Heart Failure. Canadian Journal of Cardiology, 2021, 37, 621-631.	1.7	16
942	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2Â°Pâ€TIMI 50. Journal of the American Heart Association, 2021, 10, e018673.	3.7	7
943	Anemia and Management of Heart Failure Patients. Heart Failure Clinics, 2021, 17, 195-206.	2.1	8
944	Virtual optimization of guidelineâ€directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENTâ€HF pilot study. European Journal of Heart Failure, 2021, 23, 1191-1201.	7.1	45
945	Cardiac Magnetic Resonance Imaging in Nonischemic Cardiomyopathy. Circulation, 2021, 143, 1374-1376.	1.6	1
946	An implantable cardioverter-defibrillator for primary prevention in non-ischemic cardiomyopathy: A systematic review and meta-analysis. Cardiology Journal, 2023, 30, 117-124.	1.2	2
947	A tribute to Yves JuilliÃˆre, MD, PhD (1957 to 2021). Archives of Cardiovascular Diseases, 2021, 114, 261-267.	1.6	0
948	Detecting Digoxin Toxicity by Artificial Intelligence-Assisted Electrocardiography. International Journal of Environmental Research and Public Health, 2021, 18, 3839.	2.6	23
949	How I manage acquired pure red cell aplasia in adults. Blood, 2021, 137, 2001-2009.	1.4	29
950	Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews, 2022, 27, 625-643.	3.9	135

#	ARTICLE	IF	CITATIONS
951	Cardiovascular and Renal Disease in Chronic Critical Illness. Journal of Clinical Medicine, 2021, 10, 1601.	2.4	5
952	Implementing Clinical Decision Support Tools and Pharmacovigilance to Reduce the Use of Potentially Harmful Medications and Health Care Costs in Adults With Heart Failure. Frontiers in Pharmacology, 2021, 12, 612941.	3.5	6
953	Drug-related problems and associated factors in Ethiopia: a systematic review and meta-analysis. Journal of Pharmaceutical Policy and Practice, 2021, 14, 36.	2.4	17
954	2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Tj ETQq1 1 0,784314 rgBT /Overl Outcomes. 2021, 14, e000102.	2.2	73
955	Off-pump coronary artery grafting in patients with a reduced ejection fraction. Journal of Cardiac Surgery, 2021, 36, 2609-2609.	0.7	0
956	Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain. CKJ: Clinical Kidney Journal, 2021, 14, 2391-2400.	2.9	7
957	Spironolactone and Eplerenone Use at Discharge in Heart Failure Patients With Reduced Ejection Fraction at 3 Large Hospital Systems. American Journal of Therapeutics, 2021, Publish Ahead of Print, .	0.9	0
958	Effect of left ventricular ejection fraction on the prognostic impact of chronic total occlusion in a non-infarct-related artery in patients with acute myocardial infarction. IJC Heart and Vasculature, 2021, 33, 100738.	1.1	5
959	Prognostic Significance of B-Type Natriuretic Peptide in Patients With Left Ventricular Thrombus. Frontiers in Cardiovascular Medicine, 2021, 8, 667908.	2.4	4
960	Predictors associated with increased troponin in acute decompensated and chronic heart failure patients. Romanian Journal of Laboratory Medicine, 2021, 29, 153-164.	0.2	0
961	Anemia of cardiorenal syndrome. Kidney International Supplements, 2021, 11, 35-45.	14.2	29
962	Fatty Liver Is Associated with Low N-Terminal Pro-B-Type Natriuretic Peptide in a Healthy Population. Journal of Clinical Medicine, 2021, 10, 1402.	2.4	1
963	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	1.7	362
964	Cardiovascular Issues in Hematopoietic Stem Cell Transplantation (HSCT). Current Treatment Options in Oncology, 2021, 22, 51.	3.0	9
965	Influence of left ventricular systolic function on the long-term benefit of beta-blockers after ST-segment elevation myocardial infarction. Revista Portuguesa De Cardiologia, 2021, 40, 285-290.	0.5	9
966	Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction. Cardiac Failure Review, 2021, 7, e06.	3.0	1
967	Influence of left ventricular systolic function on the long-term benefit of beta-blockers after ST-segment elevation myocardial infarction. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 285-290.	0.2	0
968	Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop. Journal of Pharmacy Practice, 2022, 35, 859-863.	1.0	3

#	ARTICLE	IF	CITATIONS
969	Risk Stratification Towards Precision Medicine in Heart Failure – Current Progress and Future Perspectives. Circulation Journal, 2021, 85, 576-583.	1.6	6
970	Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction – Results From the PARALLEL-HF Study. Circulation Journal, 2021, 85, 584-594.	1.6	37
971	Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience. Minerva Cardiology and Angiology, 2022, 70, .	0.7	2
973	The Relationship between Abnormal Circadian Blood Pressure Rhythm and Risk of Readmission in Patients with Heart Failure with Preserved Ejection Fraction. Cardiovascular Innovations and Applications, 2021, 5, 275-282.	0.3	2
974	Natural history and prognostic implications of left ventricular end-diastolic pressure in reperfused ST-segment elevation myocardial infarction: an analysis of the thrombolysis in myocardial infarction (TIMI) II randomized controlled trial. BMC Cardiovascular Disorders, 2021, 21, 243.	1.7	2
975	Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry. Circulation: Heart Failure, 2021, 14, e008277.	3.9	1
976	Progression of Preclinical Heart Failure: A Description of Stage A and B Heart Failure in a Community Population. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007216.	2.2	7
977	Heart Failure and Diabetes Mellitus: Biomarkers in Risk Stratification and Prognostication. Applied Sciences (Switzerland), 2021, 11, 4397.	2.5	2
978	Treatment prescription, adherence, and persistence after the first hospitalization for heart failure: A population-based retrospective study on 100785 patients. International Journal of Cardiology, 2021, 330, 106-111.	1.7	17
979	Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?. Future Cardiology, 2021, 17, 497-506.	1.2	2
980	Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure. Circulation Research, 2021, 128, 1468-1486.	4.5	63
981	Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients. BMC Cardiovascular Disorders, 2021, 21, 264.	1.7	1
982	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet, The, 2021, 397, 2385-2438.	13.7	530
983	Phenotypic clusters in heart failure with preserved and mid-range ejection fraction: new data and perspectives. Russian Journal of Cardiology, 2021, 26, 4436.	1.4	3
984	Captopril Versus Hydralazine-Isosorbide Dinitrate Vasodilator Protocols in Patients With Acute Decompensated Heart Failure Transitioning From Sodium Nitroprusside. Journal of Cardiac Failure, 2021, 27, 1053-1060.	1.7	4
985	Targeting Iron Deficiency in Heart Failure: Existing Evidence and Future Expectations. Circulation: Heart Failure, 2021, 14, e008299.	3.9	5
986	Consensus on basic conduct during the hospital admission of patients with acute heart failure. Revista Clínica Española, 2021, 221, 283-296.	0.5	0
987	Epidemiology of Heart Failure. Circulation Research, 2021, 128, 1421-1434.	4.5	377

#	ARTICLE	IF	CITATIONS
988	Heart failure with mid-range ejection fraction and the effect of β -blockers after acute myocardial infarction. Heart and Vessels, 2021, 36, 1848-1855.	1.2	3
989	The protocol and rationale for the efficacy and Tolerability of sacUBitril-valSarTan in adult congenital heart disease patients with heart failure (ENTRUST ACHD HF) registry. International Journal of Cardiology Congenital Heart Disease, 2021, 3, 100096.	0.4	7
990	Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure. European Journal of Heart Failure, 2022, 24, 807-817.	7.1	26
991	Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The <sc>BEnazepril Spironolactone STudy</sc> (<sc>BESST</sc>). Journal of Veterinary Internal Medicine, 2021, 35, 1673-1687.	1.6	13
993	Vericiguat. Hospital Pharmacy, 0, , 001857872110163.	1.0	0
994	Quality of care and risk of incident atrial fibrillation in patients with newly diagnosed heart failure: a nationwide cohort study. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 539-547.	4.0	1
995	Data in a Vacuum? The Desperate Need for a Paradigm Shift to Prevent Heart Failure in Black Americans. Journal of the American Heart Association, 2021, 10, e021048.	3.7	1
996	Outcomes among acute heart failure emergency department patients by preserved vs. reduced ejection fraction. ESC Heart Failure, 2021, 8, 2889-2898.	3.1	7
997	N-Nitrosodimethylamine-Contaminated Valsartan and the Risk of Cancer. Deutsches Ärztblatt International, 2021, 118, 357-362.	0.9	9
998	Cardiomyopathy Recent Findings. , 0, , .		0
1000	Consenso de actuaci3n b3sica durante el ingreso hospitalario por insuficiencia cardiaca aguda. Revista Clinica Espanola, 2021, 221, 283-296.	0.6	5
1001	Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. American Heart Journal, 2021, 235, 82-96.	2.7	7
1002	Impact of Renin-Angiotensin System Blockers on Mortality in Veterans Undergoing Cardiac Surgery. Journal of the American Heart Association, 2021, 10, e019731.	3.7	4
1003	Funding of Studies Supporting IA Guideline Recommendations in Cardiovascular MedicineA Systematic Review. Journal of the American Heart Association, 2021, 10, e019513.	3.7	2
1004	Percutaneous coronary intervention in patients with stable coronary artery disease and left ventricular systolic dysfunction: insights from the VA CART program. American Heart Journal, 2021, 235, 149-157.	2.7	3
1005	Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper. Heart Failure Reviews, 2021, , 1.	3.9	9
1006	All-cause mortality predicted by peak oxygen uptake differs depending on spirometry pattern in patients with heart failure and reduced ejection fraction. ESC Heart Failure, 2021, 8, 2731-2740.	3.1	6
1007	Pharmacogenetics to guide cardiovascular drug therapy. Nature Reviews Cardiology, 2021, 18, 649-665.	13.7	49

#	ARTICLE	IF	CITATIONS
1009	Epinephrine administration in venoarterial extracorporeal membrane oxygenation patients is associated with mortality: a retrospective cohort study. ESC Heart Failure, 2021, 8, 2899-2906.	3.1	13
1010	Effects of pharmacist interventions on heart failure outcomes: A systematic review and meta-analysis. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 871-882.	1.0	11
1011	Pregnancy-specific Reference Intervals for BNP and NT-pro BNP—Changes in Natriuretic Peptides Related to Pregnancy. Journal of the Endocrine Society, 2021, 5, bvab091.	0.2	16
1012	Left Ventricular Noncompaction Cardiomyopathy as a Potential Cause of Bilateral Posterior Cerebral Artery Stroke – a Rare and Unique Clinical Occurrence. American Journal of Case Reports, 2021, 22, e931103.	0.8	3
1013	Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. British Journal of Clinical Pharmacology, 2021, 87, 4691-4700.	2.4	5
1014	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 499.	6.1	120
1015	Nuclear respiratory factor 1 protects H9C2 cells against hypoxia-induced apoptosis via the death receptor pathway and mitochondrial pathway. Cell Biology International, 2021, 45, 1784-1796.	3.0	8
1016	S-Nitrosylation of Histone Deacetylase 2 by Neuronal Nitric Oxide Synthase as a Mechanism of Diastolic Dysfunction. Circulation, 2021, 143, 1912-1925.	1.6	28
1017	Risk assessment model for heart failure in Chinese patients with Takayasu's arteritis. Clinical Rheumatology, 2021, 40, 4117-4126.	2.2	2
1018	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. Circulation: Heart Failure, 2021, 14, e008100.	3.9	30
1019	Sex-related differences in the pharmacological treatment of heart failure. , 2022, 229, 107891.		14
1020	Development and validation of the Tool for Pharmacists to Predict 30-day hospital readmission in patients with Heart Failure (ToPP-HF). American Journal of Health-System Pharmacy, 2021, 78, 1691-1700.	1.0	4
1021	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. The Cochrane Library, 2021, 2021, CD012721.	2.8	19
1022	Falla cardiaca con fracción de eyección preservada: generalidades y aproximación en el perioperatorio. Revista Med, 2021, 28, 49-60.	0.1	0
1023	A network meta-analysis and systematic review of change in QRS duration after left bundle branch pacing, His bundle pacing, biventricular pacing, or right ventricular pacing in patients requiring permanent pacemaker. Scientific Reports, 2021, 11, 12200.	3.3	11
1024	Role of novel biomarkers in diabetic cardiomyopathy. World Journal of Diabetes, 2021, 12, 685-705.	3.5	19
1025	State-of-the-art narrative review: multimodality imaging in electrophysiology and cardiac device therapies. Cardiovascular Diagnosis and Therapy, 2021, 11, 881-895.	1.7	3
1026	Depressed right ventricular systolic function in heart failure due to constrictive pericarditis. ESC Heart Failure, 2021, 8, 3119-3129.	3.1	2

#	ARTICLE	IF	CITATIONS
1027	OUTpatient intravenous LASix Trial in reducing hospitalization for acute decompensated heart failure (OUTLAST). PLoS ONE, 2021, 16, e0253014.	2.5	4
1028	Clinical effectiveness of a dedicated cardiac resynchronization therapy pre-assessment clinic incorporating cardiac magnetic resonance imaging and cardiopulmonary exercise testing on patient selection and outcomes. IJC Heart and Vasculature, 2021, 34, 100800.	1.1	1
1029	Central sleep apnea in patients with heart failure: whom to screen and how to treat? – A brief review. Pneumologia, 2020, 69, 142-150.	0.1	0
1030	Î2-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now?. Vascular Health and Risk Management, 2021, Volume 17, 337-348.	2.3	9
1031	Gender differences in the prevalence of frailty in heart failure: A systematic review and meta-analysis. International Journal of Cardiology, 2021, 333, 133-140.	1.7	36
1032	Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. Clinical Pharmacokinetics, 2021, 60, 1407-1421.	3.5	14
1033	Combination Biomarkers for Risk Stratification in Patients with Chronic Heart Failure Biomarkers Prognostication in HF. Journal of Cardiac Failure, 2021, 27, 1321-1327.	1.7	7
1034	Trends and Predictors of Palliative Care Consultation Among Patients Admitted for LVAD: A Retrospective Analysis From the Nationwide Inpatient Sample Database From 2006-2014. American Journal of Hospice and Palliative Medicine, 2022, 39, 353-360.	1.4	4
1035	N-terminal pro brain natriuretic peptide predicts both all-cause and cardiovascular disease mortality in Japanese hemodialysis patients. Clinical and Experimental Nephrology, 2021, 25, 1142-1150.	1.6	3
1036	Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective. Journal of Clinical Medicine, 2021, 10, 2771.	2.4	19
1037	Impact of beta-blocker use on the long-term outcomes of heart failure patients with chronic obstructive pulmonary disease. ESC Heart Failure, 2021, 8, 3791-3799.	3.1	4
1038	Multi-modality assessment and role of left atrial function as an imaging biomarker in cardiovascular disease. International Journal of Cardiovascular Imaging, 2021, 37, 3355-3369.	1.5	8
1039	Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. Journal of the American Heart Association, 2021, 10, e018684.	3.7	13
1041	A History of Heart Failure Is an Independent Risk Factor for Death in Patients Admitted with Coronavirus 19 Disease. Journal of Cardiovascular Development and Disease, 2021, 8, 77.	1.6	7
1042	Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors. Clinical Cancer Research, 2021, 27, 5343-5352.	7.0	5
1044	Treatment for hyperkalaemia in heart failure: a network meta-analysis. The Cochrane Library, 2021, .	2.8	0
1045	Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 681726.	2.4	7
1046	Cardiac Biomarkers in Pediatrics: An Undervalued Resource. Clinical Chemistry, 2021, 67, 947-958.	3.2	13

#	ARTICLE	IF	CITATIONS
1047	Managing heart failure in dialysis patients. <i>Pediatric Nephrology</i> , 2021, 36, 2531-2535.	1.7	0
1048	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the <sc>PARADIGM</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1518-1524.	7.1	20
1049	The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy—A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 933-944.	7.1	34
1050	Assessment and management of cardiovascular disease in the intensive care unit. <i>Heart</i> , 2021,, heartjnl-2019-315568.	2.9	6
1051	Therapeutic Properties of Highly Selective β^2 -blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 959-971.	2.6	8
1052	The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5973.	4.1	20
1053	The Top 100 Cited Papers in the Field of Iron Deficiency in Humans: A Bibliometric Study. <i>BioMed Research International</i> , 2021, 2021, 1-9.	1.9	6
1054	The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 662-669.	1.7	8
1055	Friedreich Ataxia: Multidisciplinary Clinical Care. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 1645-1658.	2.7	26
1056	Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008166.	3.9	13
1057	Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices. <i>Journal of Cardiac Failure</i> , 2021, 27, 1328-1336.	1.7	7
1058	Analysis of matrix metalloproteinase-9 levels among acute heart failure patients with ACE inhibitor therapy (Dr. Soetomo Regional General Hospital, Surabaya). <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2021, 32, 447-451.	1.3	2
1059	Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. <i>Circulation</i> , 2021, 143, 2370-2383.	1.6	56
1060	Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008212.	3.9	8
1061	Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study. <i>Pharmacotherapy</i> , 2021, 41, 710-721.	2.6	1
1062	Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention. <i>Current Atherosclerosis Reports</i> , 2021, 23, 50.	4.8	7
1063	Compared impact of diabetes on the risk of heart failure from acute myocardial infarction to chronic coronary artery disease. <i>Diabetes and Metabolism</i> , 2022, 48, 101265.	2.9	3
1064	Clinical utility of 12-lead electrocardiogram in evaluating heart disease in patients with muscular dystrophy: Assessment of left ventricular hypertrophy, conduction disease, and cardiomyopathy. <i>Annals of Noninvasive Electrocardiology</i> , 2021, 26, e12876.	1.1	4

#	ARTICLE	IF	CITATIONS
1065	Sudden cardiac death after acute decompensation in heart failure patients: implications of discharge haemoglobin levels. ESC Heart Failure, 2021, 8, 3917-3928.	3.1	2
1066	Dapagliflozin for the treatment of type 2 diabetes mellitus – an update. Expert Opinion on Pharmacotherapy, 2021, 22, 2303-2310.	1.8	8
1067	Nighttime home blood pressure as a mediator of N-terminal pro-brain natriuretic peptide in cardiovascular events. Hypertension Research, 2021, 44, 1138-1146.	2.7	32
1068	Early invasive coronary angiography and acute ischaemic heart failure outcomes. European Heart Journal, 2021, 42, 3756-3766.	2.2	10
1069	Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure. Journal of Cardiovascular Medicine, 2021, 22, 848-856.	1.5	6
1070	Effects of Cardiac Rehabilitation in Low- and Middle-Income Countries: A systematic Review and Meta-Analysis of Randomised Controlled Trials. Progress in Cardiovascular Diseases, 2022, 70, 119-174.	3.1	26
1071	Introductory Chapter: Anaemia and Iron Deficiency in Heart Failure. , 0, , .		0
1072	Association between intestinal oedema and oral loop diuretic resistance in hospitalized patients with acute heart failure. ESC Heart Failure, 2021, 8, 4067-4076.	3.1	7
1073	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis. JAMA Cardiology, 2021, 6, 1329.	6.1	64
1074	Out-of-Pocket Annual Health Expenditures and Financial Toxicity From Healthcare Costs in Patients With Heart Failure in the United States. Journal of the American Heart Association, 2021, 10, e022164.	3.7	27
1075	The safety of morphine in patients with acute heart failure: A systematic review and meta-analysis. Clinical Cardiology, 2021, 44, 1216-1224.	1.8	13
1076	Stress Testing in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 435-445.	2.1	2
1077	Cardiac congestion assessed by natriuretic peptides oversimplifies the definition and treatment of heart failure. ESC Heart Failure, 2021, 8, 3453-3457.	3.1	4
1078	Difference in Prognosis between Continuation and Discontinuation of A 5-Month Cardiac Rehabilitation Program in Outpatients with Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2021, 10, 3306.	2.4	1
1079	Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association. Circulation: Arrhythmia and Electrophysiology, 2021, 14, HAE0000000000000078.	4.8	54
1080	Management of Pulmonary Hypertension in Left Heart Disease. Methodist DeBakey Cardiovascular Journal, 2021, 17, 115.	1.0	7
1081	Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology. Cardiovascular Research, 2022, 118, 2085-2102.	3.8	23
1082	ADDITION of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Nephrilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial). Indian Heart Journal, 2021, 73, 605-611.	0.5	6

#	ARTICLE	IF	CITATIONS
1083	RAAS: A Convergent Player in Ischemic Heart Failure and Cancer. International Journal of Molecular Sciences, 2021, 22, 7106.	4.1	7
1084	Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides. Frontiers in Cardiovascular Medicine, 2021, 8, 683418.	2.4	6
1085	Calcium and Heart Failure: How Did We Get Here and Where Are We Going?. International Journal of Molecular Sciences, 2021, 22, 7392.	4.1	8
1086	The "Peptide for Life"™ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. European Journal of Heart Failure, 2021, 23, 1432-1436.	7.1	10
1088	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Network Open, 2021, 4, e2114501.	5.9	49
1089	Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure. Cureus, 2021, 13, e16332.	0.5	2
1090	Social media and predictive analysis regarding dietary approaches to stop hypertension. Progress in Cardiovascular Diseases, 2021, 68, 88-90.	3.1	0
1091	A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era. Frontiers in Physiology, 2021, 12, 643721.	2.8	8
1092	Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis. BMC Cardiovascular Disorders, 2021, 21, 324.	1.7	5
1093	Diabetes and heart failure notions from epidemiology including patterns in low-, middle- and high-income countries. Diabetes Research and Clinical Practice, 2021, 177, 108822.	2.8	4
1094	Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1081-1091.	2.5	6
1095	The Diagnostic Value of Soluble ST2 in Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 685904.	2.4	4
1096	Optimal blood pressure for patients with end-stage renal disease following coronary interventions. Journal of Clinical Hypertension, 2021, 23, 1622-1630.	2.0	1
1097	Meta-analysis of impact of renin-angiotensin system inhibitors on survival after transcatheter aortic valve implantation. Minerva Cardiology and Angiology, 2021, 69, 299-309.	0.7	1
1098	SGLT2 inhibitors. Nurse Practitioner, 2021, 46, 30-37.	0.3	4
1099	Ventricular non-compaction review. Heart Failure Reviews, 2022, 27, 1063-1076.	3.9	22
1100	Inflammatory Cytokines, Immune Cells, and Organ Interactions in Heart Failure. Frontiers in Physiology, 2021, 12, 695047.	2.8	22
1101	Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 2021, 144, e56-e67.	1.6	400

#	ARTICLE	IF	CITATIONS
1102	Rethinking adherence to home care in heart failure: the lessons learned from Diego Maradona's death. Home Health Care Services Quarterly, 2021, 40, 192-203.	0.7	0
1103	Screening for regenerative therapy responders in heart failure. Biomarkers in Medicine, 2021, 15, 775-783.	1.4	7
1104	High Post-Procedural Transvalvular Gradient or Delayed Mean Gradient Increase after Transcatheter Aortic Valve Implantation: Incidence, Prognosis and Associated Variables. The FRANCE-2 Registry. Journal of Clinical Medicine, 2021, 10, 3221.	2.4	7
1105	Risk assessment in patients with left ventricular systolic dysfunction following transcatheter aortic valve replacement. Journal of Cardiac Surgery, 2021, 36, 3673-3678.	0.7	3
1106	Challenging patient phenotypes in the management of anaemia of chronic kidney disease. International Journal of Clinical Practice, 2021, 75, e14681.	1.7	5
1107	The Role of Galectin-3 and ST2 in Cardiology: A Short Review. Biomolecules, 2021, 11, 1167.	4.0	14
1108	Effect of a strategy of comprehensive vasodilation versus usual care on health-related quality of life among patients with acute heart failure. ESC Heart Failure, 2021, 8, 4218-4227.	3.1	4
1109	Mortality and <scp>guideline-directed</scp> medical therapy in <scp>real-world</scp> heart failure patients with reduced ejection fraction. Clinical Cardiology, 2021, 44, 1192-1198.	1.8	19
1110	ANMCO POSITION PAPER: Use of sacubitril/valsartan in hospitalized patients with acute heart failure. European Heart Journal Supplements, 2021, 23, C176-C183.	0.1	2
1111	Binding Potassium to Improve Treatment With Renin-Angiotensin-Aldosterone System Inhibitors: Results From Multiple One-Stage Pairwise and Network Meta-Analyses of Clinical Trials. Frontiers in Medicine, 2021, 8, 686729.	2.6	1
1112	Cardiac remodeling after anthracycline and radiotherapy exposure in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study. Cancer, 2021, 127, 4646-4655.	4.1	10
1113	Characteristics of patients with heart failure with preserved ejection fraction in primary care: a cross-sectional analysis. BJGP Open, 2021, 5, BJGPO.2021.0094.	1.8	7
1114	Influenza vaccination and mortality among adults with heart failure in an integrated healthcare delivery system, 2009-2018. Journal of General Internal Medicine, 2022, 37, 2405-2412.	2.6	3
1115	Association Between Arterial Stiffness and Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 707162.	2.4	9
1116	Heart Failure Syndrome With Preserved Ejection Fraction Is a Metabolic Cluster of Non-resolving Inflammation in Obesity. Frontiers in Cardiovascular Medicine, 2021, 8, 695952.	2.4	13
1117	Problems with the outcome measures in randomized controlled trials of traditional Chinese medicine in treating chronic heart failure caused by coronary heart disease: a systematic review. BMC Complementary Medicine and Therapies, 2021, 21, 217.	2.7	7
1118	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2021, 27, 826-836.	1.7	30
1119	Iron Deficiency in CKD Without Concomitant Anemia. Kidney International Reports, 2021, 6, 2752-2762.	0.8	13

#	ARTICLE	IF	CITATIONS
1120	Efficacy and safety of diuretics in heart failure with preserved ejection fraction: a scoping review. <i>Heart</i> , 2022, 108, 593-605.	2.9	3
1121	A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3495-3503.	3.1	3
1122	Hypoxia Inducible Factors as Central Players in the Pathogenesis and Pathophysiology of Cardiovascular Diseases. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 709509.	2.4	14
1123	Improved and new-onset anemia during follow-up in patients with acute decompensated heart failure. <i>Medicine (United States)</i> , 2021, 100, e26892.	1.0	4
1124	Marginal donors and organ shortness: concomitant surgical procedures during heart transplantation: a literature review. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 167-175.	1.5	7
1125	How does emotional intelligence improve employee satisfaction and performance with mediating effect of employee engagement? Perspective from Saudi Arabian private companies. <i>International Journal of Advanced and Applied Sciences</i> , 2021, 8, 79-93.	0.4	3
1126	Dysregulation of iron metabolism in cardiovascular diseases: From iron deficiency to iron overload. <i>Biochemical Pharmacology</i> , 2021, 190, 114661.	4.4	30
1127	The Future of Exercise-Based Cardiac Rehabilitation for Patients With Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 709898.	2.4	14
1128	Metabolomic Profiling of Adults with Congenital Heart Disease. <i>Metabolites</i> , 2021, 11, 525.	2.9	8
1129	Implantable vagus nerve stimulation system performance is not affected by internal or external defibrillation shocks. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, , 1.	1.3	1
1130	Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 61.	4.8	8
1131	Time-to-event prediction analysis of patients with chronic heart failure comorbid with atrial fibrillation: a LightGBM model. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 379.	1.7	4
1132	Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2114-2122.	3.0	15
1133	Outcome Benefits Seen With 1 Year of Optimized Sacubitril/Valsartan for the Treatment of Systolic Heart Failure Managed by Pharmacists in a Cardiology Practice. <i>Annals of Pharmacotherapy</i> , 2021, , 106002802110361.	1.9	2
1134	Risk of Incident Heart Failure in Individuals With Early-Onset Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e178-e187.	3.6	7
1136	Use of sodium zirconium cyclosilicate for up-titration of renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure: a case series. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab281.	0.6	3
1137	Beyond Ejection Fraction: Novel Clinical Approaches Towards Sudden Cardiac Death Risk Stratification in Patients with Dilated Cardiomyopathy. <i>Current Cardiology Reviews</i> , 2022, 18, .	1.5	4
1138	Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. <i>Annual Review of Medicine</i> , 2022, 73, 321-337.	12.2	52

#	ARTICLE	IF	CITATIONS
1139	Implications of Left Ventricular Function on Short-Term Outcomes in COVID-19 Patients With Myocardial Injury. <i>Cardiovascular Revascularization Medicine</i> , 2021, 29, 45-49.	0.8	5
1140	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021459.	3.7	10
1141	Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1149-e1156.	4.4	2
1142	Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction. <i>Experimental Biology and Medicine</i> , 2021, 246, 2511-2521.	2.4	9
1143	Angiotensin Receptor Blocker and Neprilysin Inhibitor Suppresses Cardiac Dysfunction by Accelerating Myocardial Angiogenesis in Apolipoprotein E-Knockout Mice Fed a High-Fat Diet. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2021, 2021, 1-11.	1.7	2
1144	Target trial emulations: bridging the gap between clinical trial and real-world data. <i>European Journal of Heart Failure</i> , 2021, 23, 1708-1711.	7.1	1
1145	A machine-learning-based method to predict adverse events in patients with dilated cardiomyopathy and severely reduced ejection fractions. <i>British Journal of Radiology</i> , 2021, 94, 20210259.	2.2	5
1146	Clinical characteristics, management, and one-year risk of complications among patients with heart failure with and without type 2 diabetes in Spain. <i>Revista Clínica Española</i> , 2022, 222, 195-204.	0.5	6
1147	The Intersection of Type 2 Myocardial Infarction and Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e020849.	3.7	2
1148	Early intravenous nitroglycerin use in prehospital setting and in the emergency department to treat patients with acute heart failure: Insights from the EAHFE Spanish registry. <i>International Journal of Cardiology</i> , 2021, 344, 127-134.	1.7	5
1149	Practice Patterns and Patient Outcomes After Widespread Adoption of Remote Heart Failure Care. <i>Circulation: Heart Failure</i> , 2021, 14, e008573.	3.9	21
1150	Bioimpedance Vector Analysis for Heart Failure: Should We Put It on the Agenda?. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 744243.	2.4	4
1151	Incidence, predictors, and clinical outcomes of mechanical circulatory support-related complications in patients with cardiogenic shock. <i>Journal of Cardiology</i> , 2022, 79, 163-169.	1.9	11
1152	Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac Mortality in Heart Failure with Reduced Ejection Fraction. <i>Angiology</i> , 2021, , 000331972110473.	1.8	10
1153	Pacing-Induced Cardiomyopathy. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 741-753.	1.7	10
1154	Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. <i>ESC Heart Failure</i> , 2021, 8, 4572-4583.	3.1	21
1155	Heart transplantation in the new era of extended donor criteria. <i>Journal of Cardiac Surgery</i> , 2021, 36, 4828-4829.	0.7	6
1156	Pharmacokinetics and diuretic effect of furosemide after single intravenous, oral tablet, and newly developed oral disintegrating film administration in healthy beagle dogs. <i>BMC Veterinary Research</i> , 2021, 17, 295.	1.9	1

#	ARTICLE	IF	CITATIONS
1157	Left ventricular dimensions and cardiovascular outcomes in systolic heart failure: the WARCEF trial. ESC Heart Failure, 2021, 8, 4997-5009.	3.1	11
1158	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	8.6	13
1159	Diagnosis, treatment and predictors of prognosis of myocarditis. A narrative review. Cardiovascular Pathology, 2021, 54, 107362.	1.6	10
1160	Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2021, 144, e238-e250.	1.6	89
1161	Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study. American Heart Journal, 2021, 239, 1-10.	2.7	15
1162	Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments. Hypertension, 2021, 78, 564-577.	2.7	35
1163	Identification of the distinctive role of DPT in dilated cardiomyopathy: a study based on bulk and single-cell transcriptomic analysis. Annals of Translational Medicine, 2021, 9, 1401-1401.	1.7	6
1164	Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report. Journal of Heart and Lung Transplantation, 2021, 40, 1605-1613.	0.6	5
1165	Left Atrial Strain Associated with Functional Recovery in Patients Receiving Optimal Treatment for Heart Failure. Journal of the American Society of Echocardiography, 2021, 34, 966-975.e2.	2.8	8
1166	Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 2021, , .	3.1	9
1167	Ivabradine Ameliorates Cardiac Function in Heart Failure with Preserved and Reduced Ejection Fraction via Upregulation of miR-133a. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-23.	4.0	7
1168	Web-Based Training and Telephone Follow-up of Patients With Heart Failure. CIN - Computers Informatics Nursing, 2022, 40, 82-89.	0.5	2
1169	Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy. Journal of Clinical Medicine, 2021, 10, 4409.	2.4	5
1170	Exercise intensity assessment and prescription in cardiovascular rehabilitation: never ending story. European Journal of Preventive Cardiology, 2021, , .	1.8	0
1171	Increased Serum Levels of soluble ST2 as a Predictor of Disease Progression in Systemic Sclerosis. Scandinavian Journal of Rheumatology, 2022, 51, 315-322.	1.1	4
1172	Impact of a <scp>pharmacistâ€inclusive postâ€discharge</scp> clinic on outcomes in heart failure patients with reduced ejection fraction: Rates of hospital readmission, emergency department visits, or death. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1516-1523.	1.0	3
1173	A fourth pillar for all in the treatment of heart failure. European Heart Journal, 2021, 42, 4452-4454.	2.2	3
1174	Prognostic significance of dipstick proteinuria in heart failure with preserved ejection fraction: insight from the PURSUIT-HFpEF registry. BMJ Open, 2021, 11, e049371.	1.9	3

#	ARTICLE	IF	CITATIONS
1175	Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. <i>Journal of the American Heart Association</i> , 2021, 10, e021276.	3.7	6
1176	Importance of Optimized Guideline-Based Therapy for Preventing Rehospitalization of Chronic Heart Failure Patientsâ€œ. From the KUNIMI Acute Cohort â€œ. <i>Circulation Reports</i> , 2021, 3, 511-519.	1.0	0
1177	Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19. <i>Circulation: Heart Failure</i> , 2021, 14, e008354.	3.9	25
1178	Heart failure with mid-range or mildly reduced ejection fraction. <i>Nature Reviews Cardiology</i> , 2022, 19, 100-116.	13.7	156
1179	Faltering Under Pressure: Limitations to Noninvasive Diastolic Function Assessments. <i>Journal of the American Heart Association</i> , 2021, 10, e023189.	3.7	3
1180	Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 19-25.	1.9	10
1181	Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology. <i>Journal of the American Heart Association</i> , 2021, 10, e021584.	3.7	12
1182	Subclinical Myocardial Injury and the Phenotype of Clinical Congestion in Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 422-430.	1.7	2
1183	The Use of Machine Learning for the Care of Hypertension and Heart Failure. <i>JACC Asia</i> , 2021, 1, 162-172.	1.5	9
1184	In-hospital mortality, length of stay and hospital costs for hospitalized breast cancer patients with comorbid heart failure in the USA. <i>Current Medical Research and Opinion</i> , 2021, 37, 1-5.	1.9	1
1185	PET Cardiac Imaging (Perfusion, Viability, Sarcoidosis, and Infection). <i>Radiologic Clinics of North America</i> , 2021, 59, 835-852.	1.8	8
1186	The Effect of Angiotensin Receptor Inhibitors and Neprilysin on Aortic Stiffness in Patients with Heart Failure and Reduced Ejection Fraction. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 298-306.	0.6	0
1187	Soluble Guanylate Cyclase Stimulators in Heart Failure. <i>Cureus</i> , 2021, 13, e17781.	0.5	6
1188	Mitral and Tricuspid Valves Percutaneous Repair in Patients with Advanced Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 607-618.	2.1	9
1189	Improving Quality of Life in Heart Failure. <i>Current Cardiology Reports</i> , 2021, 23, 159.	2.9	22
1190	Potential pitfalls when interpreting plasma BNP levels in heart failure practice. <i>Journal of Cardiology</i> , 2021, 78, 269-274.	1.9	19
1191	Biomarker profile and risk stratification in cardiovascular disease during pregnancy: Action to move forward. <i>International Journal of Cardiology Congenital Heart Disease</i> , 2021, 5, 100206.	0.4	0
1192	Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension. <i>Journal of General Internal Medicine</i> , 2021, 36, 3802-3809.	2.6	2

#	ARTICLE	IF	CITATIONS
1193	Cardiac Sarcoidosis: A Clinical Overview. Current Problems in Cardiology, 2021, 46, 100936.	2.4	3
1194	Cardiac Resynchronization Therapy and Cardiac Contractility Modulation in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 599-606.	2.1	5
1195	Diuretic strategies in patients with resistance to loop-diuretics in the intensive care unit: A retrospective study from the MIMIC-III database. Journal of Critical Care, 2021, 65, 282-291.	2.2	9
1196	Disease-modifier Drugs in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 561-573.	2.1	2
1197	Early rehabilitation after acute myocardial infarction: A nationwide inpatient database study. Journal of Cardiology, 2021, 78, 456-462.	1.9	7
1198	Performance of the H2FPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: A report from the Japanese multicenter registry. International Journal of Cardiology, 2021, 342, 43-48.	1.7	17
1199	Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials. American Heart Journal, 2021, 241, 74-82.	2.7	4
1200	Caregiver subjective and physiological markers of stress and patient heart failure severity in family care dyads. Psychoneuroendocrinology, 2021, 133, 105399.	2.7	6
1201	Evaluation of patients with heart failure. , 2022, , 51-76.		0
1202	Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis. Frontiers in Cardiovascular Medicine, 2020, 7, 597472.	2.4	3
1203	Danish translation and linguistic validation of the multidimensional dyspnea profile. European Clinical Respiratory Journal, 2021, 8, 1905498.	1.5	2
1204	Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients. Cardiology Research, 2021, 12, 2-9.	1.1	1
1205	Invasive Hemodynamic Assessment in Heart Failure With Preserved Ejection Fraction. , 2021, , 93-105.		0
1206	General Treatment of Heart Failure With Preserved Ejection Fraction and Randomized Trials. , 2021, , 463-472.		0
1207	Chronische Herzinsuffizienz. , 2021, , 92-109.		0
1208	Age- and sex-matched comparison of diet quality in patients with heart failure to similarly aged healthy older adults. Journal of Nutritional Science, 2021, 10, e65.	1.9	3
1209	Increased natriuretic peptides not associated with heart failure. Russian Journal of Cardiology, 0, 25, 4140.	1.4	41
1210	Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD-AF. ESC Heart Failure, 2021, 8, 1139-1149.	3.1	18

#	ARTICLE	IF	CITATIONS
1211	Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400â€‰%000 patients from the UK Clinical Practice Research Datalink (CPRD). CKJ: Clinical Kidney Journal, 2021, 14, 2203-2212.	2.9	15
1212	Impact of the state of emergency enacted due to the COVID-19 pandemic on the physical activity of the elderly in Japan. Journal of Physical Therapy Science, 2021, 33, 345-350.	0.6	9
1213	Surgical Ventricular Remodeling (SVR): Anesthesia Considerations. , 2021, , 243-251.		0
1214	Association of long-term SBP with clinical outcomes and quality of life in heart failure with preserved ejection fraction: an analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Journal of Hypertension, 2021, 39, 1378-1385.	0.5	4
1215	Perceived Versus Actual Risks of 30-Day Readmission in Patients With Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006586.	2.2	3
1216	Impact of national valsartan recalls on Veteransâ€™ outcomes. Therapeutic Advances in Drug Safety, 2021, 12, 204209862110161.	2.4	4
1217	Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial. Kidney360, 2021, 2, 425-434.	2.1	13
1218	Cardiac Rehabilitation in Heart Failure. International Journal of Heart Failure, 2021, 3, 1.	2.7	17
1219	The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction. Therapeutic Advances in Cardiovascular Disease, 2021, 15, 175394472110026.	2.1	10
1220	High Plasma Docosahexaenoic Acid Associated to Better Prognoses of Patients with Acute Decompensated Heart Failure with Preserved Ejection Fraction. Nutrients, 2021, 13, 371.	4.1	10
1221	Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-16.	4.0	19
1222	Cardiac Rehabilitation for Frail Older People. Advances in Experimental Medicine and Biology, 2020, 1216, 131-147.	1.6	9
1223	Pharmaceutical Treatment for Heart Failure. Advances in Experimental Medicine and Biology, 2020, 1177, 269-295.	1.6	7
1224	Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Failure Reviews, 2021, 26, 1037-1062.	3.9	3
1225	Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratificationâ€™A Narrative Review. Diabetes Therapy, 2020, 11, 1271-1291.	2.5	15
1226	Intravenous iron supplementation therapy. Molecular Aspects of Medicine, 2020, 75, 100862.	6.4	44
1229	Anthracycline-induced cardiomyopathy: cellular and molecular mechanisms. Clinical Science, 2020, 134, 1859-1885.	4.3	7
1230	Usability Testing of a Sensor-Controlled Digital Game to Engage Older Adults with Heart Failure in Physical Activity and Weight Monitoring. Applied Clinical Informatics, 2020, 11, 873-881.	1.7	8

#	ARTICLE	IF	CITATIONS
1231	Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. <i>European Heart Journal</i> , 2020, 41, 1720-1729.	2.2	154
1232	Nonpharmacologic Treatment for Heart Failure. <i>Cardiology in Review</i> , 2021, 29, 48-53.	1.4	6
1233	The Role of Testosterone in Patients With Heart Failure: A Systematic Review. <i>Cardiology in Review</i> , 2021, 29, 156-161.	1.4	6
1237	Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions. <i>Circulation: Heart Failure</i> , 2020, 13, e007094.	3.9	22
1238	Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2018, 12, 217-231.	2.1	21
1239	How I treat anemia in heart failure. <i>Blood</i> , 2020, 136, 790-800.	1.4	14
1240	Prediction of sudden death in elderly patients with heart failure. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 185-192.	0.2	11
1241	Effect of β -blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 291-297.	0.2	5
1242	Japanese Heart Failure Society 2018 Scientific Statement on Nutritional Assessment and Management in Heart Failure Patients. <i>Circulation Journal</i> , 2020, 84, 1408-1444.	1.6	19
1243	Factors Associated With Elevated N-Terminal Pro B-Type Natriuretic Peptide Concentrations at the Convalescent Stage and 1-Year Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation Reports</i> , 2020, 2, 400-408.	1.0	4
1244	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure. <i>PLoS ONE</i> , 2020, 15, e0240567.	2.5	4
1245	In-Hospital and Long-Term Outcomes of Beta-Blocker Treatment in Cocaine Users: A Systematic Review and Meta-analysis. <i>Cardiology Research</i> , 2019, 10, 40-47.	1.1	2
1246	The clinically effective use of cardiac markers by restructuring laboratory profiles at Cardiology wards. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1565-1571.	2.3	2
1247	Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 79-90.	2.3	42
1248	High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 513-521.	2.3	8
1249	Re-examining ferritin-bound iron: current and developing clinical tools. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 459-471.	2.3	8
1250	Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction. <i>Cardiac Failure Review</i> , 2020, 6, 1-7.	3.0	8
1251	Asymptomatic Left Ventricle Systolic Dysfunction. <i>European Cardiology Review</i> , 2020, 15, e13.	2.2	20

#	ARTICLE	IF	CITATIONS
1255	Metabolic remodeling induced by mitokines in heart failure. <i>Aging</i> , 2019, 11, 7307-7327.	3.1	9
1256	Silent myocardial infarction and risk of heart failure. <i>Annals of Translational Medicine</i> , 2018, 6, S35-S35.	1.7	4
1257	The Predictive Role for ST2 in Patients with Acute Coronary Syndromes and Heart Failure. <i>Current Medicinal Chemistry</i> , 2020, 27, 4479-4493.	2.4	9
1258	Recently Approved and Under Investigation Drugs for Treating Patients with Heart Failure. <i>Current Cardiology Reviews</i> , 2020, 16, 202-211.	1.5	4
1259	Mobile Phone Apps to Support Heart Failure Self-Care Management: Integrative Review. <i>JMIR Cardio</i> , 2018, 2, e10057.	1.7	86
1260	Structured Telephone Support Intervention: Improved Heart Failure Outcomes. <i>JMIR Aging</i> , 2020, 3, e13513.	3.0	3
1261	Deep Neural Network for Reducing the Screening Workload in Systematic Reviews for Clinical Guidelines: Algorithm Validation Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e22422.	4.3	11
1262	Bioimpedance vector analysis in the evaluation of congestion in heart failure. <i>Biomarkers in Medicine</i> , 2020, 14, 81-85.	1.4	10
1263	Association of Plasma Leucine-Rich Î±2 Glycoprotein 1, a Modulator of Transforming Growth Factor-Î² Signaling Pathway, With Incident Heart Failure in Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 571-577.	8.6	11
1264	The effects of a 50 km ultramarathon race on high sensitivity cardiac troponin I and NT-proBNP in highly trained athletes. <i>Minerva Cardioangiologica</i> , 2020, 68, 305-312.	1.2	6
1265	COMPARISON OF CONCENTRATION DIFFERENCE BETWEEN ST2 DAN NT-PRO BNP BEFORE AND AFTER ACE-INHIBITORS IN NYHA III-IV HEART FAILURE PATIENTS. <i>Indonesian Journal of Clinical Pathology</i> , 2019, 26, 11.	0.1	2
1266	The combined measurement of high-sensitivity cardiac troponins and natriuretic peptides: a useful tool for clinicians?. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 953-963.	1.5	14
1267	Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits. <i>Acta Pharmaceutica</i> , 2021, 71, 473-484.	2.0	6
1268	Using Physical Function to Predict Hospital Readmission within 1 Year in Patients with Heart Failure. <i>Progress in Rehabilitation Medicine</i> , 2019, 4, n/a.	0.9	7
1269	Effect of Angiotensin-Converting Enzyme Blockade, Alone or Combined With Blockade of Soluble Epoxide Hydrolase, on the Course of Congestive Heart Failure and Occurrence of Renal Dysfunction in Ren-2 Transgenic Hypertensive Rats With Aorto-Caval Fistula. <i>Physiological Research</i> , 2017, 67, 401-415.	0.9	14
1270	Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2020, 2, 113.	0.1	12
1271	Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism</i> , 2020, 35, 260-271.	3.0	12
1272	Palliative and end-of-life care for heart failure patients in an aging society. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 1039-1049.	1.7	19

#	ARTICLE	IF	CITATIONS
1273	Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence. Korean Journal of Internal Medicine, 2020, 35, 498-513.	1.7	12
1274	ACE inhibitors and ARBs: Managing potassium and renal function. Cleveland Clinic Journal of Medicine, 2019, 86, 601-607.	1.3	32
1275	Meditation for Improved Clinical Outcomes in Patients with Implantable Defibrillators for Heart Failure- Pilot Study. Journal of Atrial Fibrillation, 2020, 12, 2314.	0.5	4
1276	Rationale and Design of the High Platelet Inhibition with Ticagrelor to Improve Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction (HEALING-AMI) Trial. Korean Circulation Journal, 2019, 49, 586.	1.9	5
1277	Matricellular proteins as possible biomarkers for early brain injury after aneurysmal subarachnoid hemorrhage. Neural Regeneration Research, 2018, 13, 1175.	3.0	33
1278	Eplerenone: The multifaceted drug in cardiovascular pharmacology. Journal of Pharmacy and Bioallied Sciences, 2020, 12, 381.	0.6	5
1279	A Comparative Study of Color Stability and Fluoride Release from Glass Ionomer Cements Combined with Chlorhexidine. International Journal of Clinical Pediatric Dentistry, 2013, 6, 26-29.	0.8	9
1280	Foreign Body in Root Canals of Two Adjacent Deciduous Molars: A Case Report. International Journal of Clinical Pediatric Dentistry, 2013, 6, 38-39.	0.8	5
1281	Prosthetic Rehabilitation of a Pediatric Patient with an Ocular Defect. International Journal of Clinical Pediatric Dentistry, 2013, 6, 62-65.	0.8	2
1282	Langerhans Cell Histiocytosis: An Illusion of Hope. International Journal of Clinical Pediatric Dentistry, 2013, 6, 66-70.	0.8	3
1283	The effect of beta-blockers on mortality in patients with heart failure and atrial fibrillation: A meta-analysis of observational cohort and randomized controlled studies. Cardiology Journal, 2020, 26, 744-752.	1.2	3
1284	2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. Acta Cardiologica Sinica, 2019, 35, 244-283.	0.2	50
1285	Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure. MDM Policy and Practice, 2021, 6, 238146832110416.	0.9	1
1286	Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism: Clinical and Experimental, 2022, 126, 154918.	3.4	42
1287	Inverse Associations Between Circulating Secreted Frizzled Related Protein 2 (sFRP2) and Cardiometabolic Risk Factors. Frontiers in Cardiovascular Medicine, 2021, 8, 723205.	2.4	2
1288	High alert drugs screening using gradient boosting classifier. Scientific Reports, 2021, 11, 20132.	3.3	9
1289	Moving the Needle on Atherosclerotic Cardiovascular Disease and Heart Failure with Influenza Vaccination. Current Atherosclerosis Reports, 2021, 23, 78.	4.8	7
1290	Worsened Tricuspid Regurgitation Following Pericardiectomy for Constrictive Pericarditis. Circulation: Cardiovascular Imaging, 2021, 14, e012948.	2.6	6

#	ARTICLE	IF	CITATIONS
1291	A Multivariate Model to Predict Chronic Heart Failure after Acute ST-Segment Elevation Myocardial Infarction: Preliminary Study. <i>Diagnostics</i> , 2021, 11, 1925.	2.6	2
1292	Cardiomyocyte-Specific RIP2 Overexpression Exacerbated Pathologic Remodeling and Contributed to Spontaneous Cardiac Hypertrophy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 688238.	3.7	4
1293	A clinical score to predict mortality in patients after acute heart failure from Japanese registry. <i>ESC Heart Failure</i> , 2021, , .	3.1	3
1294	Prognostic impact of systolic blood pressure in acute heart failure with preserved ejection fraction in older patients. <i>ESC Heart Failure</i> , 2021, 8, 5493-5500.	3.1	3
1295	Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 655-663.	1.4	7
1296	Differential impact of antihypertensive drugs on cardiovascular remodeling: a review of findings and perspectives for HFpEF prevention. <i>Hypertension Research</i> , 2022, 45, 53-60.	2.7	7
1297	Analytical performance evaluation of the new sST2 turbidimetric assay implemented in laboratory automation systems. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, .	2.3	2
1298	Prognostic value of an echocardiographic index reflecting right ventricular operating stiffness in patients with heart failure. <i>Heart and Vessels</i> , 2022, 37, 583-592.	1.2	0
1299	The Arrhythmic Phenotype in Cardiomyopathy. <i>Heart Failure Clinics</i> , 2021, 18, 101-113.	2.1	0
1300	Clinical Management of DMD-Associated Cardiomyopathy. , 0, , .		1
1301	Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction. <i>Circulation Journal</i> , 2023, 87, 1039-1046.	1.6	6
1302	Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 750-760.	4.0	7
1303	The Impact of Glucocorticoid Therapy on Guideline-Directed Medical Treatment Titration in Patients Hospitalized for Heart Failure with Low Blood Pressure: A Retrospective Study. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6693-6701.	1.8	4
1304	Poor efficacy of oral iron replacement therapy in pediatric patients with heart failure. <i>Cardiology in the Young</i> , 2022, 32, 1302-1309.	0.8	4
1305	Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e020474.	3.7	1
1306	Safety and efficacy of iron supplementation after myocardial infarction in mice with moderate blood loss anaemia. <i>ESC Heart Failure</i> , 2021, 8, 5445-5455.	3.1	8
1307	Hospitalization for Heart Failure in the United States, UK, Taiwan, and Japan: An International Comparison of Administrative Health Records on 413,385 Individual Patients. <i>Journal of Cardiac Failure</i> , 2022, 28, 353-366.	1.7	11
1308	Measuring lung water adds prognostic value in heart failure patients undergoing cardiac magnetic resonance. <i>Scientific Reports</i> , 2021, 11, 20162.	3.3	4

#	ARTICLE	IF	CITATIONS
1309	Shorter (GT)n repeats in the haem-oxygenase 1 gene promoter are associated with better mid-term survival in subjects with coronary artery disease and abnormal ejection fraction. Biomarkers, 2021, 26, 1-5.	1.9	3
1310	Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 863-872.	1.9	6
1311	Crouzon's Syndrome: A Case Report. International Journal of Clinical Pediatric Dentistry, 2013, 6, 33-37.	0.8	5
1312	Complex Odontome associated with Maxillary Impacted Permanent Central Incisor: A Case Report. International Journal of Clinical Pediatric Dentistry, 2013, 6, 58-61.	0.8	1
1314	Chronic Heart Failure. , 2017, , .		0
1315	Herz-Kreislauf-System. , 2018, , 145-201.		0
1316	LEVEL OF GLYCATION END PRODUCTS AND GALACTIN-3 IN PATIENTS WITH CHRONIC HEART FAILURE AND ATRIAL FIBRILLATION IN DEPENDENCE ON THE AGE AND RENAL FUNCTIONAL. EUREKA Health Sciences, 2018, 1, 34-41.	0.1	1
1319	Recognition, Diagnosis, and Management of Heart Failure with Preserved Ejection Fraction. US Cardiology Review, 2018, 12, 8-12.	0.5	0
1320	Cardiovascular and Cancer Risk: The Role of Cardio-oncology. Journal of the Advanced Practitioner in Oncology, 2018, 9, .	0.4	9
1321	Interdependence Between Atrial Fibrillation and Heart Failure. Medicina Interna (Bucharest, Romania:) Tj ETQq1 1 0.784314 rgBT /Ove	0.0	0
1322	ALGORITHM FOR THE TREATMENT OF PATIENTS WITH ACUTE HEART FAILURE. Russian Archives of Internal Medicine, 2018, 8, 247-259.	0.2	1
1323	CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: TREATMENT IN CONDITIONS OF LIMITED EVIDENCE. Kuban Scientific Medical Bulletin, 2018, 25, 106-114.	0.4	0
1324	Differentiation of umbilical cord Wharton's jelly derived mesenchymal stem cells into cardiomyocytes using 5-azacytidine. Menoufia Medical Journal, 2019, 32, 991.	0.1	2
1325	Correlation between the cytokine profile and anticongestive medication in patients with chronic chagasic cardiopathy. Revista Da Sociedade Brasileira De Medicina Tropical, 2019, 52, e20190386.	0.9	1
1326	Clinical Presentation, Spectrum of Disease, and Natural History. , 2019, , 71-82.		1
1327	Plasma B-type Natriuretic Peptide Levels in Stable Heart Failure Patients. Indian Journal of Medical Biochemistry, 2019, 23, 189-192.	0.1	0
1328	Clinical Care for Individuals with Chronic Trypanosoma cruzi Infection: Decision-Making in theÂMidst of Uncertainty. Birkhauser Advances in Infectious Diseases, 2019, , 199-224.	0.3	1
1329	Overview of the impact Î²1-adrenergic receptor gene polymorphisms have on the progression of heart failure. Journal of the National Academy of Medical Sciences of Ukraine, 2019, , 296-305.	0.3	0

#	ARTICLE	IF	CITATIONS
1330	Snapshot Evaluation of Acute and Chronic Heart Failure in Real Life in Turkey: Follow up data for mortality. <i>Anatolian Journal of Cardiology</i> , 2019, 23, 160-168.	0.9	6
1331	Hypercholesterolemia Management in Older Adults: A Scoping Review of Recent Evidence. <i>Journal of Gerontological Nursing</i> , 2019, 45, 31-42.	0.6	0
1332	Reading Level and Suitability of Congestive Heart Failure (CHF) Education in a Mobile App (CHF Info) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.0	6
1333	Evidence-Based Practice Guideline: Assessing Heart Failure in Long-Term Care Facilities. <i>Journal of Gerontological Nursing</i> , 2019, 45, 18-24.	0.6	2
1334	Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF. <i>Global Cardiology Science & Practice</i> , 2019, 2019, 3.	0.4	0
1336	Value of the natriuretic peptide level in diagnostics of newborns with heart failure. <i>Rossiyskiy Vestnik Perinatologii i Pediatrii</i> , 2019, 64, 51-59.	0.3	2
1338	Educational intervention to improve appropriate digoxin therapeutic drug monitoring: a quasi-experimental study. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, 320-324.	1.1	1
1339	Chemotherapy-Related Cardiovascular Complications. , 2020, , 815-836.		0
1340	Important Differences in Cardiovascular Care. , 2020, , 37-54.		0
1342	Arrhythmia-Induced Cardiomyopathies. <i>Contemporary Cardiology</i> , 2020, , 547-567.	0.1	0
1343	Optimizing Noncardiac Prescription in a Cardiac Patient. <i>Bengal Physician Journal</i> , 2020, 7, 63-69.	0.1	0
1344	Old and New Drugs for Treatment of Advanced Heart Failure. <i>Current Pharmaceutical Design</i> , 2020, 26, 1571-1583.	1.9	2
1345	Identification of Target Genes and Transcription Factors in Mice with LMNA-Related Dilated Cardiomyopathy by Integrated Bioinformatic Analyses. <i>Medical Science Monitor</i> , 2020, 26, e924576.	1.1	1
1346	Pharmacist- or Nurse Practitionerâ€™Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. <i>Canadian Journal of Hospital Pharmacy</i> , 2020, 73, .	0.1	2
1349	Prediction of Medium-Term Mortality in Japanese Patients With Wild-Type Transthyretin Amyloidosis. <i>Circulation Reports</i> , 2020, 2, 314-321.	1.0	3
1350	Five-Year Outcomes of Heart Failure with Preserved Ejection Fraction. <i>Open Cardiovascular Medicine Journal</i> , 2020, 14, 18-26.	0.3	3
1351	Is High Heart Rate Always Harmful to Heart Failure Patients?. <i>Circulation Journal</i> , 2020, 84, 1673-1674.	1.6	2
1352	The Utilization of Spironolactone in Heart Failure Patients at a Tertiary Hospital in Saudi Arabia. <i>Cureus</i> , 2020, 12, e10032.	0.5	1

#	ARTICLE	IF	CITATIONS
1353	Renin-“Angiotensin”-Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort Study. Drug Safety, 2022, 45, 65-74.	3.2	2
1354	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 144, e368-e454.	1.6	319
1355	Impaired Cardiac Sympathetic Innervation Increases the Risk of Cardiac Events in Heart Failure Patients with Left Ventricular Hypertrophy and Mechanical Dyssynchrony. Journal of Clinical Medicine, 2021, 10, 5047.	2.4	1
1356	A Comprehensive Analysis of the Efficacy of Resveratrol in Atherosclerotic Cardiovascular Disease, Myocardial Infarction and Heart Failure. Molecules, 2021, 26, 6600.	3.8	22
1357	Heart Failure with Preserved Ejection Fraction and Cardiomyopathy: an Under-recognized Complication of Systemic Sclerosis. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	0
1358	CARDIOVASCULAR COMPLICATIONS OF ANTITUMOR THERAPY FOR BREAST CANCER: DIAGNOSIS, PREVENTION AND TREATMENT. Siberian Journal of Oncology, 2021, 20, 138-148.	0.3	1
1359	Pharmacologic Support of the Failing Heart. , 2020, , 597-605.		0
1360	Atrial and Brain Natriuretic Peptides. , 2020, , 1-6.		0
1361	Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. Revista Espanola De Cardiologia (English Ed), 2022, 75, 31-38.	0.6	20
1362	Effectiveness and safety of Xinyin tablet in treatment of chronic heart failure. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Qverlock 10	1.0	1
1363	A constructivist approach to teaching patients with heart failure: results from an intervention study. European Journal of Cardiovascular Nursing, 2021, 20, 331-341.	0.9	1
1364	Rebranding Natriuretic Peptides. Clinical Chemistry, 2021, 67, 4-5.	3.2	1
1365	Secondary Prevention and Cardiac Rehabilitation. Contemporary Cardiology, 2021, , 673-703.	0.1	0
1366	Prevention of Heart Failure. Contemporary Cardiology, 2021, , 489-512.	0.1	1
1367	Reduced lifespan of erythrocytes in Dahl/Salt sensitive rats is the cause of the renal proximal tubule damage. Scientific Reports, 2020, 10, 22023.	3.3	8
1368	Novel technologies in the management of heart failure with preserved ejection fraction: a promise during the time of disappointment from pharmacological approaches?. Current Opinion in Cardiology, 2021, 36, 211-218.	1.8	0
1369	Prevalence of abnormalities in electrocardiogram conduction in dialysis patients: a comparative study. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 448-453.	0.9	1
1370	Palliative care plan of the patient with advanced heart failure. Medic Ro, 2020, 3, 30.	0.0	0

#	ARTICLE	IF	CITATIONS
1371	Sleep apnea syndrome and heart failure mechanisms and consequences. <i>Pneumologia</i> , 2019, 68, 61-67.	0.1	0
1372	Impact of the Fontan Operation on Organ Systems. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2019, 19, 205-214.	0.7	3
1373	Chronic Care Management. , 2020, , 501-513.		0
1374	Evaluation of pulse pressure and proportional pulse pressure as predictors of severity among patients having heart failure with reduced ejection fraction. <i>Annals of African Medicine</i> , 2020, 19, 188.	0.5	2
1375	Left atrial decompression devices. , 2020, , 85-93.		0
1377	Clinical Outcomes of Early Extubation Strategy in Patients Undergoing Extracorporeal Membrane Oxygenation as a Bridge to Heart Transplantation. <i>Journal of Korean Medical Science</i> , 2020, 35, e346.	2.5	4
1378	Organ conformal electronics for cardiac therapeutics. , 2020, , 911-937.		0
1380	Torsional Dynamics and 2D Speckle Tracking in Heart Failure with Reduced Ejection Fraction on Patients Taking Sacubitril/Valsartan and Naïve. <i>World Journal of Cardiovascular Diseases</i> , 2020, 10, 294-304.	0.2	0
1381	TH Treatment in HF. , 2020, , 391-407.		0
1383	B-type natriuretic peptide levels and diagnostic accuracy: excess fluid volume. <i>Revista Gaucha De Enfermagem / EENFUFGRS</i> , 2020, 41, e20190095.	0.6	0
1384	Research Progress of sST2 and NT-proBNP in Heart Failure with Preserved Ejection Fraction. <i>Advances in Clinical Medicine</i> , 2020, 10, 2451-2456.	0.0	0
1386	Acute Heart Failure. , 2020, , 223-231.		0
1387	ERKRANKUNGEN DES HERZENS UND DES KREISLAUFS. , 2020, , D-1-D17-4.		0
1388	Knowledge Structure of Nursing Studies on Heart Failure Patients in South Korea through Text Network Analysis. <i>Korean Journal of Adult Nursing</i> , 2020, 32, 409.	0.7	1
1389	Heart Failure with Preserved Ejection Fraction: Can Device Therapy Be Our Option?. <i>Cureus</i> , 2020, 12, e7323.	0.5	0
1390	Mass Customized Outlook for Regenerative Heart Failure Care. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11394.	4.1	3
1391	Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2021, 13, 5527.	3.7	4
1392	Improved diastolic dysfunction is associated with higher forward flow and better prognosis in chronic heart failure. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 727-737.	1.5	4

#	ARTICLE	IF	CITATIONS
1393	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovascular Diabetology, 2021, 20, 218.	6.8	38
1394	Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, , 1.	3.9	3
1395	Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association, 2021, 10, e022859.	3.7	19
1396	Ten-Year Risk-Prediction Equations for Incident Heart Failure Hospitalizations in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort Study and the Multi-Ethnic Study of Atherosclerosis. Journal of Cardiac Failure, 2022, 28, 540-550.	1.7	10
1397	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. European Journal of Heart Failure, 2022, 24, 169-180.	7.1	23
1398	Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study. PLoS ONE, 2021, 16, e0259485.	2.5	6
1399	Clinical Characteristics, Management, and Length of Hospital Stay Between Patients with New-Onset and Acute Decompensated Chronic Heart Failure: A Prospective Cohort Study in Ethiopia. Research Reports in Clinical Cardiology, 0, Volume 12, 57-66.	0.2	1
1400	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, 2022, 145, 158-169.	1.6	18
1401	Newly-Diagnosed Diabetes and Sustained Hyperglycemia are Associated with Poorer Outcomes in COVID-19 Inpatients Without Pre-Existing Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 4469-4482.	2.4	5
1402	A Meta-Analysis of Growth Differentiation Factor-15 and Prognosis in Chronic Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 630818.	2.4	15
1403	“Brown Bag Clinic”: A Pharmacist-led Approach to Reduce Heart Failure Hospital Readmission. Innovations in Pharmacy, 2021, 12, 11.	0.6	0
1404	The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design. Hipertension Y Riesgo Vascular, 2020, 37, 101-107.	0.6	0
1405	Treatment Recommendations for Adults with Various Stages of Heart Failure. Journal of Contemporary Pharmacy Practice, 2020, 67, 12-20.	0.2	0
1407	Prevalence of abnormalities in electrocardiogram conduction in dialysis patients: a comparative study. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 448-453.	0.9	1
1408	Effectiveness of angiotensin receptor inhibitors and non-lysine in functional mitral regurgitation. Klinicheskaia Meditsina, 2020, 98, 106-114.	0.1	0
1409	The Role of Adherence to Basic Pharmacotherapy of Heart Failure for Prevention of Late Adverse Events in Patients with Coronary Artery Disease and Left Ventricular Dysfunction After Surgical Revascularization of Myocardium. Rational Pharmacotherapy in Cardiology, 2020, 16, 678-685.	0.8	0
1410	Acute heart failure after liver transplantation: A narrative review. Clinical Transplantation, 2020, 34, e14079.	1.6	3
1411	Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?. Current Heart Failure Reports, 2020, 17, 449-456.	3.3	1

#	ARTICLE	IF	CITATIONS
1412	Impact of Prior Ischemic Stroke on Outcomes in Patients With Heart Failure—A Propensity-Matched Study. <i>Circulation Journal</i> , 2020, 84, 1797-1806.	1.6	3
1413	A nurse practitioner-led effort to reduce 30-day heart failure readmissions. <i>Journal of the American Association of Nurse Practitioners</i> , 2020, 32, 738-744.	0.9	6
1414	Phenotypic clustering of heart failure with preserved ejection fraction reveals different rates of hospitalization. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 45-52.	1.5	17
1415	Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study. <i>Colombia Medica</i> , 2021, 52, e2034542.	0.2	2
1416	Justice Came to Hypertension Or Did It?. <i>MÃdica</i> , 2017, 12, 231-234.	0.1	2
1418	Cardiovascular and Cancer Risk: The Role of Cardio-oncology. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 160-176.	0.4	15
1419	Heart Failure in Older Adults: A Geriatrician Call for Action. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2018, 35, S23-S29.	0.6	0
1420	Heart failure with preserved ejection fraction in the elderly: pathophysiology, diagnostic and therapeutic approach. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 421-428.	0.2	10
1421	Cardiovascular risk prediction in the elderly. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 414-420.	0.2	3
1422	Pharmacist- or Nurse Practitioner-Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. <i>Canadian Journal of Hospital Pharmacy</i> , 2020, 73, 186-192.	0.1	3
1423	Cardiovascular risk and complications associated with COVID-19. <i>American Journal of Cardiovascular Disease</i> , 2020, 10, 479-489.	0.5	10
1424	Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs for Patients with Newly Diagnosed Systolic versus Diastolic Heart Failure. <i>American Health and Drug Benefits</i> , 2020, 13, 166-174.	0.5	0
1425	Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?. <i>Journal of Geriatric Cardiology</i> , 2020, 17, 782-786.	0.2	1
1427	Heart failure in the elderly. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 219-232.	0.2	3
1428	Information Needs of Skilled Nursing Facility Staff to Support Heart Failure Disease Management. <i>AMIA ... Annual Symposium proceedings</i> , 2020, 2020, 878-885.	0.2	1
1429	Heart Rate Control in Heart Failure. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 1070-1071.	0.8	0
1430	Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets. <i>Conditioning Medicine</i> , 2020, 3, 82-97.	1.3	3
1431	Expression and significance of inflammatory reactions mediated by the IL-33/ST2 signaling pathway in the serum of heart failure patients. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 8247-8252.	0.0	3

#	ARTICLE	IF	CITATIONS
1432	Comparing the effects of teach-back method, multimedia and blended training on self-care and social support in patients with heart failure: A randomized clinical trial. Journal of Education and Health Promotion, 2021, 10, 248.	0.6	3
1433	The Effect of Early Aggressive Diuresis on Hospital Length of Stay in Acute Congestive Heart Failure. Heart Views, 2021, 22, 108-114.	0.2	0
1434	Heart failure biomarkers BNP and NT-proBNP detection using optical labels. TrAC - Trends in Analytical Chemistry, 2022, 146, 116477.	11.4	13
1435	The Profile of Romanian Patient with Central Sleep Apnea and Heart Failure. Medicina Interna (Bucharest, Romania: 1991), 2021, 18, 39-52.	0.0	0
1436	Beneficial Extracardiac Effects of Cardiovascular Medications. Current Cardiology Reviews, 2022, 18, .	1.5	3
1437	Emerging Implantable-Device Technology for Patients at the Intersection of Electrophysiology and Heart Failure Interdisciplinary Care. Journal of Cardiac Failure, 2022, 28, 991-1015.	1.7	6
1438	Recent and Upcoming Drug Therapies for Pediatric Heart Failure. Frontiers in Pediatrics, 2021, 9, 681224.	1.9	9
1439	Representation of Chronic Kidney Disease in Randomized Controlled Trials Among Patients With Heart failure With Reduced Ejection Fraction: A Systematic Review. Current Problems in Cardiology, 2023, 48, 101047.	2.4	5
1440	The influence of polymorphic variants rs2305619 Đ, rs3816527 of the PTX3 gene on clinical profile and outcomes in patients with hypertrophic cardiomyopathy: results of a 11-years follow-up. UÅenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2021, 28, 23-32.	0.2	0
1441	Fibroblast Growth Factor-23 and Subclinical Markers of Cardiac Dysfunction: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. American Heart Journal, 2021, 245, 10-10.	2.7	4
1442	Quality and Safety in the Literature: January 2022. BMJ Quality and Safety, 2021, , bmjqs-2021-014410.	3.7	0
1443	Overexpression of Heat Shock Protein 70 Improves Cardiac Remodeling and Survival in Protein Phosphatase 2A-Expressing Transgenic Mice with Chronic Heart Failure. Cells, 2021, 10, 3180.	4.1	4
1444	Integration of clinical pharmacists into a heart failure clinic within a safety-net hospital. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 575-579.e2.	1.5	8
1445	Value of Echocardiography in the Treatment of Patients With Acute Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 740439.	2.4	1
1446	Effects of Cardiac Rehabilitation Training in Patients with Heart Failure Based on Traditional Chinese Exercise: A Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-14.	1.2	5
1447	Analysis of Cardiac Vibration Signals Acquired From a Novel Implant Placed on the Gastric Fundus. Frontiers in Physiology, 2021, 12, 748367.	2.8	1
1448	Serum Meteorinâ€like is associated with weight loss in the elderly patients with chronic heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 409-417.	7.3	13
1449	Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction. Clinical Drug Investigation, 2021, 41, 1027-1036.	2.2	3

#	ARTICLE	IF	CITATIONS
1450	Evaluation of the diagnostic accuracy of current biomarkers in heart failure with preserved ejection fraction: A systematic review and meta-analysis. Archives of Cardiovascular Diseases, 2021, 114, 793-804.	1.6	10
1451	The Impact of Clinical, Biochemical, and Echocardiographic Parameters on the Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction. International Journal of Environmental Research and Public Health, 2021, 18, 12448.	2.6	0
1452	Prognostic Significance of Feature-Tracking Right Ventricular Global Longitudinal Strain in Non-ischemic Dilated Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 765274.	2.4	9
1453	Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 5483.	2.4	14
1455	Beta-blocker use in patients with chronic obstructive pulmonary disease: a systematic review. Trends in Cardiovascular Medicine, 2021, , .	4.9	1
1456	Combined prognostic value of malnutrition using GLIM criteria and renal insufficiency in elderly heart failure. ESC Heart Failure, 2022, 9, 704-711.	3.1	9
1457	Early intravenous vasodilator therapy in acute decompensated heart failure: Is the time-to-treat concept still applicable in a pre-hospital setting?. International Journal of Cardiology, 2022, 349, 103-104.	1.7	0
1458	Incidence and Risk Factors of Future Need for Long-Term Care Insurance in Japanese Elderly Patients With Left Ventricular Systolic Dysfunction. Circulation Journal, 2021, 86, 158-165.	1.6	3
1459	Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease. Kidney Research and Clinical Practice, 2021, 40, 555-565.	2.2	8
1460	Diagnostic Evaluation and Cervical Spine Surgery in the Setting of a Cardiac Left Ventricular Assist Device: Challenges and a Case Illustration. Cureus, 2021, 13, e19571.	0.5	0
1461	Drug-Related Problems Among Ambulatory Heart Failure Patients on Follow-Up at Debre Berhan Comprehensive Specialized Hospital, Ethiopia. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1165-1175.	2.0	3
1462	Right Heart Failure Management. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	1.9	0
1463	Hierarchical management of chronic heart failure: a perspective based on the latent structure of comorbidities. ESC Heart Failure, 2021, , .	3.1	5
1464	Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study. Frontiers in Cardiovascular Medicine, 2021, 8, 785109.	2.4	1
1465	Predictors and clinical outcomes of poor symptomatic improvement after transcatheter aortic valve replacement. Open Heart, 2021, 8, e001742.	2.3	10
1466	Modifiable Risk Factors Associated With Heart Failure Readmissions: 1-Year Follow-up. Journal for Nurse Practitioners, 2021, , .	0.8	1
1468	Evaluation of a multimarker panel in chronic heart failure: a 10-year follow-up. Biomarkers in Medicine, 2021, 15, 1709-1719.	1.4	1
1469	Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. The Lancet Digital Health, 2022, 4, e46-e54.	12.3	62

#	ARTICLE	IF	CITATIONS
1470	Association between lipoprotein (a) and heart failure with reduced ejection fraction development. Journal of Clinical Laboratory Analysis, 2022, 36, e24083.	2.1	6
1471	Identification of CALU and PALLD as Potential Biomarkers Associated With Immune Infiltration in Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 774755.	2.4	11
1472	Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity. Advances in Experimental Medicine and Biology, 2021, 1342, 377-387.	1.6	2
1473	Atrial and Brain Natriuretic Peptides. , 2021, , 269-275.		0
1474	OUP accepted manuscript. European Journal of Preventive Cardiology, 2022, , .	1.8	3
1475	Effect of Tricuspid Valve Repair or Replacement on Survival in Patients With Isolated Severe Tricuspid Regurgitation. American Journal of Cardiology, 2022, 162, 163-169.	1.6	4
1476	Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study. International Journal of Cardiology, 2022, 350, 62-68.	1.7	13
1477	Pharmacologic heart failure treatment: A case-based review of current guidelines. Journal of the American Association of Nurse Practitioners, 2021, 33, 1042-1049.	0.9	0
1478	ACEi to ARNi: “The Switch” An Evidence Based Review. Journal of Cardiovascular Medicine and Cardiology, 2020, , 288-292.	0.1	0
1479	Intravenous iron in heart failure and chronic kidney disease. Nefrologia, 2021, 41, 403-411.	0.4	0
1480	Comparison of heart rate and symptoms in two different methods of digoxin prescription. Journal of Cardiology & Current Research, 2021, 14, 119-124.	0.1	0
1481	Continuous Remote Patient Monitoring: Evaluation of the Heart Failure Cascade Soft Launch. Applied Clinical Informatics, 2021, 12, 1161-1173.	1.7	3
1482	Endpoints in Heart Failure Drug Development. Cardiac Failure Review, 2022, 8, e01.	3.0	10
1483	Validation of Heart Failure-Specific Risk Equations in 1.3 Million Israeli Adults and Usefulness of Combining Ambulatory and Hospitalization Data from a Large Integrated Health Care Organization. American Journal of Cardiology, 2022, 168, 105-109.	1.6	4
1484	Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy. BMC Medicine, 2022, 20, 21.	5.5	5
1485	IMPROVING PATIENT SELECTION FOR CARDIAC RESYNCHRONIZATION THERAPY: THE ROLE OF PATHOPHYSIOLOGICAL BIOMARKERS. Journal of Heart and Lung Transplantation, 2022, , .	0.6	0
1486	Relationship Between Soluble Transferrin Receptor and Clinical Outcomes in Patients With Heart Failure According to Ejection Fraction Phenotype: The New Zealand PEOPLE Study. Journal of Cardiac Failure, 2022, 28, 1255-1263.	1.7	12
1487	Behind the Scenes of TOPCAT “Bending to Inform. , 2022, 1, .		8

#	ARTICLE	IF	CITATIONS
1488	Traditional Chinese Medicine Targeting Heat Shock Proteins as Therapeutic Strategy for Heart Failure. <i>Frontiers in Pharmacology</i> , 2021, 12, 814243.	3.5	0
1489	Clinical Effect of Pulmonary Artery Diameter/Ascending Aorta Diameter Ratio on Left Ventricular Reverse Remodeling in Patients With Dilated Cardiomyopathy. <i>Circulation Journal</i> , 2022, 86, 1102-1112.	1.6	2
1490	Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics. <i>Chinese Chemical Letters</i> , 2022, , .	9.0	3
1491	Impact of Laparoscopic Sleeve Gastrectomy on Cardiovascular Pharmacotherapy in Left Ventricular Assist Device Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2022, Publish Ahead of Print, .	1.9	1
1492	Effect of SGLT2 inhibitors on cardiac function and remodeling in heart failure patients: a meta-analysis. <i>Journal of Cardiac Pharmacology</i> , 2022, 54, 1-10.	0.2	0
1493	Current State and Future Directions of Multimodality Imaging in Cardiac Sarcoidosis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 785279.	2.4	5
1494	Orthopaedic Nursing and Heart Failure. <i>Orthopaedic Nursing</i> , 2022, 41, 25-34.	0.4	0
1495	Diagnostic Accuracy of High-Sensitive Troponin for the Identification of Myocardial Infarction in Patients Presenting with Acute Heart Failure. <i>Journal of Emergency Medicine</i> , 2022, 62, 359-367.	0.7	1
1496	Racial Differences in Trends and Prognosis of Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction: the Atherosclerosis Risk in Communities (ARIC) Surveillance Study. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 118-129.	3.2	5
1497	Relationship between physical capacity and depression in heart failure patients undergoing hybrid comprehensive telerehabilitation vs. usual care: subanalysis from the TELEREH-HF Randomized Clinical Trial. <i>European Journal of Cardiovascular Nursing</i> , 2022, 21, 568-577.	0.9	4
1498	The role of SGLT2 inhibitors in heart failure. , 0, 1, 2.		0
1499	Transcatheter Implantation of Interatrial Shunt Devices to Lower Left Atrial Pressure in Heart Failure. <i>International Journal of Heart Failure</i> , 2022, 4, 12.	2.7	2
1500	Is it time to revisit ICD indications?. <i>Heart Failure Reviews</i> , 2022, , 1.	3.9	2
1501	CARDIOPULMONARY EXERCISE TESTING IN PATIENTS WITH ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION: LACK OF PROGNOSTIC PREDICTIVE POWER OF VENTILATORY VARIABLES. <i>European Journal of Preventive Cardiology</i> , 2022, , .	1.8	2
1502	The Role of CD147 in Pathological Cardiac Hypertrophy Is Regulated by Glycosylation. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-19.	4.0	11
1503	Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 348.	2.4	5
1504	Development and Validation of a Long-Term Incident Heart Failure Risk Model. <i>Circulation Research</i> , 2022, 130, 200-209.	4.5	9
1505	Nicardipine versus nitroglycerin for hypertensive acute heart failure syndrome: a single-center observational study. <i>Journal of Rural Medicine: JRM</i> , 2022, 17, 33-39.	0.5	4

#	ARTICLE	IF	CITATIONS
1506	Heart in DRESS: Cardiac Manifestations, Treatment and Outcome of Patients with Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 704.	2.4	26
1507	Differences in maternal soluble ST2 levels in the third trimester of normal pregnancy versus preeclampsia. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2022, 13, 100140.	1.1	5
1508	Diagnostic Value of Serum Concentration of Galectin-3 in Patients With Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 829151.	2.4	4
1509	Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. European Heart Journal, 2022, 43, 1941-1951.	2.2	68
1510	Overcoming the Limits of Ejection Fraction and Ventricular-Arterial Coupling in Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 750965.	2.4	8
1511	A Radiomic MRI based Nomogram for Prediction of Heart Failure with Preserved Ejection Fraction in Systemic Lupus Erythematosus Patients: Insights From a Three-Center Prospective Study. Journal of Magnetic Resonance Imaging, 2022, 56, 779-789.	3.4	1
1512	Using machine learning to uncover heterogeneity of beta blocker response in heart failure. Cell Reports Medicine, 2022, 3, 100504.	6.5	0
1513	Acetylcholine Reduces IKr and Prolongs Action Potentials in Human Ventricular Cardiomyocytes. Biomedicines, 2022, 10, 244.	3.2	3
1515	Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: A systemic review and meta-analysis. Clinical Cardiology, 2022, 45, 5-17.	1.8	17
1516	Drug Treatment of Heart Failure in Children: Gaps and Opportunities. Paediatric Drugs, 2022, 24, 121-136.	3.1	3
1517	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR0000000000001038.	1.6	177
1518	Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death. Journal of the American Heart Association, 2022, 11, e022833.	3.7	11
1519	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
1520	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. Drugs, 2022, 82, 375-405.	10.9	7
1521	Mental health-related risk factors and interventions in patients with heart failure: a position paper endorsed by the European Association of Preventive Cardiology (EAPC). European Journal of Preventive Cardiology, 2022, 29, 1124-1141.	1.8	24
1522	Serial cardiac biomarker assessment in adults with congenital heart disease hospitalized for decompensated heart failure. International Journal of Cardiology Congenital Heart Disease, 2022, 7, 100336.	0.4	2
1523	Does diabetes increase the risk of cardiovascular events in patients with negative treadmill stress echocardiography?. Endocrine Journal, 2022, 69, 785-796.	1.6	1
1524	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. European Heart Journal, 2022, 43, 1157-1172.	2.2	297

#	ARTICLE	IF	CITATIONS
1525	Iron Deficiency Impacts Diastolic Function, Aerobic Exercise Capacity, and Patient Phenotyping in Heart Failure With Preserved Ejection Fraction: A Subanalysis of the OptimEx-Clin Study. <i>Frontiers in Physiology</i> , 2021, 12, 757268.	2.8	7
1526	Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?. <i>Journal of Internal Medicine</i> , 2022, 291, 713-731.	6.0	23
1527	Adjuvant postmastectomy radiotherapy might be associated with better survival in women with heart failure receiving total mastectomy. <i>Radiation Oncology</i> , 2022, 17, 33.	2.7	0
1528	Relationship between spleen size and exercise tolerance in advanced heart failure patients with a left ventricular assist device. <i>BMC Research Notes</i> , 2022, 15, 40.	1.4	1
1529	Leveraging Multiple Biomarkers to Assess Risk of Acute Heart Failure: Is More Better?. <i>Journal of Cardiac Failure</i> , 2022, 28, 234-236.	1.7	0
1530	Female sex-specific and -predominant cardiovascular risk factors and heart failure practice guidelines. <i>American Heart Journal</i> , 2022, 247, 63-67.	2.7	6
1531	Comparative effects of left bundle branch area pacing, His bundle pacing, biventricular pacing in patients requiring cardiac resynchronization therapy: A network meta-analysis. <i>Clinical Cardiology</i> , 2022, 45, 214-223.	1.8	19
1532	Distractions when viewing in-hospital heart failure self-care videos and change in heart failure self-care knowledge. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2022, 53, 67-71.	1.6	0
1534	Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 760152.	2.4	7
1535	Clinical Experience of Use of Sacubitril/Valsartan in a Patient with Dilated Cardiomyopathy, Chronic Heart Failure with Reduced Ejection Fraction and Ventricular Arrhythmias. , 2021, 1, 39-48.		1
1536	Nitric Oxide Is the Cause of Nitroglycerin Tolerance: Providing an Old Dog New Tricks for Acute Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842210860.	2.0	0
1537	Antiarrhythmic agents and torsades de pointes. , 2022, , 183-211.		0
1538	Factors associated with the identification of drug therapy problems among older patients in Primary Health Care. <i>Einstein (Sao Paulo, Brazil)</i> , 2022, 20, eAO6544.	0.7	0
1541	Clinical Implications of Functional Mitral Regurgitation Severity in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF). <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2022, 76, 17.	0.9	2
1542	Herz-Kreislauf-System. , 2022, , 181-246.		0
1543	Predictors of Referral to Cardiac Rehabilitation in Patients following Hospitalisation with Heart Failure: A Multivariate Regression Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1232.	2.4	3
1544	Clinical value of the HATCH score for predicting adverse outcomes in patients with heart failure. <i>Heart and Vessels</i> , 2022, 37, 1363-1372.	1.2	5
1545	Sexual Dimorphism in Cardiovascular Biomarkers: Clinical and Research Implications. <i>Circulation Research</i> , 2022, 130, 578-592.	4.5	13

#	ARTICLE	IF	CITATIONS
1546	Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention. Current Diabetes Reports, 2022, 22, 129-136.	4.2	5
1547	Prognostic Value of Serum Galectin-3 in Chronic Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 783707.	2.4	8
1548	Depressive Symptoms and Incident Heart Failure in the Jackson Heart Study: Differential Risk Among Black Men and Women. Journal of the American Heart Association, 2022, 11, e022514.	3.7	9
1549	Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS). Journal of Clinical Medicine, 2022, 11, 1762.	2.4	2
1550	Epidemiology of Asymptomatic Pre-heart Failure: a Systematic Review. Current Heart Failure Reports, 2022, 19, 146-156.	3.3	5
1551	Role of biomarkers in the heart failure clinic. Kosin Medical Journal, 2022, 37, 4-17.	0.3	2
1552	Deleterious synergistic effects of acute heart failure and diabetes mellitus in patients with acute coronary syndrome: Data from the FAST-MI Registries. Archives of Cardiovascular Diseases, 2022, , .	1.6	0
1553	Subjective and Objective Impact of Angiotensin Receptorâ€“Neprilysin Inhibitors on Systemic Right Ventricle Patients. Heart Lung and Circulation, 2022, 31, 964-973.	0.4	6
1554	Moving the Paradigm Forward for Prediction and Risk-Based Primary Prevention of Heart Failure in Special Populations. Current Atherosclerosis Reports, 2022, 24, 343-356.	4.8	1
1555	Prognostic Cardiac Magnetic Resonance Markers of Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy for Predicting Heart Failure Outcomes. Journal of the American Heart Association, 2022, 11, e023167.	3.7	12
1556	Team-based strategies to prevent heart failure. Current Opinion in Cardiology, 2022, Publish Ahead of Print, .	1.8	0
1557	Serum galectin-3 and aldosterone: potential biomarkers of cardiac complications in patients with COVID-19. Minerva Endocrinology, 2022, 47, .	1.1	8
1558	Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2022, 8, e10.	3.0	0
1559	Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk. ESC Heart Failure, 2022, 9, 1564-1573.	3.1	3
1560	Precision measurement of cardiac structure and function in cardiovascular magnetic resonance using machine learning. Journal of Cardiovascular Magnetic Resonance, 2022, 24, 16.	3.3	30
1561	Multifactorial Benefits of Chronic Vagus Nerve Stimulation on Autonomic Function and Cardiac Electrical Stability in Heart Failure Patients With Reduced Ejection Fraction. Frontiers in Physiology, 2022, 13, 855756.	2.8	9
1562	Fluid and Salt Balance and the Role of Nutrition in Heart Failure. Nutrients, 2022, 14, 1386.	4.1	5
1563	Kinesiophobia and Its Association With Fatigue in CHF Patients. Clinical Nursing Research, 2022, 31, 1316-1324.	1.6	12

#	ARTICLE	IF	CITATIONS
1564	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	3.3	10
1565	Artificial Intelligence-Enabled Electrocardiography Predicts Left Ventricular Dysfunction and Future Cardiovascular Outcomes: A Retrospective Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 455.	2.5	12
1567	Comprehensive Monitoring in Patients With Dual Lumen Right Atrium to Pulmonary Artery Right Ventricular Assist Device. <i>ASAIO Journal</i> , 2022, 68, 1461-1469.	1.6	4
1568	Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction. <i>Journal of Pharmacy Practice</i> , 2023, 36, 905-914.	1.0	4
1569	Effects of early rehabilitation on functional outcomes in patients after coronary artery bypass graft surgery: a randomized controlled trial. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210870.	1.0	5
1570	Differential mRNA Expression and Circular RNA-Based Competitive Endogenous RNA Networks in the Three Stages of Heart Failure in Transverse Aortic Constriction Mice. <i>Frontiers in Physiology</i> , 2022, 13, 777284.	2.8	8
1571	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	3.9	8
1573	Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy Patients. <i>Journal of the American Heart Association</i> , 2022, 11, e024505.	3.7	21
1574	Time in Target Range for Systolic Blood Pressure and Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2022, 11, e022765.	3.7	16
1575	Clinical Impact of Circulating Galectin-3 on Ventricular Arrhythmias and Heart Failure Hospitalization Independent of Prior Ventricular Arrhythmic Events in Patients with Implantable Cardioverter-defibrillators. <i>Internal Medicine</i> , 2022, 61, 969-977.	0.7	4
1576	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. <i>Journal of the American Heart Association</i> , 2022, 11, e021327.	3.7	5
1577	Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2022, 43, 2224-2234.	2.2	22
1578	Spironolactone alleviates myocardial fibrosis via inhibition of Etsâ€¹ in mice with experimental autoimmune myocarditis. <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 369.	1.8	3
1579	Representativeness of the GALACTICâ€œHF Clinical Trial in Patients Having Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2022, 11, e023766.	3.7	4
1580	Effectiveness of Telemedicine Visits in Reducing 30â€œDay Readmissions Among Patients With Heart Failure During the COVIDâ€œ19 Pandemic. <i>Journal of the American Heart Association</i> , 2022, 11, e023935.	3.7	29
1581	Outcomes and Predictors of Mortality Among Cardiac Intensive Care Unit Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 1088-1099.	1.7	6
1582	Understanding left ventricular diastolic dysfunction in anesthesia and intensive care patients: a glass with progressive shape change. <i>Minerva Anestesiologica</i> , 2022, 88, .	1.0	11
1583	Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension. <i>ERJ Open Research</i> , 2022, 8, 00002-2022.	2.6	8

#	ARTICLE	IF	CITATIONS
1584	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001063.	1.6	756
1585	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001062.	1.6	133
1586	Heart failure readmission reductions during the COVID-19 pandemic. Nursing Management, 2022, 53, 26-33.	0.4	2
1587	Are the recommendation of sodium and fluid restriction in Heart Failure patients changing over the past years? Systematic review and meta-analysis. Clinical Nutrition ESPEN, 2022, , .	1.2	1
1588	Mendelian Randomization Study of Heart Failure and Stroke Subtypes. Frontiers in Cardiovascular Medicine, 2022, 9, 844733.	2.4	6
1589	Soluble ST2 Is a Sensitive and Specific Biomarker for Fulminant Myocarditis. Journal of the American Heart Association, 2022, 11, e024417.	3.7	16
1590	An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure. Journal of Clinical Medicine, 2022, 11, 2020.	2.4	6
1591	Direct Cardiac Compression Devices to Augment Heart Biomechanics and Function. Annual Review of Biomedical Engineering, 2022, 24, 137-156.	12.3	9
1592	Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines. , 2022, 238, 108185.		16
1593	Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF). Biomedicine and Pharmacotherapy, 2022, 149, 112894.	5.6	15
1594	The roles of the mitophagy inducer Danqi pill in heart failure: A new therapeutic target to preserve energy metabolism. Phytomedicine, 2022, 99, 154009.	5.3	6
1595	Effect of monthly vitamin D supplementation on cardiac biomarkers: A post-hoc analysis of a randomized controlled trial. Journal of Steroid Biochemistry and Molecular Biology, 2022, 220, 106093.	2.5	1
1596	Cardiotoxicity in pediatric lymphoma survivors. Expert Review of Cardiovascular Therapy, 2021, 19, 957-974.	1.5	5
1597	Sleep-related breathing disorders in patients with heart failure: current aspects of treatment. Part II. Russian Journal of Cardiology, 2022, 26, 4724.	1.4	0
1598	Characterizing Pain Leading to Emergency Medical Services Activation in Heart Failure. Journal of Cardiovascular Nursing, 2022, 37, 427-436.	1.1	1
1599	Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium. Europace, 2022, 24, 538-551.	1.7	16
1600	Medical management of acute heart failure. Faculty Reviews, 2021, 10, 82.	3.9	6
1601	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1016-1030.	1.7	5

#	ARTICLE	IF	CITATIONS
1602	Prognostic Value of Multiple Circulating Biomarkers for 2-Year Death in Acute Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 779282.	2.4	12
1603	Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, E12-E14.	3.0	5
1604	Under-Enrollment of Obese Heart Failure with Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials. <i>Journal of Cardiac Failure</i> , 2022, 28, 723-731.	1.7	3
1605	Aspects of Lyophilization of Cardiac Bioimplant. <i>Innovative Biosystems and Bioengineering</i> , 2021, 5, 200-206.	0.7	1
1606	Chronic heart failure and hypotensive effects of sacubitril/valsartan. A clinical case. <i>Cor Et Vasa</i> , 2021, 63, 715-718.	0.1	0
1607	Sacubitril/valsartan in everyday clinical practice: an observational study based on the experience of a heart failure clinic. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1217-1227.	1.7	4
1608	Call on the reserve: Coronary vasomotor dysfunction is a potential biomarker of cardiovascular risk in patients with breast cancer. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 3082-3085.	2.1	1
1609	New Perspectives in the Treatment of Acute and Chronic Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiovascular Emergencies</i> , 2021, 7, 88-99.	0.2	0
1610	Adjunctive Techniques for Repair of Ischaemic Mitral Regurgitation. <i>Cardiac Failure Review</i> , 2021, 7, e20.	3.0	0
1611	Heart Failure and Disability in Community-Dwelling Older Adults in the United States—1999 to 2018: Data From National Health and Nutrition Examination Survey. <i>Clinical Nursing Research</i> , 2022, 31, 571-578.	1.6	1
1612	Biomarkers of heart failure: current state of problem. <i>Innovative Medicine of Kuban</i> , 2021, , 67-72.	0.2	1
1613	The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases. <i>Biomolecules</i> , 2022, 12, 46.	4.0	28
1614	Regulatory relationships of demographic, clinical characteristics and quality of care for heart failure patients in southern China. <i>International Journal for Quality in Health Care</i> , 2022, 34, .	1.8	0
1615	Soluble ST2 concentrations associate with in-hospital mortality and need for mechanical ventilation in unselected patients with COVID-19. <i>Open Heart</i> , 2021, 8, e001884.	2.3	9
1616	Adjuvant Whole Breast Radiotherapy Improve Survival in Women with Heart Failure with Reduced Ejection Fraction Receiving Breast-Conserving Surgery. <i>Journal of Personalized Medicine</i> , 2021, 11, 1358.	2.5	2
1617	Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 1349-1354.	1.7	6
1618	Prognostic Value of Late Enhanced Cardiac Magnetic Resonance Imaging Derived Texture Features in Dilated Cardiomyopathy Patients With Severely Reduced Ejection Fractions. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 766423.	2.4	3
1619	Prognostic value of cartilage intermediate layer protein 1 in chronic heart failure. <i>ESC Heart Failure</i> , 2022, 9, 345-352.	3.1	3

#	ARTICLE	IF	CITATIONS
1620	Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care. <i>Children</i> , 2021, 8, 1200.	1.5	2
1622	Arterial stiffness and pulsatile hemodynamics in heart failure. , 2022, , 565-589.		4
1623	Accelerated and personalized therapy for heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2022, 43, 2573-2587.	2.2	41
1624	Prognostic Value of Short-Term Follow-up of Multiple Biomarkers After Discharge in Hospitalized Patients With Acute Heart Failure (POSTBIO-HF): Rationale and Study Design. <i>International Journal of Heart Failure</i> , 0, 4, .	2.7	2
1625	Native T1 heterogeneity for predicting reverse remodeling in patients with non-ischemic dilated cardiomyopathy. <i>Heart and Vessels</i> , 2022, 37, 1541-1550.	1.2	7
1626	Continuous Intravenous Inotropic Support for Advanced Heart Failure: Palliative Considerations. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2022, 36, 59-67.	0.8	2
1627	Troponin is unrelated to outcomes in heart failure patients discharged from the emergency department. <i>Journal of the American College of Emergency Physicians Open</i> , 2022, 3, e12695.	0.7	2
1628	Palliative care in heart failure. <i>Revista Portuguesa De Cardiologia</i> , 2022, , .	0.5	1
1629	Annals for Hospitalists Inpatient Notes - Intravenous Iron Supplementation for Patients With Heart Failure—What Hospitalists Should Know. <i>Annals of Internal Medicine</i> , 2022, 175, HO2-HO3.	3.9	3
1631	Value of FT3/FT4 Ratio in Prognosis of Patients With Heart Failure: A Propensity-Matched Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 859608.	2.4	11
1632	Prioritizing Quad Therapy and the Path Forward in Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2022, 145, 1105-1107.	1.6	0
1633	Multiple cArDiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) — Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 1245-1254.	1.7	22
1634	FDA Indication Extrapolations—Allowing Flexibility While Providing Greater Clarity. <i>JAMA Network Open</i> , 2022, 5, e227961.	5.9	0
1635	Short-term effects of COVID-19 on the risk of traumatic fractures in China cities. <i>Scientific Reports</i> , 2022, 12, 6528.	3.3	7
1636	Effect of hypothyroidism on contractile performance of isolated end-stage failing human myocardium. <i>PLoS ONE</i> , 2022, 17, e0265731.	2.5	2
1637	Comparison of clinical symptoms and bioimpedance to pulmonary capillary wedge pressure in heart failure. <i>American Heart Journal Plus</i> , 2022, , 100133.	0.6	0
1638	Favorable Impact of a Multidisciplinary Team Approach on Heart Transplantation Outcomes in a Mid-Volume Center. <i>Journal of Clinical Medicine</i> , 2022, 11, 2296.	2.4	4
1639	Cell-free long noncoding RNAs as predictive biomarkers for cardiovascular diseases. <i>International Journal of Cardiology</i> , 2022, 359, 115-117.	1.7	2

#	ARTICLE	IF	CITATIONS
1640	Hypertension and Heart Failure. <i>Cardiology Clinics</i> , 2022, 40, 237-244.	2.2	19
1643	A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 743-755.	2.6	9
1644	Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. <i>European Journal of Internal Medicine</i> , 2022, 102, 8-16.	2.2	10
1647	Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labelled Pilot Clinical Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 765081.	2.4	0
1649	Circulating cardiac biomarkers and echocardiographic abnormalities in patients with scrub typhus: A prospective cohort study from a tertiary care center in North India. <i>Journal of Vector Borne Diseases</i> , 2021, 58, 193.	0.4	2
1650	The effect of early aggressive diuresis on hospital length of stay in acute congestive heart failure. <i>Heart Views</i> , 2021, 22, 108.	0.2	1
1651	Comparing the effects of teach-back method, multimedia and blended training on self-care and social support in patients with heart failure: A randomized clinical trial. <i>Journal of Education and Health Promotion</i> , 2021, 10, 248.	0.6	4
1652	Gut microbiome in heart failure and aortic stenosis. <i>Vnitřní Lekarství</i> , 2022, 68, E04-E10.	0.2	1
1653	Utility of perinatal natriuretic peptide for predicting neonatal heart failure. <i>Pediatrics International</i> , 2022, 64, .	0.5	0
1654	Sex and Race Differences in N-Terminal Pro-B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community. <i>JAMA Cardiology</i> , 2022, 7, 623.	6.1	23
1655	Systolic Blood Pressure and 1-Year Clinical Outcomes in Patients Hospitalized for Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 877293.	2.4	4
1656	Relationship Between Initial Urine Output and Mortality in Patients Hospitalized in Cardiovascular Intensive Care Units: More Is Not Better. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 853217.	2.4	0
1657	Strategic Recommendations to Bridge the Gaps in Awareness, Diagnosis and Prevention of Heart Failure in the Middle East Region and Africa. <i>Journal of the Saudi Heart Association</i> , 2022, 34, 53-65.	0.4	1
1658	Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2022, 8, e16.	3.0	6
1659	Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. <i>Journal of Molecular Cell Biology</i> , 2022, 14, .	3.3	16
1660	Diuretic combinations in critically ill patients with respiratory failure: A systematic review and meta-analysis. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 178-191.	1.8	2
1661	Association of Pathogenic DNA Variants Predisposing to Cardiomyopathy With Cardiovascular Disease Outcomes and All-Cause Mortality. <i>JAMA Cardiology</i> , 2022, 7, 723.	6.1	15
1662	Left Atrial Strain Has Superior Prognostic Value to Ventricular Function and Delayed-Enhancement in Dilated Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1015-1026.	5.3	35

#	ARTICLE	IF	CITATIONS
1663	Re: Polypharmacy in palliative care for advanced heart failure: the PAL-HF Experience. Journal of Cardiac Failure, 2022, , .	1.7	0
1664	Left Ventricular Assist Devices: A Primer for the Non-Mechanical Circulatory Support Provider. Journal of Clinical Medicine, 2022, 11, 2575.	2.4	1
1665	Mitochondrial damage and activation of the cytosolic DNA sensor cGASâ€“STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice. Cell Death Discovery, 2022, 8, 258.	4.7	61
1666	Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: <scp>the EVALUATEâ€“HF trial</scp>. European Journal of Heart Failure, 2022, 24, 1200-1208.	7.1	10
1667	Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF). Journal of Cardiovascular Translational Research, 2022, 15, 1424-1435.	2.4	4
1668	Real-world implementation of guidelines for heart failure management: A systematic review and meta-analysis. Hellenic Journal of Cardiology, 2022, 66, 72-79.	1.0	7
1669	Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients. Journal of Cardiovascular Translational Research, 2022, 15, 1192-1202.	2.4	4
1670	Exercise for chronic heart failure. , 2022, , 261-271.		1
1671	Behavioral Interventions for the Patientâ€“Caregiver Unit in Patients with Chronic Heart Failure: A Systematic Review of Caregiver Outcomes. Journal of Multidisciplinary Healthcare, 2022, Volume 15, 921-939.	2.7	5
1672	Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension. Cardiovascular Diabetology, 2022, 21, 75.	6.8	11
1674	Implementing Equity: Improving Blood Pressure and Glycemic Control Among Adults With Heart Failure. Circulation: Heart Failure, 2022, 15, e009650.	3.9	1
1675	Long-Term Beta-Blocker Therapy in Patients With Stable Coronary Artery Disease After Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	0
1676	Blood Pressure and Glycemic Control Among Ambulatory US Adults With Heart Failure: National Health and Nutrition Examination Survey 2001 to 2018. Circulation: Heart Failure, 2022, 15, 101161CIRCHEARTFAILURE121009229.	3.9	5
1677	Effects of Î²â€“blocker administration on cardiac function: a coronary computed tomography angiography study. Current Medical Imaging, 2022, 18, .	0.8	0
1678	Curable congestive heart failure in patients with primary aldosteronism: two cases reports.. American Journal of Translational Research (discontinued), 2022, 14, 2689-2696.	0.0	0
1680	Malthusian Trajectory for Heart Failure and Novel Translational Ambulatory Technologies. Current Cardiology Reviews, 2023, 19, .	1.5	0
1682	Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCAT. Journal of Cardiac Failure, 2022, 28, 1390-1397.	1.7	3
1683	Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure. Journal of Personalized Medicine, 2022, 12, 898.	2.5	2

#	ARTICLE	IF	CITATIONS
1684	Novel Biomarkers of Kidney Disease in Advanced Heart Failure: Beyond GFR and Proteinuria. Current Heart Failure Reports, 0, , .	3.3	1
1685	Angiotensin <scp>Receptorâ€Neprilysin</scp> Inhibitor Attenuates Cardiac Hypertrophy and Improves Diastolic Dysfunction in A Mouse Model of Heart Failure with Preserved Ejection Fraction. Clinical and Experimental Pharmacology and Physiology, 0, , .	1.9	3
1686	Prognostic impact of the updated 2018 <scp>HFAâ€ESC</scp> definition of advanced heart failure: results from the <scp>HELPA€HF</scp> registry. European Journal of Heart Failure, 2022, 24, 1493-1503.	7.1	22
1687	Design of <scp>Midâ€Q</scp> Response: A prospective, randomized trial of adaptive cardiac resynchronization therapy in Asian patients. Journal of Arrhythmia, 0, , .	1.2	0
1688	Biomarkers in Cardiorenal Syndrome and Potential Insights Into Novel Therapeutics. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	10
1689	Role of depressive symptoms in the prognosis of heart failure and its potential clinical predictors. ESC Heart Failure, 2022, 9, 2676-2685.	3.1	10
1690	Educational Interventions to Improve Heart Failure Self-Care. Journal for Nurse Practitioners, 2022, , .	0.8	0
1691	Non-cardiovascular medication and readmission for heart failure: an observational cohort study. International Journal of Clinical Pharmacy, 0, , .	2.1	1
1692	SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?. Current Atherosclerosis Reports, 2022, 24, 627-634.	4.8	8
1693	Myocardial Iron Deficiency and Mitochondrial Dysfunction in Advanced Heart Failure in Humans. Journal of the American Heart Association, 2022, 11, .	3.7	22
1694	Prevention of heart failure and cardiomyopathy in patients with cancer. , 2023, , 69-79.		0
1695	Diagnosis and management of cardiomyopathy and heart failure during cancer treatment. , 2023, , 138-145.		0
1696	Prevention and management of cardiomyopathy and heart failure in cancer survivors. , 2023, , 252-257.		0
1697	Continuous Remote Patient Monitoring in Patients With Heart Failure (Cascade Study): Protocol for a Mixed Methods Feasibility Study. JMIR Research Protocols, 2022, 11, e36741.	1.0	1
1698	Safety and efficacy of a wireless pulmonary artery pressure sensor: primary endpoint results of the SIRONA 2 clinical trial. ESC Heart Failure, 2022, 9, 2862-2872.	3.1	19
1699	Association of dementia with in-hospital outcomes in primary heart failure and acute myocardial infarction hospitalizations. Progress in Cardiovascular Diseases, 2022, 73, 24-31.	3.1	3
1700	Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. BMJ, The, 0, , e068424.	6.0	18
1701	Outcomes of guideline-based medical therapy in patients with acute heart failure and reduced left ventricular ejection fraction. Medicine (United States), 2022, 101, e29452.	1.0	0

#	ARTICLE	IF	CITATIONS
1702	A multidisciplinary approach to heart failure care in the hospital: improving the patient journey. Hospital Practice (1995), 0, , .	1.0	0
1703	Effect of Corticosteroids on Left Ventricular Function in Patients With Cardiac Sarcoidosis. American Journal of Cardiology, 2022, 177, 108-115.	1.6	4
1704	Positive airway pressure therapy in heart failure patients comorbid with obstructive sleep apnea: Cardiovascular outcomes and nighttimeâ€duration effect. European Journal of Clinical Investigation, 2022, 52, .	3.4	7
1705	Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. Science Translational Medicine, 2022, 14, .	12.4	24
1706	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. Circulation: Cardiovascular Quality and Outcomes, 0, , .	2.2	5
1707	Transcatheter Mitral Cerclage Ventriculoplasty. JACC: Cardiovascular Interventions, 2022, 15, 1249-1263.	2.9	5
1708	Real-world clinical burden among patients with and without heart failure worsening after cardiac resynchronization therapy. Current Medical Research and Opinion, 2022, 38, 1489-1498.	1.9	1
1709	Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMPâ€CHF. Journal of the American Heart Association, 2022, 11, .	3.7	3
1710	Searching for an experimental rodent model of heart failure with preserved ejection fraction: Re-visited. Biomedicine and Pharmacotherapy, 2022, 152, 113251.	5.6	3
1711	Soluble ST2: a valuable prognostic marker in heart failure. Heart Failure Reviews, 2022, 27, 2155-2164.	3.9	8
1712	The Valsalva load test and spectral tracking echocardiography effectiveness in the diagnosis of heart failure with preserved left ventricular ejection fraction. Kardiologiya, 2022, 62, 30-36.	0.7	0
1713	A prospective study on sex differences in functional capacity, quality of life and prognosis in patients with heart failure. Medicine (United States), 2022, 101, e29795.	1.0	2
1714	Clinical implications of the universal definition for the prevention and treatment of heart failure. Clinical Cardiology, 2022, 45, .	1.8	1
1715	Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect. Scientific Reports, 2022, 12, .	3.3	1
1716	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. Endocrinology and Metabolism, 2022, 37, 415-429.	3.0	3
1717	CNP, the Third Natriuretic Peptide: Its Biology and Significance to the Cardiovascular System. Biology, 2022, 11, 986.	2.8	4
1718	Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPESTâ€CRT Upgrade trial. European Journal of Heart Failure, 2022, 24, 1652-1661.	7.1	9
1719	Low Prevalence of Cardiomyopathy in Patients with Mitochondrial Disease and Neurological Manifestations. Journal of Cardiovascular Development and Disease, 2022, 9, 221.	1.6	1

#	ARTICLE	IF	CITATIONS
1720	Impact of Modified H<sub>2</sub>FPEF Score on Chronic Limb-Threatening Ischemia in Patients With Lower Extremity Artery Disease Who Underwent Endovascular Therapy. Circulation Reports, 2022, , .	1.0	0
1721	Effect of Î²â€blocker on patients with moderate functional mitral regurgitation undergoing surgical aortic valve replacement. ESC Heart Failure, 0, , .	3.1	1
1722	Digital health in older adults for the prevention and management of cardiovascular diseases and frailty. <i>A clinical consensus statement from the ESC Council for Cardiology Practice/Taskforce on Geriatric Cardiology, the ESC Digital Health Committee and the ESC Working Group on eâ€Cardiology</i>. ESC Heart Failure, 2022, 9, 2808-2822.	3.1	12
1723	Safety and efficacy considerations amongst the elderly population in the updated treatment of heart failure: a review. Expert Review of Cardiovascular Therapy, 2022, 20, 529-541.	1.5	3
1724	Traditional Cancer Therapies and Perioperative Implications. , 2023, , 46-55.		0
1725	Breaking the Bank: The Financial Burden of Living With Heart Failure. Journal of Cardiac Failure, 2022, 28, 1434-1436.	1.7	1
1726	Evaluation of the effect of intravenous nitroglycerine on short-term survival of patients with acute heart failure according to congestion and perfusion status at emergency department arrival. European Journal of Emergency Medicine, 2022, 29, 437-449.	1.1	4
1727	Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through Î²3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial. Circulation: Heart Failure, 2022, 15, .	3.9	13
1728	Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2Â°Pâ€TIMI 50 trial. Clinical Cardiology, 2022, 45, 831-838.	1.8	4
1729	Prognostic Role of sST2 in Acute Heart Failure and COVID-19 Infectionâ€A Narrative Review on Pathophysiology and Clinical Prospective. International Journal of Molecular Sciences, 2022, 23, 8230.	4.1	7
1730	Diabetes mellitus and heart failure â€” a modern look at the mechanisms of development. Diabetes Mellitus, 2022, 25, 267-274.	1.9	4
1731	Right ventricle remodeling in chronic thromboembolic pulmonary hypertension. Journal of Translational Internal Medicine, 2022, 10, 125-133.	2.5	8
1732	High platelet reactivity is a predictor of left ventricular remodelling in patients with acute myocardial infarction. ESC Heart Failure, 2022, 9, 3565-3574.	3.1	2
1733	Cost-of-disease of Heart Failure in Turkey: A Delphi Panel-based Analysis of Direct and Indirect Costs. Balkan Medical Journal, 2022, 39, 282-289.	0.8	4
1734	Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
1735	Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 1139-1149.	4.5	1
1736	Effects of guideline-directed medical therapy in patients with left bundle branch block-induced cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.6	0
1737	Anemia and Heart Failure: A Narrative Review. Cureus, 2022, , .	0.5	5

#	ARTICLE	IF	CITATIONS
1738	The effect of occlusive polytetrafluoroethylene outflow graft protectors in left ventricular assist device recipients.. Journal of Heart and Lung Transplantation, 2022, , .	0.6	1
1739	Systems Pharmacology-Based Strategy to Investigate Pharmacological Mechanisms of Total Flavonoids in <i>Dracocephalum moldavica</i> on Chronic Heart Failure. International Journal of Molecular Sciences, 2022, 23, 8409.	4.1	4
1740	Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment. Journal of Cardiovascular Pharmacology, 2022, 80, 522-530.	1.9	5
1741	Von Willebrand factor (vWF) in patients with heart failure with preserved ejection fraction (HFpEF): A retrospective observational study. Medicine (United States), 2022, 101, e29854.	1.0	5
1742	Assays Specific for BNP1-32 and NT-proBNP Exhibit a Similar Performance to Two Widely Used Assays in the Diagnosis of Heart Failure. Clinical Chemistry, 0, , .	3.2	1
1743	Validation of R-hf risk score for risk stratification in ischemic heart failure patients: A prospective cohort study. Annals of Medicine and Surgery, 2022, 80, 104333.	1.1	0
1744	Relation of Sociodemographic Factors With Primary Cause of Hospitalization Among Patients With Left Ventricular Assist Devices (from the National Inpatient Sample 2012 to 2017). American Journal of Cardiology, 2022, 180, 81-90.	1.6	3
1745	Use and Outâ€ofâ€Pocket Cost of Sacubitrilâ€Valsartan in Patients With Heart Failure. Journal of the American Heart Association, 2022, 11, .	3.7	4
1746	Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995â€2021. Medicine (United States), 2022, 101, e29398.	1.0	2
1747	Prospective Observational Study of N-terminal Proâ€Brain Natriuretic Peptide Levels in Obese and Nonobese Women during Pregnancy. American Journal of Perinatology, 2023, 40, 467-474.	1.4	1
1748	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal Cardiovascular Imaging, 2022, 23, e333-e465.	1.2	97
1749	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 2022, 43, 4229-4361.	2.2	705
1750	Management of Iron Deficiency in Heart Failure: A Review of Evidence. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, .	1.9	0
1751	Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66). Heart Lung and Circulation, 2022, , .	0.4	0
1752	Soluble ST2 as a Potential Biomarker for Abdominal Aortic Aneurysmsâ€A Single-Center Retrospective Cohort Study. International Journal of Molecular Sciences, 2022, 23, 9598.	4.1	2
1753	A statistical learning framework for predicting left ventricular ejection fraction based on glutathione peroxidase-3 level in ischemic heart disease. Computers in Biology and Medicine, 2022, 149, 105929.	7.0	2
1754	Nursesâ€™ personal perceptions of clinical work adaptation during COVID-19. Heart and Lung: Journal of Acute and Critical Care, 2022, 56, 175-180.	1.6	0
1755	Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a <sc>populationâ€based</sc> cohort study of >25â€™000 Medicare beneficiaries. European Journal of Heart Failure, 2022, 24, 1506-1515.	7.1	11

#	ARTICLE	IF	CITATIONS
1756	Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 1673-1682.	1.7	1
1757	Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity. <i>American Journal of Medicine</i> , 2022, 135, 1468-1477.	1.5	0
1758	Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI2P2S classification. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	3
1759	Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113701.	5.6	3
1760	Influence of β_1 Adrenergic Receptor Genotype on Longitudinal Measures of Left Ventricular Ejection Fraction and Responsiveness to β_1 -Blocker Therapy in Patients With Duchenne Muscular Dystrophy. <i>Clinical Medicine Insights: Cardiology</i> , 2022, 16, 117954682211168.	1.8	1
1761	Short-Chain Fatty Acids-A Healthy Bus between Gut Microbiota and Organs beyond the Gut. <i>Advances in Bioscience and Biotechnology (Print)</i> , 2022, 13, 362-387.	0.7	1
1762	2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Data Standards. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	2.2	12
1763	Fear of movement and its associated psychosocial factors in heart failure patients: a cross-sectional study. <i>European Journal of Cardiovascular Nursing</i> , 2023, 22, 273-281.	0.9	7
1764	JCS 2022 Guideline on Management and Re-Interventional Therapy in Patients With Congenital Heart Disease Long-Term After Initial Repair. <i>Circulation Journal</i> , 2022, 86, 1591-1690.	1.6	6
1765	The Prevalence of Cognitive Frailty and Its Association with Sleep duration and Depression Among Older Adults with Heart Failure. <i>Clinical Gerontologist</i> , 2024, 47, 416-425.	2.2	5
1766	Effect of Integrative Chinese and Western Medicine Therapy on Long-Term Clinical Outcomes in Patients with Heart Failure: A Real-World Study Including 394 Patients. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-9.	1.2	0
1767	Comparative Study on Prediction of Mortality in Heart Failure Patients using Nine Machine Learning Algorithms. <i>The Journal of Korean Institute of Information Technology</i> , 2022, 20, 105-114.	0.3	1
1768	Chronic intermittent hypoxia accelerates cardiac dysfunction and cardiac remodeling during cardiac pressure overload in mice and can be alleviated by PHD3 overexpression. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	5
1769	How Do I Optimize Heart Failure Medications for Patients with Hypotension or Chronic Kidney Disease?. , 2022, 1, .		0
1770	Increased risk of metastasis in patients with incidental use of renin-angiotensin system inhibitors: a retrospective analysis for multiple types of cancer based on electronic medical records. <i>Hypertension Research</i> , 0, , .	2.7	2
1771	The effect of paclitaxel plus carboplatin chemotherapy on subclinical cardiotoxicity in patients with non-small cell lung cancer: A speckle tracking echocardiography-based study. <i>Revista Portuguesa De Cardiologia</i> , 2022, , .	0.5	3
1772	Effects and Safety of Oral Iron for Heart Failure with Iron Deficiency: A Systematic Review and Meta-Analysis with Trial Sequential Analysis. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-16.	2.5	0
1773	Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. , 0, Publish Ahead of Print, .		0

#	ARTICLE	IF	CITATIONS
1774	Impact of Socioeconomic Status on Mortality and Readmission in Patients With Heart Failure With Reduced Ejection Fraction: The ARIC Study. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	10
1775	Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study. <i>Clinical Chemistry</i> , 2022, 68, 1391-1398.	3.2	3
1776	Detection of myocardial fibrosis: Where we stand. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	8
1777	Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	14
1778	Long-term outcomes of papillary muscle relocation anteriorly for functional mitral regurgitation. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, 35, .	1.1	3
1779	Effects of multifaceted optimization management for chronic heart failure: a multicentre, randomized controlled study. <i>ESC Heart Failure</i> , 0, , .	3.1	1
1780	Targets and management of hypertension in heart failure: focusing on the stages of heart failure. <i>Journal of Clinical Hypertension</i> , 2022, 24, 1218-1225.	2.0	1
1781	Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST-CHF study. <i>ESC Heart Failure</i> , 2023, 10, 200-210.	3.1	7
1782	Trajectory of left ventricular ejection fraction in response to therapies in patients with muscular dystrophy. <i>Echocardiography</i> , 0, , .	0.9	0
1783	Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria. <i>Mayo Clinic Proceedings</i> , 2022, 97, 2099-2106.	3.0	2
1784	The coping in heart failure (COPE-HF) partnership intervention for heart failure symptoms: Implications for palliative care. <i>Progress in Palliative Care</i> , 2023, 31, 169-178.	1.2	1
1785	Nuanxinkang prevents the development of myocardial infarction-induced chronic heart failure by promoting PINK1/Parkin-mediated mitophagy. <i>Phytomedicine</i> , 2023, 108, 154494.	5.3	8
1786	Medical therapy for patients with recent-onset heart failure with reduced ejection fraction during the COVID-19 pandemic: Insights from the Veteran's affairs healthcare system. <i>American Heart Journal Plus</i> , 2022, 22, 100210.	0.6	0
1787	Left ventricular strain patterns and their relationships with cardiac biomarkers in hypertrophic cardiomyopathy patients with preserved left ventricular ejection fraction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	0
1788	Evaluating the evidence for sacubitril/valsartan across the continuum of heart failure. <i>Pharmacotherapy</i> , 0, , .	2.6	0
1789	Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction. <i>Cardiology Clinics</i> , 2022, 40, 473-489.	2.2	5
1790	Epidemiology, Diagnosis, Pathophysiology, and Initial Approach to Heart Failure with Preserved Ejection Fraction. <i>Cardiology Clinics</i> , 2022, 40, 397-413.	2.2	6
1791	Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study. <i>International Journal of Heart Failure</i> , 2022, 4, 193.	2.7	8

#	ARTICLE	IF	CITATIONS
1792	Riskâ€“Benefit Balance of Reninâ€“Angiotensinâ€“Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. <i>Journal of Clinical Medicine</i> , 2022, 11, 5828.	2.4	2
1793	Association between remnant cholesterol and heart failure: A prospective cohort study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	3
1794	Transient gene therapy using cell cycle factors reverses reninâ€“angiotensinâ€“aldosterone system activation in heart failure rat model. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 1245-1250.	3.1	1
1795	Spironolactone Utilization among Patients with Reduced and Preserved Ejection Fraction Heart Failure. , 2022, 1, 89-100.		0
1797	Clinical performance and quality measures for heart failure management in China: the Chinaâ€“Heart Failure registry study. <i>ESC Heart Failure</i> , 2023, 10, 342-352.	3.1	4
1798	New principles for the treatment of chronic heart failure: the phenomenon of sodium-glucose cotransporter type 2 inhibitors. <i>Meditinskiy Sovet</i> , 2022, , 44-51.	0.5	0
1799	Serum Uric Acid Is Associated with the Progression of Left Ventricular Diastolic Dysfunction in Apparently Healthy Subjects. <i>Disease Markers</i> , 2022, 2022, 1-12.	1.3	2
1801	Inpatient Quality-of-Care Measures for Heart Failure: Treatment Gaps and Opportunities in the Contemporary Era. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	2.2	2
1802	Detection of soluble suppression of tumorigenicity 2 and N-terminal B-type natriuretic peptide in a rat model of aortic regurgitation: differential responses to omecamtiv mecarbil. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, .	1.3	0
1803	The impact of informal caregiversâ€™ preparedness on short-term outcomes of heart failure patients with insufficient self-care. <i>European Journal of Cardiovascular Nursing</i> , 2023, 22, 628-637.	0.9	5
1804	Artificial Muscles and Soft Robotic Devices for Treatment of Endâ€“Stage Heart Failure. <i>Advanced Materials</i> , 2023, 35, .	21.0	9
1805	Research progress on the relationship between mitochondrial function and heart failure: A bibliometric study from 2002 to 2021. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	4
1806	In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial. <i>Circulation: Heart Failure</i> , 0, , .	3.9	3
1807	Medication Complexity Among Older Adults with HF: How Can We Assess Better?. <i>Drugs and Aging</i> , 2022, 39, 851-861.	2.7	3
1808	Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review. <i>Supportive Care in Cancer</i> , 2022, 30, 10471-10482.	2.2	3
1809	Liver stiffness assessed by magnetic resonance elastography predicts clinical outcomes in patients with heart failure and without chronic liver disease. <i>European Radiology</i> , 2023, 33, 2062-2074.	4.5	4
1810	Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	8
1811	Clinician Adoption of an Artificial Intelligence Algorithm to Detect Left Ventricular Systolic Dysfunction in Primary Care.. <i>Mayo Clinic Proceedings</i> , 2022, 97, 2076-2085.	3.0	4

#	ARTICLE	IF	CITATIONS
1812	Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. <i>Kidney International</i> , 2022, 102, 990-999.	5.2	78
1813	Cardiorenal Syndromes. <i>Critical Care Nursing Clinics of North America</i> , 2022, 34, 383-393.	0.8	0
1814	Advances in congestive heart failure biomarkers. <i>Advances in Clinical Chemistry</i> , 2023, , 205-248.	3.7	3
1815	Signaling network model of cardiomyocyte morphological changes in familial cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2023, 174, 1-14.	1.9	4
1817	Contemporary Data on the Status and Medical Management of Acute Heart Failure. <i>Current Cardiology Reports</i> , 0, , .	2.9	2
1818	Heterogeneity in multi-centre trial participating centers: Lessons from the TOPCAT trial on interpreting trial data for clinical practice. <i>Journal of Clinical Epidemiology</i> , 2022, , .	5.0	0
1819	Oxidative stress markers-driven prognostic model to predict post-discharge mortality in heart failure with reduced ejection fraction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	2
1820	Development and Piloting of a Community-Partnered Heart Failure Training Course for Home Health Care Workers. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	2.2	3
1821	Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Internal Medicine</i> , 2022, 182, 1278.	5.1	26
1822	Prospective evaluation of smartwatch-enabled detection of left ventricular dysfunction. <i>Nature Medicine</i> , 2022, 28, 2497-2503.	30.7	38
1823	Renal function during hospitalization and outcome in Chinese patients with acute decompensated heart failure: A retrospective study and literature review. <i>Clinical Cardiology</i> , 0, , .	1.8	2
1824	Multifactorial effects of outpatient cardiac rehabilitation in patients with heart failure: a nationwide retrospective cohort study. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 442-450.	1.8	5
1825	Perioperative changes in left ventricular systolic function following surgical revascularization. <i>PLoS ONE</i> , 2022, 17, e0277454.	2.5	1
1827	Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups. <i>JACC: Heart Failure</i> , 2023, 11, 161-172.	4.1	6
1828	Importance of NT-proBNP and conventional risk factors for prediction of death in older adults with and without diabetes mellitus—a report from the Atherosclerosis Risk in Communities (ARIC) study. <i>Diabetes Research and Clinical Practice</i> , 2022, , 110164.	2.8	6
1830	Animal-assisted therapy for cardiac conditions. , 2023, , 147-164.		1
1831	Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2023, 188, 52-60.	1.6	1
1832	Hemodynamic Gain Index and Exercise Capacity in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2023, 190, 17-24.	1.6	2

#	ARTICLE	IF	CITATIONS
1833	Artificial intelligence-enabled electrocardiogram screens low left ventricular ejection fraction with a degree of confidence. Digital Health, 2022, 8, 205520762211432.	1.8	1
1834	Assessing Myocardial Involvement in Systemic Lupus Erythematosus Patients without Cardiovascular Symptoms by Technetium-99m-sestamibi Myocardial Perfusion Imaging: A Correlation Study on NT-proBNP. Current Medical Imaging, 2022, 19, .	0.8	0
1835	Identification of echocardiographic subgroups in patients with coronary heart disease combined with heart failure based on latent variable stratification. International Journal of Cardiology, 2023, 373, 90-98.	1.7	1
1836	Left Ventricle Wall Motion Analysis with Real-Time MRI Feature Tracking in Heart Failure Patients: A Pilot Study. Diagnostics, 2022, 12, 2946.	2.6	0
1837	Cardiac Rehabilitation for Older Women with Heart Failure. Journal of Personalized Medicine, 2022, 12, 1980.	2.5	0
1838	Severity of and Recovery From Anemia After Transcatheter Aortic Valve Replacement: An Analysis of the PARTNER Trials and Registries. , 2023, 2, 100531.		1
1839	Prognostic value of plasma sAXL in patients with heart failure: insights from the DRAGONâ€”HF trial. ESC Heart Failure, 0, , .	3.1	2
1840	Educational Nursing Intervention in Reducing Hospital Readmission and the Mortality of Patients with Heart Failure: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Development and Disease, 2022, 9, 420.	1.6	1
1841	Frequency and predictors of hyperkalemia in the heart failure outpatient clinic. Acta Medica Alanya, 0, , .	0.2	0
1842	Skeletal muscle phenotypic switching in heart failure with preserved ejection fraction. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
1843	Dynamic Evolution of Cardiac Function and Glucose and Lipid Metabolism in Ovariectomized Rats and the Intervention Effect of Erxian Decoction. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-14.	1.2	1
1844	Effect of reninâ€”angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy. Open Heart, 2022, 9, e002135.	2.3	2
1845	Cardiovascular predictors of mortality and exacerbations in patients with COPD. Scientific Reports, 2022, 12, .	3.3	4
1846	Diagnostic utility of total NT-proBNP testing by immunoassay based on antibodies targeting glycosylation-free regions of NT-proBNP. Clinical Chemistry and Laboratory Medicine, 2023, 61, 485-493.	2.3	3
1847	Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Failure, 2023, 10, 1066-1076.	3.1	9
1849	Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Nephilysin Inhibitors in Patients With Heart Failure. Journal of the American Heart Association, 2022, 11, .	3.7	3
1850	Clinical Predictors of Adherence to Exercise Training Among Individuals With Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2023, 43, 205-213.	2.1	2
1851	C-Reactive Protein, Interleukin-6, Trimethylamine-N-Oxide, Syndecan-1, Nitric Oxide, and Tumor Necrosis Factor Receptor-1 in Heart Failure with Preserved Versus Reduced Ejection Fraction: a Meta-Analysis. Current Heart Failure Reports, 2023, 20, 1-11.	3.3	5

#	ARTICLE	IF	CITATIONS
1852	Outcomes and predictors of one-year mortality in patients hospitalized with Acute Heart Failure. IJC Heart and Vasculature, 2022, 43, 101159.	1.1	1
1853	Pre-diagnostic predictors of mortality in patients with heart failure: The multi-ethnic study of atherosclerosis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
1854	Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review. Cost Effectiveness and Resource Allocation, 2022, 20, .	1.5	3
1855	Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real-world analysis. PACE - Pacing and Clinical Electrophysiology, 2023, 46, 50-58.	1.2	4
1856	A New Era in Cardiac Rehabilitation Delivery: Research Gaps, Questions, Strategies, and Priorities. Circulation, 2023, 147, 254-266.	1.6	30
1857	Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Annals of Internal Medicine, 2023, 176, 381-387.	3.9	35
1858	Valvular Heart Disease in the Elderly: Clinical and Multi-Modality Imaging Perspectives. Contemporary Cardiology, 2023, , 277-302.	0.1	0
1859	Clinical application and new utility of sST2 in emergency area. Italian Journal of Emergency Medicine, 2022, 11, .	0.1	0
1860	Cardiac sympathetic innervation and mortality risk scores in patients with heart failure. European Journal of Clinical Investigation, 0, , .	3.4	1
1861	Diuretics and Ultrafiltration in Heart Failure. CardioRenal Medicine, 2023, , 56-65.	1.9	5
1862	Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2023, 37, 108389.	2.3	7
1864	Treatment outcomes and associated factors among chronic ambulatory heart failure patients at Jimma Medical Center, South West Ethiopia: prospective observational study. BMC Cardiovascular Disorders, 2023, 23, .	1.7	1
1865	Design and pilot implementation for the BETTER CARE-HF trial: A pragmatic cluster-randomized controlled trial comparing two targeted approaches to ambulatory clinical decision support for cardiologists. American Heart Journal, 2023, 258, 38-48.	2.7	3
1866	Quantifying inflammation using interleukin-6 for improved phenotyping and risk stratification in acute heart failure. European Journal of Heart Failure, 2023, 25, 174-184.	7.1	7
1868	Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 1173-1179.	0.9	0
1870	External Validation of the Japanese Clinical Score for Mortality Prediction in Patients With Acute Heart Failure. Circulation Journal, 2023, 87, 543-550.	1.6	1
1871	Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact?. Cancers, 2023, 15, 207.	3.7	6
1872	Estimating right atrial pressure using upright computed tomography in patients with heart failure. European Radiology, 0, , .	4.5	0

#	ARTICLE	IF	CITATIONS
1873	Missed opportunities in medical therapy for patients with heart failure in an electronically-identified cohort. BMC Cardiovascular Disorders, 2022, 22, .	1.7	3
1874	Preferred Place of End-of-Life Care Based on Clinical Scenario: A Cross-Sectional Study of a General Japanese Population. Healthcare (Switzerland), 2023, 11, 406.	2.0	1
1875	Medications for When the Heart Fails. Physician Assistant Clinics, 2023, , .	0.1	0
1876	Biomarker sST2 in Adults with Transposition of the Great Arteries Palliated by Mustard Procedure: A Five-Year Follow-up. Pediatric Cardiology, 2023, 44, 927-932.	1.3	0
1877	The Efficacy and Safety of Tolvaptan in Heart Failure Patients with Congestive Signs: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2023, 3, 30-39.		0
1878	Validation of the Meta-Analysis Global Group in Chronic Heart Failure risk score for the prediction of 1-year mortality in a Chinese cohort. Chinese Medical Journal, 2022, 135, 2829-2835.	2.3	1
1879	Association between cardiopulmonary function, health-related quality of life and cognitive impairment among the older nursing home residents in Shanghai, China. Primary Health Care Research and Development, 2023, 24, .	1.2	0
1880	The soluble suppression of tumorigenicity 2 as a biomarker of early cardiac remodeling in bradycardia patients receiving permanent pacemaker therapy. Future Science OA, 2023, 9, .	1.9	0
1881	Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. Biomedicines, 2023, 11, 662.	3.2	3
1882	Monitoring Cardiac Biomarkers with Aptamer-Based Molecular Pendulum Sensors. Angewandte Chemie, 2023, 135, .	2.0	1
1883	Exercises in activating lymphatic system on fluid overload symptoms, abnormal weight gains, and physical functions among patients with heart failure: A randomized controlled trial. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	1
1884	A Computable Algorithm for Medication Optimization in Heart Failure With Reduced Ejection Fraction. , 2023, 2, 100289.		0
1885	Features of drug pharmacotherapy in patients with heart failure after pacemaker implantation. Medicina Sâlogodnă, 2020, 88, 21-26.	0.2	0
1886	Trends in pharmacotherapy utilization among patients with heart failure with preserved ejection fraction. American Heart Journal Plus, 2023, 26, 100259.	0.6	0
1887	Effects of β^2 -blockers on all-cause mortality in patients with diabetes and coronary heart disease: A systematic review and meta-analysis. Frontiers in Cell and Developmental Biology, 0, 11, .	3.7	1
1888	Latest Standard Management for Heart Failure with Guideline-Directed Medical Therapy (GDMT). , 2022, 3, 35-40.		0
1889	Efficacy of peritoneal dialysis in patients with refractory congestive heart failure: a systematic review and meta-analysis. Heart Failure Reviews, 2023, 28, 1053-1063.	3.9	2
1890	Global historical retrospect and future prospects on biomarkers of heart failure: A bibliometric analysis and science mapping. Heliyon, 2023, 9, e13509.	3.2	3

#	ARTICLE	IF	CITATIONS
1891	II. Details: Therapeutic Agents for Chronic Heart Failure; 1. ARNI and ACE Inhibitor»ARB. The Journal of the Japanese Society of Internal Medicine, 2022, 111, 221-227.	0.0	0
1892	The clinical burden of newly diagnosed Heart failure among patients with Reduced, mildly Reduced, and preserved ejection fraction. IJC Heart and Vasculature, 2023, 47, 101182.	1.1	1
1893	Diagnostic accuracy of natriuretic peptide screening for left ventricular systolic dysfunction in the community: systematic review and meta-analysis. ESC Heart Failure, 2023, 10, 1643-1655.	3.1	2
1895	LncRNA PVT1 as a Novel Biomarker for Diabetes-related Complications. Current Medicinal Chemistry, 2024, 31, 688-696.	2.4	1
1896	Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2023, 24, e108-e120.	10.7	27
1897	Red Blood Cell Distribution Width: A Risk Factor for Prognosis in Patients with Ischemic Cardiomyopathy after Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2023, 12, 1584.	2.4	0
1898	Safety and feasibility of angiotensin receptor neprilysin inhibitor in real-world patients with acute decompensated heart failure. Minerva Cardiology and Angiology, 2023, 71, .	0.7	1
1899	Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Annals of Pharmacotherapy, 2023, 57, 1291-1301.	1.9	1
1900	Hepatocyte Growth Factor and 10-Year Change in Left Ventricular Structure: The Multi-Ethnic Study of Atherosclerosis (MESA). CJC Open, 2023, 5, 364-372.	1.5	0
1901	Î±/Î²- and Î²-Blocker Exposure in Pregnancy and the Risk of Neonatal Hypoglycemia and Small for Gestational Age. Circulation Journal, 2023, 87, 569-577.	1.6	2
1902	The association of plasma NT-proBNP level and progression of diabetic kidney disease. Renal Failure, 2023, 45, .	2.1	1
1903	A deep learning system for heart failure mortality prediction. PLoS ONE, 2023, 18, e0276835.	2.5	2
1904	Assessment of the Myocardial Stress Biomarker NT-proBNP in Real Clinical Practice. Obshchaya Reanimatologiya, 2023, 19, 4-12.	1.0	6
1905	Cardiorenal syndrome in the pediatric population: A systematic review. Annals of Pediatric Cardiology, 2022, 15, 493.	0.5	0
1906	Diet-Induced Microbiome's Impact on Heart Failure: A Double-Edged Sword. Nutrients, 2023, 15, 1223.	4.1	5
1907	Identification and verification of feature biomarkers associated in heart failure by bioinformatics analysis. Scientific Reports, 2023, 13, .	3.3	3
1908	Efficacy of disease management program used among patients with chronic heart failure: protocol for a systematic review and network meta-analysis. Systematic Reviews, 2023, 12, .	5.3	0
1909	Prevalence and Correlates of Elevated NT-proBNP in Pregnant Women in the General U.S. Population. , 2023, 2, 100265.		7

#	ARTICLE	IF	CITATIONS
1910	Impact of pharmacist-led interventions on heart failure medication adherence: a prospective cohort study. <i>Journal of Pharmaceutical Health Services Research</i> , 0, , .	0.6	0
1911	Monitoring Cardiac Biomarkers with Aptamer-Based Molecular Pendulum Sensors. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	13.8	3
1912	Serum-soluble suppression of tumourigenicity-2 as a biomarker in children with congestive heart failure. <i>Cardiology in the Young</i> , 0, , 1-6.	0.8	0
1913	Differential Gene Expression Among Patients With Heart Failure Experiencing Pain. <i>Nursing Research</i> , 2023, 72, 175-184.	1.7	0
1914	Role of hospitalists in Japan for heart failure in the elderly: single center retrospective cohort study. <i>Hospital Practice (1995)</i> , 2023, 51, 135-140.	1.0	1
1915	WGCNA combined with machine learning algorithms for analyzing key genes and immune cell infiltration in heart failure due to ischemic cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	3
1916	Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis. <i>Cureus</i> , 2023, , .	0.5	0
1917	Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences. <i>Pharmaceutics</i> , 2023, 15, 1002.	4.5	1
1918	Growth Differentiation Factor 15 and Clinical Outcomes in Japanese Patients With Heart Failure. <i>Circulation Journal</i> , 2023, 87, 1120-1129.	1.6	1
1919	Effects of the perimenopausal period on the course of heart failure. <i>Cukurova Medical Journal</i> , 2023, 48, 136-144.	0.2	0
1920	Digoxin and Standard-of-Care Therapy for Heart Failure Patients with COVID-19: Analysis of Data from the US Military Health System (MHS) Data Repository. <i>Drugs - Real World Outcomes</i> , 0, , .	1.6	1
1921	Heart failure therapy challenges in obese patients. <i>Medicinski Glasnik Specijalne Bolnice Za Bolesti Ātitaste Ā½lezde Ā Bolesti Metabolizma Zlatibor</i> , 2023, 28, 21-42.	0.1	0
1922	The association between comorbidities and self-care of heart failure: a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2023, 23, .	1.7	1
1923	Clinical Usefulness of Right Ventricle-Pulmonary Artery Coupling in Cardiovascular Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 2526.	2.4	7
1924	The history and mystery of sacubitril/valsartan: From clinical trial to the real world. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	1
1925	Predictive value of global longitudinal strain by left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2023, 10, 1937-1947.	3.1	2
1926	Transitions of Care and Self-Care Strategies for the Heart Failure Patient. , 2023, , 107-125.		0
1927	Diagnostics of anemia and iron deficiency in patients with chronic heart failure. <i>Medicni Perspektivi</i> , 2023, 28, 77-82.	0.4	0

#	ARTICLE	IF	CITATIONS
1928	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis. Korean Circulation Journal, 2023, 53, 195.	1.9	3
1929	Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension. Hypertension Research, 2023, 46, 1727-1737.	2.7	7
1930	Cardiac and Pulmonary Rehabilitation: Two Underutilized Approaches with Some Unexpected Benefits. Journal of Clinical Medicine, 2023, 12, 2847.	2.4	1
1931	Discontinuation of Intravenous Catecholamine by Oral Ivabradine in a Patient with Decompensated Heart Failure with Low Cardiac Output Syndrome. Kurume Medical Journal, 2023, , .	0.1	0
1932	Surgical Ventricular Remodeling in Ischemic Cardiomyopathy. , 2023, , 497-509.		0
1933	Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. Journal of Cardiac Failure, 2023, 29, 787-804.	1.7	9
1934	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis. International Journal of Heart Failure, 2023, 5, 51.	2.7	5
1935	Artificial intelligence in cardiovascular imaging: enhancing image analysis and risk stratification. BJR Open, 2023, 5, .	0.6	4
1936	UpdatED: The emergency medicine pharmacotherapy literature of 2022. American Journal of Emergency Medicine, 2023, , .	1.6	0
1937	Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. European Journal of Heart Failure, 2023, 25, 616-631.	7.1	14
1938	Impact of Diabetes and Hypertension on Left Ventricular Structure and Function: The Jackson Heart Study. Journal of the American Heart Association, 2023, 12, .	3.7	2
1939	âœœHeart failure at either end of the spectrumâœœ. Heart and Lung: Journal of Acute and Critical Care, 2023, 61, 65.	1.6	0
1940	Efficacy of dapagliflozin in the treatment of HFrEF with obstructive sleep apnea syndrome (DAHOS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 2023, 24, .	1.6	2
1941	Novel Biomarkers of Cardiovascular Disease. , 2024, , 409-435.		0
1942	Serum lipidomics reveals phosphatidylethanolamine and phosphatidylcholine disorders in patients with myocardial infarction and post-myocardial infarction-heart failure. Lipids in Health and Disease, 2023, 22, .	3.0	1
1943	Interleukin-33/sST2: Dynamic assessment in patients with acute coronary syndrome. Advances in Medical Sciences, 2023, 68, 195-201.	2.1	0
1944	Characteristics of cardiopulmonary exercise testing in patients with combined post- and pre-capillary pulmonary hypertension due to left heart disease. PLoS ONE, 2023, 18, e0286057.	2.5	0
1945	The diagnostic value of sST2 for myocardial fibrosis in idiopathic inflammatory myopathies in subclinical stage of cardiac involvement. Rheumatology, 2024, 63, 1172-1179.	1.9	1

#	ARTICLE	IF	CITATIONS
1946	Budget Impact Analysis of Utilization of Sacubitril/Valsartan for the Treatment of Heart Failure With Reduced Ejection Fraction in the Philippines. Value in Health Regional Issues, 2023, 36, 105-116.	1.2	1
1947	Utilization and Optimization of Beta-Blockers on Heart Failure Patients with Reduced Ejection Fraction (HFrEF) at Cardiac Clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A Cross-Sectional Study. Research Reports in Clinical Cardiology, 0, Volume 14, 21-33.	0.2	0
1948	Advances in symptomatic therapy for left ventricular non-compaction in children. Frontiers in Pediatrics, 0, 11, .	1.9	0
1949	The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis. International Urology and Nephrology, 2024, 56, 181-190.	1.4	3
1950	CARDIOVASCULAR DISEASES AND OBSTRUCTIVE SLEEP APNEA SYNDROME. REVIEW. Medical Science of Ukraine (MSU), 2023, 19, 115-126.	0.2	0
1951	Pulmonary Congestion in Heart Failure With Reduced Ejection Fraction: Comparison Between Lung Ultrasound and Remote Dielectric Sensing. Arquivos Brasileiros De Cardiologia - Imagem Cardiovascular, 2023, 36, .	0.0	0
1952	Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction. Journal of Korean Medical Science, 2023, 38, .	2.5	0
1953	Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia. Frontiers in Pharmacology, 0, 14, .	3.5	0
1954	Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States. Circulation: Cardiovascular Quality and Outcomes, 2023, 16, .	2.2	2
1955	Disparities in Postdischarge Ambulatory Care Follow-up Among Medicaid Beneficiaries With Diabetes, Hospitalized for Heart Failure. Journal of the American Heart Association, 2023, 12, .	3.7	2
1956	NT-proBNP cut-off value for ruling out heart failure in atrial fibrillation patients – A prospective clinical study. American Journal of Emergency Medicine, 2023, 71, 18-24.	1.6	2
1957	Native T1 high region and left ventricular ejection fraction recovery in patients with dilated cardiomyopathy. International Journal of Cardiovascular Imaging, 2023, 39, 1785-1793.	1.5	0
1958	A Kaposi's sarcoma-associated herpes virus-encoded microRNA contributes to dilated cardiomyopathy. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	0
1959	Sexual Functions Following Cardiac Resynchronization Therapy: Evaluation of Male Patients and Their Partners. Cureus, 2023, , .	0.5	0
1960	Prognostic Value of Liver Fibrotic Markers in Patients With Heart Failure. American Journal of Cardiology, 2023, 200, 115-123.	1.6	1
1961	Physical Frailty and Use of Guideline-Recommended Drugs in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American Heart Association, 2023, 12, .	3.7	5
1962	Pacing-Induced Cardiomyopathy. Cardiology Clinics, 2023, 41, 449-461.	2.2	0
1964	Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes. Contemporary Diabetes, 2023, , 779-819.	0.0	0

#	ARTICLE	IF	CITATION
1965	Effects of sacubitril-valsartan in patients undergoing maintenance dialysis. Renal Failure, 2023, 45, .	2.1	0
1966	Remote monitoring titration clinic to implement guideline-directed therapy for heart failure patients with reduced ejection fraction: a pilot quality-improvement intervention. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	3
1967	Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review. Annals of Pharmacotherapy, 2024, 58, 255-272.	1.9	0
1968	Effect of probiotic supplementation on in-hospital mortality in patients with acute myocardial infarction: a study protocol for an open-label, randomized, controlled, superiority clinical trial. Trials, 2023, 24, .	1.6	1
1969	Novel Approaches to Sleep Apnea in Heart Failure. Heart Failure Clinics, 2023, , .	2.1	0
1970	MRAs may have lost their cornerstone position for heart failure treatment in the age of SGLT-2 inhibitors: A meta-analysis of randomized controlled trials. Heart Failure Reviews, 0, , .	3.9	0
1971	Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists. Cardiology and Therapy, 0, , .	2.6	0
1972	Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of America. Journal of Cardiac Failure, 2023, 29, 1059-1077.	1.7	13
1973	ð’ð~ðšðžðð~ð;ðçðððð~ð’ð†ðžðœðððšð•ðð•ST2 ð’ ð”ð†ðð“ððžð;ðçð~ð ð†ð¥ððžðð†ðšðððžð†ð;ð•ðð ð•ð’ðžð†ððð•ð”ð		
1974	Implementation of a heart failure educational intervention for patients with recent admissions for acute decompensated heart failure. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
1977	Comparison of short and long forms of the Flinders program of chronic disease SELF-management for participants starting SGLT-2 inhibitors for congestive heart failure (SELFMAN-HF): protocol for a prospective, observational study. Frontiers in Medicine, 0, 10, .	2.6	1
1978	Progressive Cardiac Metabolic Defects Accompany Diastolic and Severe Systolic Dysfunction in Spontaneously Hypertensive Rat Hearts. Journal of the American Heart Association, 2023, 12, .	3.7	0
1979	Immune checkpoint inhibitorâ€related myocarditis in thymic epithelial tumors: Recent progress and perspectives. , 2023, 2, .		0
1980	Clinical Features, Socioeconomic Status, Management, and Outcomes of Acute Heart Failure: PEACE MENA Registry Phase I Results. Current Vascular Pharmacology, 2023, 21, .	1.7	0
1981	The Role of Sleep Apnea in Diabetes Mellitus and Cardiovascular Disease. Contemporary Cardiology, 2023, , 333-374.	0.1	0
1982	Perspectives of hospitalized heart failure patients: preferred and perceived participation roles in treatment decisions. Heart and Vessels, 0, , .	1.2	1
1983	Sacubitril/Valsartan in Dialysis Patients: Update on Current Perspectives. Cardiovascular Drugs and Therapy, 0, , .	2.6	1
1984	Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction. Heart Failure Clinics, 2023, , .	2.1	0

#	ARTICLE	IF	CITATIONS
1985	The Lebanese Society of Cardiology Consensus Statement on the Use of Natriuretic Peptides for the Management of Heart Failure. World Journal of Cardiovascular Diseases, 2023, 13, 297-308.	0.2	0
1986	Soluble Suppression of Tumorigenicity-2 as a Candidate Prognostic Marker for Stroke: A Systematic Review. Annals of Laboratory Medicine, 2023, 43, 585-595.	2.5	0
1988	Clinical Progress of Kawasaki Disease. Advances in Clinical Medicine, 2023, 13, 10281-10290.	0.0	0
1989	Prognostic Role of Metabolic Exercise Testing in Heart Failure. Journal of Clinical Medicine, 2023, 12, 4438.	2.4	1
1990	<i>PRDM16</i> Deletion Is Associated With Sex-dependent Cardiomyopathy and Cardiac Mortality: A Translational, Multi-Institutional Cohort Study. Circulation Genomic and Precision Medicine, 2023, 16, 390-400.	3.6	2
1991	Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure. ESC Heart Failure, 2023, 10, 2826-2836.	3.1	3
1992	Efficacy and safety analysis of angiotensin receptor neprilysin inhibition (ARNI) in patients with heart failure: a real-world retrospective study. BMC Cardiovascular Disorders, 2023, 23, .	1.7	0
1993	Postmortem biochemical analysis of soluble ST2 in the pericardial fluid of patients with sudden cardiac death caused by ischemic heart disease: a pilot study. Forensic Science, Medicine, and Pathology, 0, , .	1.4	0
1994	Novel Biomarkers and the Multiple-Marker Approach in Early Detection, Prognosis, and Risk Stratification of Cardiac Diseases: A Narrative Review. Cureus, 2023, , .	0.5	4
1995	Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes. American Journal of Nephrology, 2023, 54, 258-267.	3.1	1
1996	Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype. Scientific Reports, 2023, 13, .	3.3	1
1997	Associations between diet quality and NT-proBNP in U.S. adults, NHANES 1999-2004. American Journal of Preventive Cardiology, 2023, 16, 100528.	3.0	1
1998	Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review. ESC Heart Failure, 2023, 10, 2760-2772.	3.1	2
1999	Compression wraps as adjuvant therapy in the management of acute systolic heart failure. Heliyon, 2023, 9, e19008.	3.2	0
2000	Cardiac Troponin T and NT-proBNP for Prediction of 30-Day Readmission or Death in Patients with Acute Dyspnea: Data from the Akershus Cardiac Examination 2 Study. Cardiology, 2023, 148, 506-516.	1.4	1
2001	Deciphering the Dilemma: Anticoagulation for Heart Failure With Preserved Ejection Fraction (HFpEF). Cureus, 2023, , .	0.5	17
2003	Rationale and design of the ARAMIS trial: Anakinra versus placebo, a double blind randomized controlled trial for the treatment of acute myocarditis. Archives of Cardiovascular Diseases, 2023, 116, 460-466.	1.6	6
2004	Evaluation of the efficacy and safety of an integrated telerehabilitation platform for home-based cardiac REHAbilitation in patients with heart failure (E-REHAB): protocol for a randomised controlled trial. BMJ Open, 2023, 13, e073846.	1.9	0

#	ARTICLE	IF	CITATIONS
2005	In-Hospital Management and Long-term Clinical Outcomes and Adherence in Patients With Acute Decompensated Heart Failure: Primary Results of the First Brazilian Registry of Heart Failure (BREATHE). Journal of Cardiac Failure, 2023, , .	1.7	0
2006	Noninvasive Positive Pressure Ventilation in Acute Decompensated Heart Failure. , 2023, , 387-401.		0
2007	NIV and Cardiac Diseases with Left Ventricular Mechanics. , 2023, , 403-413.		0
2008	Changes in Left Ventricular Global Longitudinal Strain in Patients With Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial. Journal of the American Heart Association, 0, , .	3.7	0
2009	Summary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines. Cardiology and Therapy, 0, , .	2.6	0
2010	JCS/JSCVS/JATS/JSVS 2020 Guideline on Diagnosis and Treatment of Aortic Aneurysm and Aortic Dissection. Circulation Journal, 2023, 87, 1410-1621.	1.6	8
2011	Importance of anemia in heart failure over blood pressure variability. Clinical Cardiology, 2023, 46, 1495-1503.	1.8	0
2012	Heart failure care: The time has come to tackle the cardiovascular “epidemic” of the XXI century. Revista Portuguesa De Cardiologia, 2023, , .	0.5	0
2013	Human Gut Microbiota in Heart Failure: Trying to Unmask an Emerging Organ. Biomedicines, 2023, 11, 2574.	3.2	0
2014	Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey. ESC Heart Failure, 2023, 10, 2773-2787.	3.1	0
2015	Use of 3D Printing Techniques to Fabricate Implantable Microelectrodes for Electrochemical Detection of Biomarkers in the Early Diagnosis of Cardiovascular and Neurodegenerative Diseases. ACS Measurement Science Au, 2023, 3, 315-336.	4.4	0
2016	Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N-oxide. Nature Communications, 2023, 14, .	12.8	0
2017	Biomarkers of Collagen Metabolism Are Associated with Left Ventricular Function and Prognosis in Dilated Cardiomyopathy: A Multi-Modal Study. Journal of Clinical Medicine, 2023, 12, 5695.	2.4	0
2018	Prevalence of chronic pain and chronic widespread pain among subjects with heart failure in the general population: The HUNT study. European Journal of Pain, 2024, 28, 273-284.	2.8	0
2019	Increasing trends of overweight and obesity in treatment-naïve people living with HIV in Shenzhen from 2014 to 2020: an emerging health concern. Frontiers in Public Health, 0, 11, .	2.7	0
2020	Sex-related differences in functional capacity and its implications in risk stratification before major non-cardiac surgery: a post hoc analysis of the international METS study. EClinicalMedicine, 2023, 64, 102223.	7.1	0
2021	Admission hyponatraemia as heart failure events predictor in patients with acute heart failure. ESC Heart Failure, 2023, 10, 2966-2972.	3.1	0
2022	Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0

#	ARTICLE	IF	CITATIONS
2023	Effects of Exercise on Circulating Extracellular Vesicles in Cardiovascular Disease. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 241-258.	1.6	0
2024	Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	3
2025	Uso do Modelo de Risco ADHERE como Preditor de Piora Intra-Hospitalar de Insuficiência Cardíaca em uma Coorte. <i>Arquivos Brasileiros De Cardiologia</i> , 2023, 120, .	0.8	0
2026	Combination Diuretic Therapy With Thiazides: A Systematic Review on the Beneficial Approach to Overcome Refractory Fluid Overload in Heart Failure. <i>Cureus</i> , 2023, , .	0.5	0
2027	Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide. <i>Diabetes Therapy</i> , 2023, 14, 1867-1887.	2.5	1
2028	Evaluation of the Efficacy of Sacubitril/Valsartan on Radiofrequency Ablation in Patients with Hypertension and Persistent Atrial Fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	0
2030	Cost-effectiveness of new quadruple therapy compared with standard treatment for patients with heart failure in China. <i>Journal of Cardiovascular Pharmacology</i> , 2023, , .	1.9	0
2031	Timing of prescription of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients hospitalized for acute heart failure with reduced/mildly reduced ejection fraction: a retrospective analysis. <i>Heart and Vessels</i> , 2024, 39, 25-34.	1.2	1
2032	Heart Failure: Recent Advances and Breakthroughs. <i>Disease-a-Month</i> , 2024, 70, 101634.	1.1	0
2033	Relationship between left ventricular mechanical dyssynchrony with cardiac resynchronization therapy response in chronic heart failure patients with left bundle branch block. <i>Journal of Arrhythmology</i> , 2023, 30, 61-72.	0.2	0
2035	Heart failure and diabetes: Understanding the bidirectional relationship. <i>Medicine (United States)</i> , 2023, 102, e34906.	1.0	2
2036	Long-Term Outcomes of Cardiac Sarcoid: Prognostic Implications of Isolated Cardiac Involvement and Impact of Diagnostic Delays. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.7	1
2037	The effect of dapagliflozin on anemia in elderly patients with heart failure by bioinformatics analysis. <i>Technology and Health Care</i> , 2023, , 1-11.	1.2	1
2038	How do we define high and low dose intensity of heart failure medications: a scoping review. <i>BMC Cardiovascular Disorders</i> , 2023, 23, .	1.7	0
2039	NT-proBNP and cardiovascular event risk in individuals with prediabetes undergoing cardiovascular evaluation. <i>Diabetes Research and Clinical Practice</i> , 2023, 205, 110923.	2.8	0
2040	Effect of Glucagon-like Peptide-1 Receptor Agonist on Cardiac Structure and Function in Patients with Heart Failure: A Systematic Review and Meta-analysis. , 0, , 117-129.		0
2041	Renin Angiotensin Aldosterone System Blockers. , 2024, , 258-273.		0
2042	New Approaches to Cardiovascular Toxicity Assessment in Patients with Hematological Malignancies: A Literature Review. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2023, 16, 331-336.	0.4	0

#	ARTICLE	IF	CITATIONS
2043	Blood Pressure Control in a Diverse Population of Hypertensive Patients With Heart Failure. American Journal of Cardiology, 2023, 208, 25-30.	1.6	1
2044	Insights into the Role of Galectin-3 as a Diagnostic and Prognostic Biomarker of Atrial Fibrillation. Disease Markers, 2023, 2023, 1-13.	1.3	0
2045	Characterization of <i>de novo</i> malignancy after orthotopic heart transplantation: single-centre outcomes over 20 years. European Journal of Cardio-thoracic Surgery, 2023, 64, .	1.4	0
2046	Time of eating and mortality in U.S. adults with heart failure: Analyses of the National Health and Nutrition Examination Survey 2003â€“2018. Nutrition, Metabolism and Cardiovascular Diseases, 2024, 34, 445-454.	2.6	1
2047	Sustained Effect of Clinical Decision Support for Heart Failure: A Natural Experiment Using Implementation Science. Applied Clinical Informatics, 2023, 14, 822-832.	1.7	2
2048	HFpEF: New biomarkers and their diagnostic and prognostic value. Current Problems in Cardiology, 2024, 49, 102155.	2.4	0
2050	Predictors of outcome in a contemporary cardiac sarcoidosis population: Role of brain natriuretic peptide, left ventricular function and myocardial inflammation. European Journal of Heart Failure, 2023, 25, 2287-2298.	7.1	3
2051	Obesity as a risk factor in atrial fibrillation and heart failure. Journal of Diabetes and Metabolic Disorders, 0, , .	1.9	1
2052	The therapeutic value of bifidobacteria in cardiovascular disease. Npj Biofilms and Microbiomes, 2023, 9, .	6.4	1
2053	System pharmacology-based determination of the functional components and mechanisms in chronic heart failure treatment: an example of Zhenwu decoction. Journal of Biomolecular Structure and Dynamics, 0, , 1-19.	3.5	0
2054	MFG-E8 facilitates heart repair through M1/M2 polarization after myocardial infarction by inhibiting CaMKII. International Immunopharmacology, 2024, 126, 111216.	3.8	0
2055	Association of anaemia on heart failure and left ventricular function: A bidirectional Mendelian randomization study. ESC Heart Failure, 0, , .	3.1	0
2056	Fibroblast activation protein: Pivoting cancer/chemotherapeutic insight towards heart failure. Biochemical Pharmacology, 2024, 219, 115914.	4.4	0
2057	Weight fluctuations preceding and succeeding heart failure diagnosis: Implications for all-cause mortality. Current Problems in Cardiology, 2024, 49, 102173.	2.4	0
2059	Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: A retrospective cohort study. Medicine (United States), 2023, 102, e35589.	1.0	0
2060	Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure. Expert Opinion on Investigational Drugs, 2023, 32, 1157-1170.	4.1	0
2061	Risk Factors and Cellular Differences in Heart Failure: The Key Role of Sex Hormones. Biomedicines, 2023, 11, 3052.	3.2	0
2062	The feasibility of relaxation-enhanced angiography without contrast and triggering for preprocedural planning of transcatheter aortic valve implantation. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0

#	ARTICLE	IF	CITATIONS
2063	Intravenous Iron Technique Evaluation in Chronic Heart Failure With Iron Deficiency Anemia. Cureus, 2023, , .	0.5	0
2065	A Supportive Heart Failure Care Program to Reduce Hospital Readmissions. Home Healthcare Now, 2023, 41, 321-329.	0.2	0
2066	Long-term prognostic value of high-sensitivity cardiac troponin-I in patients with idiopathic dilated cardiomyopathy. Open Medicine (Poland), 2023, 18, .	1.3	0
2068	Sacubitril/Valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction Focusing on the Impact on the Quality of Life: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Cureus, 2023, , .	0.5	0
2069	Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study. The Lancet Global Health, 2023, 11, e1874-e1884.	6.3	1
2070	Managing hypertension in African Americans with heart failure: A guide for the primary care clinician. Journal of the National Medical Association, 2023, , .	0.8	0
2071	Association of mild kidney dysfunction with diastolic dysfunction and heart failure with preserved ejection fraction. ESC Heart Failure, 2024, 11, 315-326.	3.1	1
2072	The Safety and Efficacy of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Patients With Heart Failure and Myocardial Infarction: A Meta-Analysis of Clinical Trials. Cureus, 2023, , .	0.5	0
2073	Non-coding RNAs modulate pyroptosis in myocardial ischemia-reperfusion injury: A comprehensive review. International Journal of Biological Macromolecules, 2024, 257, 128558.	7.5	0
2074	Proteomics Analysis of Serum Reveals Potential Biomarkers for Heart Failure Patients with Phlegm-Blood Stasis Syndrome. Journal of Proteome Research, 0, , .	3.7	0
2075	Physiological stress improves stem cell modeling of dystrophic cardiomyopathy. DMM Disease Models and Mechanisms, 0, , .	2.4	0
2076	Sex Differences in Circulating Biomarkers of Heart Failure. Current Heart Failure Reports, 0, , .	3.3	0
2077	Safety of prehospital intravenous bolus dose nitroglycerin in patients with acute pulmonary edema: A 4â€year review. Journal of the American College of Emergency Physicians Open, 2023, 4, .	0.7	0
2078	ANDROGEN STATUS AND HEART FAILURE SEVERITY IN MEN WITH ISCHEMIC HEART DISEASE: A COMPREHENSIVE ANALYSIS. Art of Medicine, 0, , 158-162.	0.1	0
2079	Chronic Kidney Disease - Peridialysis Period: Predialysis, Dialysis Preparation, and Initial Dialysis Prescription. Journal of Biomedical and Clinical Research, 2023, 16, 105-117.	0.2	0
2080	Posicionamento do Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia sobre o Uso do Strain Mioc�rdico na Rotina do Cardiologista â€ 2023. Arquivos Brasileiros De Cardiologia, 2023, 120, .	0.8	2
2081	Comprehensive review on gene mutations contributing to dilated cardiomyopathy. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
2083	Predicting Ejection Fraction from Electrocardiogram Signals using a Multi-task Learning Model. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
2084	Investigating automated regression models for estimating left ventricular ejection fraction levels in heart failure patients using circadian ECG features. PLoS ONE, 2023, 18, e0295653.	2.5	0
2085	Applying Evidence-Based Practice Guidelines in Primary Care: A Heart Failure Scenario. Journal for Nurse Practitioners, 2024, 20, 104878.	0.8	0
2086	A Noninvasive Circulating Signature of Combined Right Ventricular Pressure and Volume Overload in Tetralogy of Fallot/Pulmonary Atresia/Major Aortopulmonary Collateral Arteries. World Journal for Pediatric & Congenital Heart Surgery, 0, , .	0.8	1
2087	Use of Imaging-Guided Decongestion for Reducing Heart Failure Readmission and Death in High-risk Patients: A multi-site Randomized Trial of a Nurse-led Strategy at Point-of-Care. Journal of Cardiac Failure, 2023, , .	1.7	0
2088	Progressive Left Ventricular Remodeling for Predicting Mortality in Children With Dilated Cardiomyopathy: The Pediatric Cardiomyopathy Registry. Journal of the American Heart Association, 2024, 13, .	3.7	0
2089	Development and validation of a novel combinatorial nomogram model to predict in-hospital deaths in heart failure patients. BMC Cardiovascular Disorders, 2024, 24, .	1.7	0
2090	Evaluation of a New NT-proBNP Immunoassay on an Automated Core Laboratory System. Journal of applied laboratory medicine, The, 2024, 9, 579-585.	1.3	0
2091	Identification of hub genes in heart failure by integrated bioinformatics analysis and machine learning. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
2092	Cardiovascular effects of the post-COVID-19 condition. , 2024, 3, 118-129.		0
2093	Could admission level of uric acid predict total diuretic dose in acute heart failure?. BMC Cardiovascular Disorders, 2024, 24, .	1.7	0
2094	Circulating biomarker- and magnetic resonance-based nomogram predicting long-term outcomes in dilated cardiomyopathy. Chinese Medical Journal, 2024, 137, 73-81.	2.3	0
2095	Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach. International Journal of Molecular Sciences, 2024, 25, 794.	4.1	1
2096	Circulating erythroferrone has diagnostic utility for acute decompensated heart failure in patients presenting with acute or worsening dyspnea. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
2097	Clinical outcomes and anticoagulation therapy in elderly nonâ€valvular atrial fibrillation and heart failure patients. ESC Heart Failure, 2024, 11, 902-913.	3.1	0
2100	Associations of galectin-3 levels with measures of vascular disease in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2024, 65, 152357.	3.4	0
2101	Insuffisance cardiaque. , 2023, , 213-228.		0
2102	Exo-miR-144-3p as a promising diagnostic biomarker for depressive symptoms in heart failure. Neurobiology of Disease, 2024, 192, 106415.	4.4	0
2103	Evaluation of <sc>PHARMâ€CHF</sc>, a pharmacistâ€led heart failure medication titration clinic: A preâ€post study. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
2104	Diagnostic and clinical significance of cell free DNA levels in patients with chronic heart failure. Medical and Social Expert Evaluation and Rehabilitation, 2024, 26, 155-164.	0.2	0
2105	Sodium intake and the risk of heart failure and hypertension: epidemiological and Mendelian randomization analysis. Frontiers in Nutrition, 0, 10, .	3.7	0
2106	Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem. Cardiovascular Drugs and Therapy, 0, , .	2.6	0
2107	Right ventricular outflow tract stenting for late presenter unrepaired Fallot physiology: a single-center experience. Frontiers in Cardiovascular Medicine, 0, 11, .	2.4	0
2108	Advanced Treatment of Refractory Congestive Heart Failure by Peritoneal Ultrafiltration with Icodextrin in Patients without End-Stage Renal Disease. , 0, , .		0
2109	Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review. Cureus, 2024, , .	0.5	0
2110	Microbial Features Linked to Medication Strategies in Cardiometabolic Disease Management. ACS Pharmacology and Translational Science, 2024, 7, 991-1001.	4.9	1
2111	Iron deficiency and supplementation in heart failure. Nature Reviews Cardiology, 0, , .	13.7	1
2112	Inpatient vs. Outpatient: A Systematic Review of Information Needs throughout the Heart Failure Patient Journey. Journal of Clinical Medicine, 2024, 13, 1085.	2.4	0
2113	Anti-hypertensive effect of a novel angiotensin II receptor neprilysin inhibitor (ARNi) -S086 in DSS rat model. Frontiers in Cardiovascular Medicine, 0, 11, .	2.4	0
2114	Impact of angiotensin receptor-neprilysin inhibition (ARNi) in improving ejection fraction and left and right ventricular remodeling in heart failure. Current Problems in Cardiology, 2024, 49, 102464.	2.4	0
2115	Telemedicine and patients with heart failure: evidence and unresolved issues. Einstein (Sao Paulo,) Tj ETQq1 1 0.784314 rgBT ₀ /Overlook	0.7	0
2116	Prognostic implication of heart failure stage and left ventricular ejection fraction for patients with in-hospital cardiac arrest: a 16-year retrospective cohort study. Clinical Research in Cardiology, 0, , .	3.3	0
2117	Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes â€“ detailed studies on CYP3A inhibitors. European Journal of Pharmaceutical Sciences, 2024, , 106735.	4.0	0
2118	Association of Sex With Cardiovascular Outcomes in Heart Failure Patients With Obstructive or Central Sleep Apnea. Journal of the American Heart Association, 0, , .	3.7	0
2119	Structural effect of the H992D/H418D mutation of angiotensin-converting enzyme in the Indian population: implications for health and disease. Journal of Biomolecular Structure and Dynamics, 0, , 1-18.	3.5	0
2120	DAHOS Study: Efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome â€” A 3-month, multicenter, randomized controlled clinical trial. European Journal of Clinical Pharmacology, 2024, 80, 771-780.	1.9	0
2121	Cardiac progenitor cell therapy: mechanisms of action. Cell and Bioscience, 2024, 14, .	4.8	0

#	ARTICLE	IF	CITATIONS
2122	Clinical Outcomes of Renin-Angiotensin Aldosterone Blockade in Patients with Advanced Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Canadian Journal of Cardiology, 2024, , .	1.7	0
2123	Adherence to Treatment Guidelines in Ambulatory Heart Failure Patients with Reduced Ejection Fraction in a Latin-American Country: Observational Study of the Colombian Heart Failure Registry (RECOLFACA). Cardiology, 0, , 1-9.	1.4	0
2124	Impact of Cardiorenal Anaemia Syndrome on Clinical Features in Elderly Outpatients with Chronic Heart Failure: A Japanese Community Hospital Experience. European Journal of Medical and Health Sciences, 2024, 6, 7-13.	0.2	0
2125	Regional disparities and risk factors of mortality among patients at high risk of sudden cardiac death in emerging countries: a nonrandomized controlled trial. BMC Medicine, 2024, 22, .	5.5	0
2126	Preeclampsia prevention and cardiovascular health: Future challenges. Asian Journal of Surgery, 2024, , .	0.4	0
2127	Growth and differentiation factor-15: A link between inflammaging and cardiovascular disease. Biomedicine and Pharmacotherapy, 2024, 174, 116475.	5.6	0
2128	Sex Differenced in Diastolic Function and Long-term Clinical Outcomes in Patient With Peripheral Artery Disease Who Underwent Percutaneous Transluminal Angioplasty: Single Center, Cohort Study. , 2024, 3, 72.		0
2129	Prevalence and impact of sarcopenia in individuals with heart failure with reduced ejection fraction (the SARC-HF study): A prospective observational study protocol. PLoS ONE, 2024, 19, e0300918.	2.5	0
2130	What Do We Know So Far About Ventricular Arrhythmias and Sudden Cardiac Death Prediction in the Mitral Valve Prolapse Population? Could Biomarkers Help Us Predict Their Occurrence?. Current Cardiology Reports, 0, , .	2.9	0